Welcome to STN International! Enter x:x

LOGINID:ssspta1617srh

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Welcome to STN International Web Page URLs for STN Seminar Schedule - N. America BLAST(R) searching in REGISTRY available in STN on the Web NEWS Jan 29 FSTA has been reloaded and moves to weekly updates NEWS Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update frequency Access via Tymnet and SprintNet Eliminated Effective 3/31/02 NEWS Feb 19 NEWS 6 Mar 08 Gene Names now available in BIOSIS NEWS 7 Mar 22 TOXLIT no longer available TRCTHERMO no longer available NEWS 8 Mar 22 US Provisional Priorities searched with P in CA/CAplus NEWS 9 Mar 28 and USPATFULL NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY Apr 02 NEWS 11 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead. NEWS 12 "Ask CAS" for self-help around the clock Apr 08 NEWS 13 BEILSTEIN: Reload and Implementation of a New Subject Area Apr 09 NEWS 14 Apr 09 ZDB will be removed from STN NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available NEWS 19 May 31 PCTFULL to be reloaded. File temporarily unavailable. NEWS 20 Jun 03 New e-mail delivery for search results now available February 1 CURRENT WINDOWS VERSION IS V6.0d, NEWS EXPRESS CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002 NEWS HOURS STN Operating Hours Plus Help Desk Availability NEWS INTER General Internet Information NEWS LOGIN Welcome Banner and News Items NEWS PHONE Direct Dial and Telecommunication Network Access to STN

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

CAS World Wide Web Site (general information)

FILE 'HOME' ENTERED AT 18:10:30 ON 07 JUN 2002

=> apl

NEWS WWW

APL IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> fil capl

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 18:10:37 ON 07 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jun 2002 VOL 136 ISS 23 FILE LAST UPDATED: 5 Jun 2002 (20020605/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s wo200035436/pn

L1 1 WO200035436/PN (WO200035436/PN)

=> d

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

AN 2000:420949 CAPLUS

DN 133:73860

TI Preparation of 2-(4-bromo or 4-iodo phenylamino)benzoic acid derivatives as MEK inhibitors

IN Dudley, David Thomas; Flory, Craig Mason; Saltiel, Alan Robert

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 106 pp. CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PANTENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2000035436 A2 20000622 WO 1999-US29783 19991215 <-WO 2000035436 A3 20011018

W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE,
HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG,
MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ,
VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1143957 A2 20011017 EP 1999-966278 19991215

EP 1143957 A3 20020227

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, FI

PRAI US 1998-112544P P 19981216 US 1999-164651P P 19991110

US 1999-164651P P 19991110 WO 1999-US29783 W 19991215

OS MARPAT 133:73860

=> sel rn l1
E1 THROUGH E327 ASSIGNED

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

3.06

3.27

FILE 'REGISTRY' ENTERED AT 18:11:17 ON 07 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 5 JUN 2002 HIGHEST RN 426206-38-4 DICTIONARY FILE UPDATES: 5 JUN 2002 HIGHEST RN 426206-38-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s e1-327

1 13194-68-8/BI

(13194-68-8/RN)

1 142805-58-1/BI

(142805-58-1/RN)

1 1583-58-0/BI

(1583-58-0/RN)

1 176317-02-5/BI

(176317-02-5/RN)

1 212628-43-8/BI

(212628-43-8/RN)

1 212628-44-9/BI

(212628-44-9/RN)

1 212628-45-0/BI

(212628-45-0/RN)

1 212628-46-1/BI

(212628-46-1/RN)

1 212628-47-2/BI

(212628-47-2/RN)

1 212628-48-3/BI

(212628-48-3/RN)

```
1 212628-49-4/BI
    (212628-49-4/RN)
1 212628-50-7/BI
    (212628-50-7/RN)
1 212628-51-8/BI
    (212628-51-8/RN)
1 212628-52-9/BI
    (212628-52-9/RN)
1 212628-53-0/BI
    (212628-53-0/RN)
1 212628-54-1/BI
    (212628-54-1/RN)
1 212628-55-2/BI
    (212628-55-2/RN)
1 212628-56-3/BI
    (212628-56-3/RN)
1 212628-57-4/BI
    (212628-57-4/RN)
1 212628-58-5/BI
    (212628-58-5/RN)
1 212628-59-6/BI
    (212628-59-6/RN)
1 212628-60-9/BI
    (212628-60-9/RN)
1 212628-61-0/BI
    (212628-61-0/RN)
1 212628-62-1/BI
    (212628-62-1/RN)
1 212628-63-2/BI
    (212628-63-2/RN)
1 212628-65-4/BI
    (212628-65-4/RN)
1 212628-67-6/BI
    (212628-67-6/RN)
1 212628-69-8/BI
    (212628-69-8/RN)
1 212628-71-2/BI
    (212628-71-2/RN)
1 212628-72-3/BI
    (212628-72-3/RN)
1 212628-73-4/BI
    (212628-73-4/RN)
1 212628-74-5/BI
    (212628-74-5/RN)
1 212628-75-6/BI
    (212628-75-6/RN)
1 212628-76-7/BI
    (212628-76-7/RN)
1 212628-77-8/BI
    (212628-77-8/RN)
1 212628-78-9/BI
    (212628-78-9/RN)
1 212628-79-0/BI
    (212628-79-0/RN)
1 212628-80-3/BI
    (212628-80-3/RN)
1 212628-81-4/BI
    (212628-81-4/RN)
1 212628-82-5/BI
    (212628-82-5/RN)
1 212628-83-6/BI
```

(212628-83-6/RN)

```
1 212628-84-7/BI
    (212628-84-7/RN)
1 212628-85-8/BI
    (212628-85-8/RN)
1 212628-86-9/BI
    (212628-86-9/RN)
1 212628-87-0/BI
    (212628-87-0/RN)
1 212628-88-1/BI
    (212628-88-1/RN)
1 212628-89-2/BI
    (212628-89-2/RN)
1 212628-90-5/BI
    (212628-90-5/RN)
1 212628-91-6/BI
    (212628-91-6/RN)
1 212628-92-7/BI
    (212628-92-7/RN)
1 212628-93-8/BI
    (212628-93-8/RN)
1 212628-94-9/BI
    (212628-94-9/RN)
1 212628-95-0/BI
    (212628-95-0/RN)
1 212628-96-1/BI
    (212628-96-1/RN)
1 212628-97-2/BI
    (212628-97-2/RN)
1 212628-98-3/BI
    (212628-98-3/RN)
1 212628-99-4/BI
    (212628-99-4/RN)
1 212629-00-0/BI
    (212629-00-0/RN)
1 212629-01-1/BI
    (212629-01-1/RN)
1 212629-02-2/BI
    (212629-02-2/RN)
1 212629-03-3/BI
    (212629-03-3/RN)
1 212629-04-4/BI
    (212629-04-4/RN)
1 212629-05-5/BI
    (212629-05-5/RN)
1 212629-06-6/BI
    (212629-06-6/RN)
1 212629-07-7/BI
    (212629-07-7/RN)
1 212629-08-8/BI
    (212629-08-8/RN)
1 212629-09-9/BI
    (212629-09-9/RN)
1 212629-10-2/BI
    (212629-10-2/RN)
1 212629-11-3/BI
    (212629-11-3/RN)
1 212629-12-4/BI
    (212629-12-4/RN)
1 212629-13-5/BI
    (212629-13-5/RN)
1 212629-14-6/BI
```

(212629-14-6/RN)

```
1 212629-15-7/BI
    (212629-15-7/RN)
1 212629-16-8/BI
    (212629-16-8/RN)
1 212629-17-9/BI
    (212629-17-9/RN)
1 212629-18-0/BI
    (212629-18-0/RN)
1 212629-19-1/BI
    (212629-19-1/RN)
1 212629-20-4/BI
    (212629-20-4/RN)
1 212629-21-5/BI
    (212629-21-5/RN)
1 212629-22-6/BI
    (212629-22-6/RN)
1 212629-23-7/BI
    (212629-23-7/RN)
1 212629-24-8/BI
    (212629-24-8/RN)
1 212629-25-9/BI
    (212629-25-9/RN)
1 212629-26-0/BI
    (212629-26-0/RN)
1 212629-27-1/BI
    (212629-27-1/RN)
1 212629-28-2/BI
    (212629-28-2/RN)
1 212629-29-3/BI
    (212629-29-3/RN)
1 212629-30-6/BI
    (212629-30-6/RN)
1 212629-31-7/BI
    (212629-31-7/RN)
1 212629-32-8/BI
    (212629-32-8/RN)
1 212629-33-9/BI
    (212629-33-9/RN)
1 212629-34-0/BI
    (212629-34-0/RN)
1 212629-35-1/BI
    (212629-35-1/RN)
1 212629-36-2/BI
    (212629-36-2/RN)
1 212629-37-3/BI
    (212629-37-3/RN)
1 212629-38-4/BI
    (212629-38-4/RN)
1 212629-39-5/BI
    (212629-39-5/RN)
1 212629-40-8/BI
    (212629-40-8/RN)
1 212629-41-9/BI
    (212629-41-9/RN)
1 212629-42-0/BI
    (212629-42-0/RN)
1 212629-43-1/BI
    (212629-43-1/RN)
1 212629-44-2/BI
    (212629-44-2/RN)
1 212629-45-3/BI
```

(212629-45-3/RN)

```
1 212629-46-4/BI
    (212629-46-4/RN)
1 212629-47-5/BI
    (212629-47-5/RN)
1 212629-48-6/BI
    (212629-48-6/RN)
1 212629-50-0/BI
    (212629-50-0/RN)
1 212629-52-2/BI
    (212629-52-2/RN)
1 212629-54-4/BI
    (212629-54-4/RN)
1 212629-56-6/BI
    (212629-56-6/RN)
1 212629-58-8/BI
    (212629-58-8/RN)
1 212629-60-2/BI
    (212629-60-2/RN)
1 212629-62-4/BI
    (212629-62-4/RN)
1 212629-64-6/BI
    (212629-64-6/RN)
1 212629-66-8/BI
    (212629-66-8/RN)
1 212629-68-0/BI
    (212629-68-0/RN)
1 212629-69-1/BI
    (212629-69-1/RN)
1 212629-71-5/BI
    (212629-71-5/RN)
1 212629-73-7/BI
    (212629-73-7/RN)
1 212629-75-9/BI
    (212629-75-9/RN)
1 212629-77-1/BI
    (212629-77-1/RN)
1 212629-78-2/BI
    (212629-78-2/RN)
1 212629-79-3/BI
    (212629-79-3/RN)
1 212629-80-6/BI
    (212629-80-6/RN)
1 212629-81-7/BI
    (212629-81-7/RN)
1 212629-82-8/BI
    (212629-82-8/RN)
1 212629-83-9/BI
    (212629-83-9/RN)
1 212629-84-0/BI
    (212629-84-0/RN)
1 212629-85-1/BI
    (212629-85-1/RN)
1 212629-86-2/BI
    (212629-86-2/RN)
1 212629-87-3/BI
    (212629-87-3/RN)
1 212629-88-4/BI
    (212629-88-4/RN)
1 212629-89-5/BI
    (212629-89-5/RN)
1 212629-90-8/BI
```

(212629-90-8/RN)

```
1 212629-91-9/BI
    (212629-91-9/RN)
1 212629-92-0/BI
    (212629-92-0/RN)
1 212629-93-1/BI
    (212629-93-1/RN)
1 212629-94-2/BI
    (212629-94-2/RN)
1 212629-95-3/BI
    (212629-95-3/RN)
1 212629-98-6/BI
    (212629-98-6/RN)
1 212629-99-7/BI
    (212629-99-7/RN)
1 212630-00-7/BI
    (212630-00-7/RN)
1 212630-03-0/BI
    (212630-03-0/RN)
1 212630-04-1/BI
    (212630-04-1/RN)
1 212630-05-2/BI
    (212630-05-2/RN)
1 212630-06-3/BI
    (212630-06-3/RN)
1 212630-07-4/BI
    (212630-07-4/RN)
1 212630-08-5/BI
    (212630-08-5/RN)
1 212630-09-6/BI
    (212630-09-6/RN)
1 212630-10-9/BI
    (212630-10-9/RN)
1 212630-11-0/BI
    (212630-11-0/RN)
1 212630-12-1/BI
    (212630-12-1/RN)
1 212630-13-2/BI
    (212630-13-2/RN)
1 212630-14-3/BI
    (212630-14-3/RN)
1 212630-15-4/BI
    (212630-15-4/RN)
1 212630-16-5/BI
    (212630-16-5/RN)
1 212630-17-6/BI
    (212630-17-6/RN)
1 212630-18-7/BI
    (212630-18-7/RN)
1 212630-19-8/BI
    (212630-19-8/RN)
1 212630-20-1/BI
    (212630-20-1/RN)
1 212630-21-2/BI
    (212630-21-2/RN)
1 212630-22-3/BI
    (212630-22-3/RN)
1 212630-23-4/BI
    (212630-23-4/RN)
1 212630-24-5/BI
    (212630-24-5/RN)
1 212630-25-6/BI
```

(212630-25-6/RN)

```
1 212630-26-7/BI
    (212630-26-7/RN)
1 212630-27-8/BI
    (212630-27-8/RN)
1 212630-28-9/BI
    (212630-28-9/RN)
1 212630-29-0/BI
    (212630-29-0/RN)
1 212630-30-3/BI
    (212630-30-3/RN)
1 212630-31-4/BI
    (212630-31-4/RN)
1 212630-32-5/BI
    (212630-32-5/RN)
1 212630-33-6/BI
    (212630-33-6/RN)
1 212630-34-7/BI
    (212630-34-7/RN)
1 212630-35-8/BI
    (212630-35-8/RN)
1 212630-36-9/BI
    (212630-36-9/RN)
1 212630-37-0/BI
    (212630-37-0/RN)
1 212630-38-1/BI
    (212630-38-1/RN)
1 212630-39-2/BI
    (212630-39-2/RN)
1 212630-40-5/BI
    (212630-40-5/RN)
1 212630-41-6/BI
    (212630-41-6/RN)
1 212630-42-7/BI
    (212630-42-7/RN)
1 212630-43-8/BI
    (212630-43-8/RN)
1 212630-44-9/BI
    (212630-44-9/RN)
1 212630-45-0/BI
    (212630-45-0/RN)
1 212630-46-1/BI
    (212630-46-1/RN)
1 212630-47-2/BI
    (212630-47-2/RN)
1 212630-48-3/BI
    (212630-48-3/RN)
1 212630-49-4/BI
    (212630-49-4/RN)
1 212630-50-7/BI
    (212630-50-7/RN)
1 212630-51-8/BI
    (212630-51-8/RN)
1 212630-52-9/BI
    (212630-52-9/RN)
1 212630-53-0/BI
    (212630-53-0/RN)
1 212630-54-1/BI
    (212630-54-1/RN)
1 212630-55-2/BI
    (212630-55-2/RN)
1 212630-56-3/BI
```

(212630-56-3/RN)

```
1 212630-57-4/BI
    (212630-57-4/RN)
1 212630-58-5/BI
    (212630-58-5/RN)
1 212630-59-6/BI
    (212630-59-6/RN)
1 212630-60-9/BI
    (212630-60-9/RN)
1 212630-61-0/BI
    (212630-61-0/RN)
1 212630-62-1/BI
    (212630-62-1/RN)
1 212630-63-2/BI
    (212630-63-2/RN)
1 212630-64-3/BI
    (212630-64-3/RN)
1 212630-65-4/BI
    (212630-65-4/RN)
1 212630-66-5/BI
    (212630-66-5/RN)
1 212630-67-6/BI
    (212630-67-6/RN)
1 212630-68-7/BI
    (212630-68-7/RN)
1 212630-69-8/BI
    (212630-69-8/RN)
1 212630-70-1/BI
    (212630-70-1/RN)
1 212630-71-2/BI
    (212630-71-2/RN)
1 212630-72-3/BI
    (212630-72-3/RN)
1 212630-73-4/BI
    (212630-73-4/RN)
1 212630-74-5/BI
    (212630-74-5/RN)
1 212630-75-6/BI
    (212630-75-6/RN)
1 212630-76-7/BI
    (212630-76-7/RN)
1 212630-77-8/BI
    (212630-77-8/RN)
1 212630-78-9/BI
    (212630-78-9/RN)
1 212630-79-0/BI
    (212630-79-0/RN)
1 212630-80-3/BI
    (212630-80-3/RN)
1 212630-81-4/BI
    (212630-81-4/RN)
1 212630-82-5/BI
    (212630-82-5/RN)
1 212630-83-6/BI
    (212630-83-6/RN)
1 212630-84-7/BI
    (212630-84-7/RN)
1 212630-85-8/BI
    (212630-85-8/RN)
1 212630-86-9/BI
    (212630-86-9/RN)
1 212630-87-0/BI
```

(212630-87-0/RN)

```
1 212630-88-1/BI
    (212630-88-1/RN)
1 212630-89-2/BI
    (212630-89-2/RN)
1 212630-90-5/BI
    (212630-90-5/RN)
1 212630-91-6/BI
    (212630-91-6/RN)
1 212630-92-7/BI
    (212630-92-7/RN)
1 212630-94-9/BI
    (212630-94-9/RN)
1 212630-96-1/BI
    (212630-96-1/RN)
1 212630-98-3/BI
    (212630-98-3/RN)
1 212630-99-4/BI
    (212630-99-4/RN)
1 212631-00-0/BI
    (212631-00-0/RN)
1 212631-01-1/BI
    (212631-01-1/RN)
1 212631-02-2/BI
    (212631-02-2/RN)
1 212631-03-3/BI
    (212631-03-3/RN)
1 212631-04-4/BI
    (212631-04-4/RN)
1 212631-05-5/BI
    (212631-05-5/RN)
1 212631-06-6/BI
    (212631-06-6/RN)
1 212631-07-7/BI
    (212631-07-7/RN)
1 212631-08-8/BI
    (212631-08-8/RN)
1 212631-09-9/BI
    (212631-09-9/RN)
1 212631-13-5/BI
    (212631-13-5/RN)
1 212631-15-7/BI
    (212631-15-7/RN)
1 212631-28-2/BI
    (212631-28-2/RN)
1 212631-29-3/BI
    (212631-29-3/RN)
1 212631-30-6/BI
    (212631-30-6/RN)
1 212631-32-8/BI
    (212631-32-8/RN)
1 212631-33-9/BI
    (212631-33-9/RN)
1 212631-34-0/BI
    (212631-34-0/RN)
1 212631-35-1/BI
    (212631-35-1/RN)
1 212631-36-2/BI
    (212631-36-2/RN)
1 212631-37-3/BI
    (212631-37-3/RN)
1 212631-38-4/BI
```

(212631-38-4/RN)

```
1 212631-39-5/BI
    (212631-39-5/RN)
1 212631-40-8/BI
    (212631-40-8/RN)
1 212631-41-9/BI
    (212631-41-9/RN)
1 212631-42-0/BI
    (212631-42-0/RN)
1 212631-43-1/BI
    (212631-43-1/RN)
1 212631-44-2/BI
    (212631-44-2/RN)
1 212631-45-3/BI
    (212631-45-3/RN)
1 212631-46-4/BI
    (212631-46-4/RN)
1 212631-47-5/BI
    (212631-47-5/RN)
1 212631-48-6/BI
    (212631-48-6/RN)
1 212631-49-7/BI
    (212631-49-7/RN)
1 212631-50-0/BI
    (212631-50-0/RN)
1 212631-51-1/BI
    (212631-51-1/RN)
1 212631-52-2/BI
    (212631-52-2/RN)
1 212631-54-4/BI
    (212631-54-4/RN)
1 212631-55-5/BI
    (212631-55-5/RN)
1 212631-56-6/BI
    (212631-56-6/RN)
1 212631-57-7/BI
    (212631-57-7/RN)
1 212631-58-8/BI
    (212631-58-8/RN)
1 212631-59-9/BI
    (212631-59-9/RN)
1 212631-60-2/BI
    (212631-60-2/RN)
1 212631-61-3/BI
    (212631-61-3/RN)
1 212631-62-4/BI
    (212631-62-4/RN)
1 212631-63-5/BI
    (212631-63-5/RN)
1 212631-64-6/BI
    (212631-64-6/RN)
1 212631-65-7/BI
    (212631-65-7/RN)
1 212631-66-8/BI
    (212631-66-8/RN)
1 212631-67-9/BI
    (212631-67-9/RN)
1 212631-68-0/BI
    (212631-68-0/RN)
1 212631-69-1/BI
    (212631-69-1/RN)
1 212631-70-4/BI
```

(212631-70-4/RN)

```
1 212631-71-5/BI
    (212631-71-5/RN)
1 212631-72-6/BI
    (212631-72-6/RN)
1 212631-73-7/BI
    (212631-73-7/RN)
1 212631-75-9/BI
    (212631-75-9/RN)
1 212631-76-0/BI
    (212631-76-0/RN)
1 212631-77-1/BI
    (212631-77-1/RN)
1 212631-78-2/BI
    (212631-78-2/RN)
1 212631-79-3/BI
    (212631-79-3/RN)
1 212631-80-6/BI
    (212631-80-6/RN)
1 212631-81-7/BI
    (212631-81-7/RN)
1 212631-82-8/BI
    (212631-82-8/RN)
1 212631-83-9/BI
    (212631-83-9/RN)
1 212631-84-0/BI
    (212631-84-0/RN)
1 212631-85-1/BI
    (212631-85-1/RN)
1 212631-86-2/BI
    (212631-86-2/RN)
1 219777-46-5/BI
    (219777-46-5/RN)
1 219777-60-3/BI
    (219777-60-3/RN)
1 219778-04-8/BI
    (219778-04-8/RN)
1 219778-52-6/BI
    (219778-52-6/RN)
1 219794-13-5/BI
    (219794-13-5/RN)
1 219794-21-5/BI
    (219794-21-5/RN)
1 277315-06-7/BI
    (277315-06-7/RN)
1 277315-07-8/BI
    (277315-07-8/RN)
1 277315-08-9/BI
    (277315-08-9/RN)
1 277315-09-0/BI
    (277315-09-0/RN)
1 277315-10-3/BI
    (277315-10-3/RN)
1 277315-12-5/BI
    (277315-12-5/RN)
1 277335-40-7/BI
    (277335-40-7/RN)
1 277335-43-0/BI
    (277335-43-0/RN)
1 278609-85-1/BI
    (278609-85-1/RN)
1 278609-99-7/BI
```

(278609-99-7/RN)

1 278610-42-7/BI (278610-42-7/RN)

1 278610-51-8/BI

(278610-51-8/RN)

1 352-33-0/BI

(352-33-0/RN)

1 57381-34-7/BI

(57381-34-7/RN)

1 6723-30-4/BI

(6723-30-4/RN)

1 79955-99-0/BI

(79955-99-0/RN)

1 96515-79-6/BI

(96515-79-6/RN)

L2

327 (13194-68-8/BI OR 142805-58-1/BI OR 1583-58-0/BI OR 176317-02-5/ BI OR 212628-43-8/BI OR 212628-44-9/BI OR 212628-45-0/BI OR 212628-46-1/BI OR 212628-47-2/BI OR 212628-48-3/BI OR 212628-49-4/BI OR 212628-50-7/BI OR 212628-51-8/BI OR 212628-52-9/BI OR 212628-53-0/BI OR 212628-54-1/BI OR 212628-55-2/BI OR 212628-56-3/BI OR 212628-57-4/BI OR 212628-58-5/BI OR 212628-59-6/BI OR 212628-60-9/BI OR 212628-61-0/BI OR 212628-62-1/BI OR 212628-63-2/BI OR 212628-65-4/BI OR 212628-67-6/BI OR 212628-69-8/BI OR 212628-71-2/BI OR 212628-72-3/BI OR 212628-73-4/BI OR 212628-74-5/BI OR 212628-75-6/BI OR 212628-76-7/BI OR 212628-77-8/BI OR 212628-78-9/BI OR 212628-79-0/BI OR 212628-80-3/BI OR 212628-81-4/BI OR 212628-82-5/BI OR 212628-83-6/BI OR 212628-84-7/BI OR 212628-85-8/BI OR 212628-86-9/BI OR 212628-87-0/BI OR 212628-88-1/BI OR 212628-89-2/BI OR 212628-90-5/BI OR 212628-91-6/BI OR 212628-92-7/BI OR 212628-93-8/BI OR 212628-94-9/BI OR 212628-95-0/BI OR 212628-96-1/BI OR 212628-97-2/BI OR 2

=> d tot

L2ANSWER 1 OF 327 REGISTRY COPYRIGHT 2002 ACS

278610-51-8 REGISTRY RN

CN Benzoic acid, 5-chloro-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN5-Chloro-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzoic acid

CNPD 296767

3D CONCORD FS

MF C14 H9 Cl F2 I N O2

SR

LCSTN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 6 REFERENCES IN FILE CA (1967 TO DATE)
- 6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 2 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 278610-42-7 REGISTRY

CN Benzoic acid, 5-chloro-2-[(2-chloro-4-iodophenyl)amino]-3,4-difluoro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Chloro-4-iodophenylamino)-5-chloro-3,4-difluorobenzoic acid

CN 5-Chloro-2-(2-chloro-4-iodophenylamino)-3,4-difluorobenzoic acid

CN PD 296770

FS 3D CONCORD

MF C13 H6 C12 F2 I N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

$$C1$$
 F
 $C1$
 F
 $C1$
 F

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1967 TO DATE)

6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 3 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 278609-99-7 REGISTRY

CN Benzoic acid, 5-chloro-3,4-difluoro-2-[(4-iodophenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Iodophenylamino)-5-chloro-3,4-difluorobenzoic acid

CN PD 296711

CN PD 296771

FS 3D CONCORD

MF C13 H7 C1 F2 I N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)

5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 4 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 278609-85-1 REGISTRY

CN Benzamide, 5-chloro-N-(cyclopropylmethoxy)-3,4-difluoro-2-[(4-iodophenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:
CN 2-(4-Iodophenylamino)-N-cyclopropylmethoxy-5-chloro-3,4-difluorobenzamide
CN PD 297190

FS 3D CONCORD

MF C17 H14 C1 F2 I N2 O2

SR CA

CH₂-O-NH-C

STN Files:

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CA, CAPLUS, TOXCENTER

4 REFERENCES IN FILE CA (1967 TO DATE)

4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 5 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 277335-43-0 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)methyl]-N-[[5-(3-methoxyphenyl)-3-methyl-2-penten-4-ynyl]oxy]- (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylbenzyl)-N-[5-(3-methoxyphenyl)-3-methylpent-2-en-4-ynyloxy]benzamide

FS 3D CONCORD

MF C28 H23 Br F2 I N O3

SR CA

LC

LC STN Files: CA, CAPLUS, TOXCENTER

Br
$$C-NH-O-CH_2-CH=C-C=C$$
 OMe

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1967 TO DATE)

6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 6 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **277335-40-7** REGISTRY

CN Benzamide, 5-bromo-2-[(2-ethyl-4-iodophenyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(4-iodo-2-ethylphenylamino)-N-(2-pyrrolidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C21 H25 Br I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 7 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **277315-12-5** REGISTRY

CN Benzenamine, 2-methyl-4-nitro-N-[2-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C14 H12 N6 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)

5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 8 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 277315-10-3 REGISTRY

CN Benzamide, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C20 H24 F I N4 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)

5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 9 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 277315-09-0 REGISTRY

CN 3-Pyrrolidinol, 1-[5-fluoro-2-[(4-iodo-2-methylphenyl)amino]benzoyl](9CI) (CA INDEX NAME)

OTHER NAMES:

CN [5-Fluoro-2-(4-iodo-2-methylphenylamino)phenyl]-(3-hydroxypyrrolidin-1-yl)methanone

FS 3D CONCORD

MF C18 H18 F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)

5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 10 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 277315-08-9 REGISTRY

CN 3-Pyrrolidinol, 1-[5-chloro-2-[(4-iodo-2-methylphenyl)amino]benzoyl](9CI) (CA INDEX NAME)

OTHER NAMES:

CN [5-Chloro-2-(4-iodo-2-methylphenylamino)phenyl]-(3-hydroxypyrrolidin-1-yl)methanone

FS 3D CONCORD

MF C18 H18 Cl I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE) 5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 11 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 277315-07-8 REGISTRY

CN 3-Pyrrolidinol, 1-[5-bromo-2-[(4-iodo-2-methylphenyl)amino]benzoyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN [5-Bromo-2-(4-iodo-2-methylphenylamino)phenyl]-(3-hydroxypyrrolidin-1-yl)methanone

FS 3D CONCORD

MF C18 H18 Br I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)

5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 12 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 277315-06-7 REGISTRY

CN 3-Pyrrolidinol, 1-[2-[(4-iodo-2-methylphenyl)amino]-5-nitrobenzoyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (3-Hydroxypyrrolidin-1-yl)-[2-(4-iodo-2-methylphenylamino)-5-nitrophenyl]methanone

FS 3D CONCORD

MF C18 H18 I N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)

5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 13 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 219794-21-5 REGISTRY

CN Benzenecarbothioic acid, 2-[(4-iodo-2-methylphenyl)amino]-5-nitro-, S-(phenylmethyl) ester (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Iodo-2-methylphenylamino)-5-nitrothiobenzoic acid S-benzyl ester

FS 3D CONCORD

MF C21 H17 I N2 O3 S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 14 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 219794-13-5 REGISTRY

OTHER NAMES:

CN 5-Bromo-2-(4-iodo-2-methylphenylamino)thiobenzoic acid S-benzyl ester

FS 3D CONCORD

MF C21 H17 Br I N O S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & & & \\ \text{Ph-CH}_2-\text{S-C} & & \text{Me} \\ & & & \\ & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 15 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **219778-52-6** REGISTRY

CN Benzamide, 5-bromo-N-(cyclobutylmethoxy)-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-cyclobutylmethoxy-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

CN PD 180841

FS 3D CONCORD

MF C19 H18 Br F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 7 REFERENCES IN FILE CA (1967 TO DATE)
- 7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 16 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 219778-04-8 REGISTRY

CN Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-N-(cyclobutylmethoxy)-3,4-difluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Chloro-4-iodophenylamino)-N-cyclobutylmethoxy-3,4-difluorobenzamide

CN 3,4-Difluoro-2-(2-chloro-4-iodophenylamino)-N-cyclobutylmethoxybenzamide

CN PD 185625

FS 3D CONCORD

MF C18 H16 Cl F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 17 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 219777-60-3 REGISTRY

CN Benzamide, 3,4-difluoro-N-hydroxy-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Methyl-4-iodophenylamino)-N-hydroxy-3,4-difluorobenzamide

CN 3,4-Difluoro-N-hydroxy-2-(4-iodo-2-methylphenylamino)benzamide

CN PD 188563

FS 3D CONCORD

MF C14 H11 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 18 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 219777-46-5 REGISTRY

CN Benzamide, N-[(4,4-dimethyl-2-pentynyl)oxy]-4-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-(3-tert-Butylpropyn-2-yl)oxy-4-fluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C21 H22 F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

F

NH

$$C-NH-O-CH_2-C = C-Bu-t$$
 O

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 19 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-86-2 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-N-((tetrahydro-2H-pyran-2-yl)oxy)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C19 H18 Br F2 I N2 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 20 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212631-85-1** REGISTRY

CN Benzoic acid, 5-bromo-2,3,4-trifluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2,3 4-trifluorobenzoic acid

FS 3D CONCORD

MF C7 H2 Br F3 O2

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1967 TO DATE)

10 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 21 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212631-84-0** REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[(tetrahydro-2H-

pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-N-((tetrahydro-2H-pyran-2-yl)oxy)-2-(4-iodo-2-

methylphenylamino) benzamide

FS 3D CONCORD

MF C19 H20 F I N2 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 22 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-83-9 REGISTRY

CN 1H-Tetrazole, 5-(5-chloro-2-fluorophenyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-(5-Chloro-2-fluorophenyl)-1H-tetrazole

FS 3D CONCORD

MF C7 H4 Cl F N4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 23 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-82-8 REGISTRY

CN Benzaldehyde, 5-chloro-2-fluoro-, oxime (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-fluorobenzaldehyde oxime

FS 3D CONCORD

MF C7 H5 Cl F N O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 24 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-81-7 REGISTRY

CN Benzamide, 2-[(2-bromo-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Bromo-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide

MF C17 H14 Br F2 I N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 25 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-80-6 REGISTRY

CN Benzamide, 2-[(2-bromo-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-4-fluoro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Bromo-4-iodophenylamino)-N-cyclopropylmethoxy-4-fluorobenzamide

MF C17 H15 Br F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 26 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-79-3 REGISTRY

CN Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide

CN 3,4-Difluoro-2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxybenzamide

CN PD 184352

FS 3D CONCORD

MF C17 H14 Cl F2 I N2 O2

SR CA

LC STN Files: BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, DRUGNL, DRUGUPDATES, EMBASE, PHAR, SYNTHLINE, TOXCENTER, USPATFULL

24 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

24 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 27 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212631-78-2** REGISTRY

CN Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-4fluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-4-fluorobenzamide

CN PD 203311

FS 3D CONCORD

MF C17 H15 Cl F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 9 REFERENCES IN FILE CA (1967 TO DATE)
- 9 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 28 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-77-1 REGISTRY

CN Benzamide, N-(cyclopropylmethoxy)-3,4-difluoro-2-[(2-fluoro-4iodophenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide

FS 3D CONCORD

MF C17 H14 F3 I N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 29 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-76-0 REGISTRY

CN Benzamide, N-(cyclopropylmethoxy)-4-fluoro-2-[(2-fluoro-4-iodophenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopropylmethoxy-4-fluoro-2-(2-fluoro-4-iodophenylamino) benzamide

FS 3D CONCORD

MF C17 H15 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 30 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-75-9 REGISTRY

CN Benzamide, 2-[(2-bromo-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-4-nitro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Bromo-4-iodophenylamino)-N-cyclopropylmethoxy-4-nitrobenzamide

MF C17 H15 Br I N3 O4

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 31 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212631-73-7** REGISTRY

CN Benzamide, 2-[(2-bromo-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4,5-trifluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Bromo-4-iodophenylamino)-N-cyclopropylmethoxy-3,4,5trifluorobenzamide

MF C17 H13 Br F3 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 32 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-72-6 REGISTRY

CN Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-N-ethoxy-4-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Chloro-4-iodophenylamino)-N-ethoxy-4-nitrobenzamide

FS 3D CONCORD

MF C15 H13 Cl I N3 O4

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 33 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-71-5 REGISTRY

CN Benzamide, 5-bromo-2-[(2-bromo-4-iodophenyl)amino]-N-ethoxy-3,4-difluoro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(2-bromo-4-iodophenylamino)-N-ethoxy-3,4-difluorobenzamide

MF C15 H11 Br2 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 34 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-70-4 REGISTRY

CN Benzamide, 5-chloro-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide

CN PD 297189

FS 3D CONCORD

MF C17 H13 Cl2 F2 I N2 O2

SR CA

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 35 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-69-1 REGISTRY

CN Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4,5-trifluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4,5-trifluorobenzamide

FS 3D CONCORD

MF C17 H13 Cl F3 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 36 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN **212631-68-0** REGISTRY
- CN Benzamide, N-(cyclopropylmethoxy)-2-[(2-fluoro-4-iodophenyl)amino]-4-nitro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopropylmethoxy-2-(2-fluoro-4-iodophenylamino)-4-nitrobenzamide

FS 3D CONCORD

MF C17 H15 F I N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 37 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-67-9 REGISTRY

CN Benzamide, 5-bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide

CN PD 184161

FS 3D CONCORD

MF C17 H13 Br Cl F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 38 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-66-8 REGISTRY

CN Benzamide, 5-chloro-N-(cyclopropylmethoxy)-3,4-difluoro-2-[(2-fluoro-4iodophenyl)amino]- (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide

FS 3D CONCORD

MF C17 H13 Cl F3 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & & & & \\ & &$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 39 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-65-7 REGISTRY

CN Benzamide, N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-[(2-fluoro-4iodophenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(2-fluoro-4-iodophenylamino)benzamide

FS 3D CONCORD

MF C17 H13 F4 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ &$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 40 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-64-6 REGISTRY

CN Benzamide, N-(cyclopropylmethoxy)-2-[(4-iodo-2-methylphenyl)amino]-4-nitro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopropylmethoxy-2-(4-iodo-2-methylphenylamino)-4-nitrobenzamide

FS 3D CONCORD

MF C18 H18 I N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 41 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-63-5 REGISTRY

CN Benzamide, 5-bromo-N-(cyclopropylmethoxy)-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide

FS 3D CONCORD

MF C17 H13 Br F3 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 42 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-62-4 REGISTRY

CN Benzamide, 5-chloro-N-(cyclopropylmethoxy)-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

CN PD 298127

FS 3D CONCORD

MF C18 H16 Cl F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 43 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-61-3 REGISTRY

CN Benzamide, N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-[(4-iodo-2-

methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-

methylphenylamino)benzamide

CN PD 198306

FS 3D CONCORD

MF C18 H16 F3 I N2 O2

CI COM

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1967 TO DATE)

12 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 44 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-60-2 REGISTRY

CN Benzamide, 2-[(2-bromo-4-iodophenyl)amino]-3,4-difluoro-N-hydroxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Bromo-4-iodophenylamino)-3,4-difluoro-N-hydroxybenzamide

MF C13 H8 Br F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 45 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-59-9 REGISTRY

CN Benzamide, 2-[(2-bromo-4-iodophenyl)amino]-4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Bromo-4-iodophenylamino)-4-fluoro-N-hydroxybenzamide

MF C13 H9 Br F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 46 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-58-8 REGISTRY

CN Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-3,4-difluoro-N-hydroxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Chloro-4-iodophenylamino)-3,4-difluoro-N-hydroxybenzamide

FS 3D CONCORD

MF C13 H8 C1 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 47 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-57-7 REGISTRY

CN Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Chloro-4-iodophenylamino)-4-fluoro-N-hydroxybenzamide

CN PD 185848

FS 3D CONCORD

MF C13 H9 Cl F I N2 O2

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 48 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-56-6 REGISTRY

CN Benzamide, 3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-hydroxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(2-fluoro-4-iodophenylamino)-N-hydroxybenzamide

FS 3D CONCORD

MF C13 H8 F3 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 49 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-55-5 REGISTRY

CN Benzamide, 4-fluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-hydroxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(2-fluoro-4-iodophenylamino)-N-hydroxybenzamide

FS 3D CONCORD

MF C13 H9 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 50 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-54-4 REGISTRY

CN Benzamide, 2-[(2-bromo-4-iodophenyl)amino]-N-hydroxy-4-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Bromo-4-iodophenylamino)-N-hydroxy-4-nitrobenzamide

MF C13 H9 Br I N3 O4

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 51 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-52-2 REGISTRY

CN Benzamide, 2-[(2-bromo-4-iodophenyl)amino]-3,4,5-trifluoro-N-hydroxy-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Bromo-4-iodophenylamino)-3,4,5-trifluoro-N-hydroxybenzamide

MF C13 H7 Br F3 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 52 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212631-51-1** REGISTRY

CN Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-N-hydroxy-4-methyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Chloro-4-iodophenylamino)-N-hydroxy-4-methylbenzamide

FS 3D CONCORD

MF C14 H12 Cl I N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 53 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-50-0 REGISTRY

CN Benzamide, 5-bromo-2-[(2-bromo-4-iodophenyl)amino]-3,4-difluoro-N-hydroxy-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(2-bromo-4-iodophenylamino)-3,4-difluoro-N-hydroxybenzamide

MF C13 H7 Br2 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 54 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-49-7 REGISTRY

CN Benzamide, 5-chloro-2-[(2-chloro-4-iodophenyl)amino]-3,4-difluoro-N-hydroxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-(2-chloro-4-iodophenylamino)-3,4-difluoro-N-hydroxybenzamide

FS 3D CONCORD

MF C13 H7 Cl2 F2 I N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 55 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-48-6 REGISTRY

CN Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-3,4,5-trifluoro-N-hydroxy-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Chloro-4-iodophenylamino)-3,4,5-trifluoro-N-hydroxybenzamide

FS 3D CONCORD

MF C13 H7 Cl F3 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 56 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-47-5 REGISTRY

CN Benzamide, 2-[(2-fluoro-4-iodophenyl)amino]-N-hydroxy-4-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Fluoro-4-iodophenylamino)-N-hydroxy-4-nitrobenzamide

FS 3D CONCORD

MF C13 H9 F I N3 O4

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 57 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212631-46-4 REGISTRY
- CN Benzamide, 5-bromo-2-[(2-chloro-4-iodophenyl)amino]-3,4-difluoro-N-hydroxy-(9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Bromo-2-(2-chloro-4-iodophenylamino)-3,4-difluoro-N-hydroxybenzamide
- CN PD 184386
- FS 3D CONCORD
- MF C13 H7 Br Cl F2 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 58 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212631-45-3 REGISTRY
- CN Benzamide, 5-chloro-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-hydroxy- (9CI) (CA INDEX NAME)

- CN 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-N-hydroxybenzamide
- FS 3D CONCORD
- MF C13 H7 Cl F3 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 59 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-44-2 REGISTRY

CN Benzamide, 3,4,5-trifluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-hydroxy-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4,5-Trifluoro-2-(2-fluoro-4-iodophenylamino)-N-hydroxybenzamide

FS 3D CONCORD

MF C13 H7 F4 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 60 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-43-1 REGISTRY

CN Benzamide, N-hydroxy-2-[(4-iodo-2-methylphenyl)amino]-4-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Hydroxy-2-(4-iodo-2-methylphenylamino)-4-nitrobenzamide

FS 3D CONCORD

MF C14 H12 I N3 O4

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 61 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-42-0 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-hydroxy-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-N-hydroxybenzamide

FS 3D CONCORD

MF C13 H7 Br F3 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 62 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-41-9 REGISTRY

CN Benzamide, 5-chloro-3,4-difluoro-N-hydroxy-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C14 H10 Cl F2 I N2 O2

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 63 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212631-40-8 REGISTRY

OTHER NAMES:

- CN 3,4,5-Trifluoro-N-hydroxy-2-(4-iodo-2-methylphenylamino)benzamide
- FS 3D CONCORD
- MF C14 H10 F3 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 64 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212631-39-5 REGISTRY
- CN Benzamide, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

- CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(tetrahydropyran-2-yloxy)benzamide
- FS 3D CONCORD
- MF C19 H20 F I N2 O3
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 65 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-38-4 REGISTRY

CN Benzamide, 5-fluoro-N-hydroxy-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Fluoro-N-hydroxy-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C14 H12 F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 66 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212631-37-3** REGISTRY

CN Benzamide, 4-bromo-2-[(4-iodo-2-methylphenyl)amino]-N-(phenylmethoxy)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Bromo-2-(4-iodo-2-methylphenylamino)-N-phenylmethoxybenzamide

FS 3D CONCORD

MF C21 H18 Br I N2 O2

SR CA

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 67 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-36-2 REGISTRY

CN Benzamide, 5-chloro-N-hydroxy-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-N-hydroxy-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C14 H12 Cl I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 68 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-35-1 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-(pyridin-3-ylmethoxy)benzamide

FS 3D CONCORD

MF C20 H15 Br F2 I N3 O2

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 69 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN **212631-34-0** REGISTRY
- CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(2-thienylmethoxy)- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-(thiophen-2-ylmethoxy)benzamide
- FS 3D CONCORD
- MF C19 H14 Br F2 I N2 O2 S
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 4 REFERENCES IN FILE CA (1967 TO DATE)
- 4 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 70 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212631-33-9 REGISTRY
- CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[[3-(3-methoxyphenyl)-2-propynyl]oxy]- (9CI) (CA INDEX NAME)

- CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-[3-(3-methoxyphenyl)prop-2-ynyloxy]benzamide
- FS 3D CONCORD
- MF C24 H18 Br F2 I N2 O3
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} \text{Br} & \bigcirc \\ \hline \\ \text{C-NH-O-CH}_2\text{-C} \end{array} \\ \text{OMe} \\ \hline \\ \text{I} \\ \end{array}$$

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 71 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-32-8 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(2-propynyloxy)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-(prop-2-ynyloxy)benzamide

FS 3D CONCORD

MF C17 H12 Br F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$HC \equiv C - CH_2 - O - NH - C$$
 Br
 F

Me

 F

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 4 REFERENCES IN FILE CA (1967 TO DATE)
- 4 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 72 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-30-6 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[(3-methyl-2-penten-4-ynyl)oxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-(3-methylpent-2-en-4-ynyloxy)benzamide

FS 3D CONCORD

MF C20 H16 Br F2 I N2 O2

SR CA

$$\begin{array}{c|c} Me & O \\ \hline HC \Longrightarrow C-C \Longrightarrow CH-CH_2-O-NH-C & Me \\ \hline \\ Br & F \end{array}$$

- 4 REFERENCES IN FILE CA (1967 TO DATE)
- 4 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 73 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212631-29-3 REGISTRY
- CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[(3-methyl-2-butenyl)oxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-(3-methylbut-2-enyloxy)benzamide
- FS 3D CONCORD
- MF C19 H18 Br F2 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 74 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212631-28-2 REGISTRY
- CN Benzamide, 5-bromo-N-butoxy-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

- CN 5-Bromo-N-butoxy-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide
- FS 3D CONCORD
- MF C18 H18 Br F2 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 75 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212631-15-7** REGISTRY

CN Benzamide, N-(cyclopentyloxy)-4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopentyloxy-4-fluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C19 H20 F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 76 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-13-5 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(2-propenyloxy)(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(prop-2-enyloxy)benzamide

FS 3D CONCORD

MF C17 H16 F I N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 77 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-09-9 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-N-[(4,4-dimethyl-2-pentynyl)oxy]-3,4-difluoro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-N-(4,4-dimethyl-2-pentynyloxy)-3,4-difluorobenzamide

FS 3D CONCORD

MF C21 H21 Br F2 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$t-Bu-C = C-CH_2-O-NH-C \qquad Me$$

$$F \qquad Br$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 78 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-08-8 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-N-(2-butenyloxy)-3,4-difluoro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-N-(but-2-enyloxy)-3,4-difluorobenzamide

FS 3D CONCORD

MF C18 H17 Br F2 N2 O2

SR CA

$$\begin{array}{c} \text{Me-CH-CH-CH}_2\text{-O-NH-C} & \text{Me} \\ \hline \\ \text{F} & \text{Br} \end{array}$$

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 79 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-07-7 REGISTRY

CN Benzamide, N-(2-butenyloxy)-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-(But-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C18 H17 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$Me-CH=CH-CH_2-O-NH-C$$

$$F$$

$$Me$$

$$NH$$

$$F$$

$$I$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 80 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-06-6 REGISTRY

CN Benzamide, N-(2-butenyloxy)-4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-(But-2-enyloxy)-4-fluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C18 H18 F I N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 81 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-05-5 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-[(2-methyl-2-propenyl)oxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(2-methylallyloxy)benzamide

FS 3D CONCORD

MF C18 H17 Br F2 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} CH_2 & O \\ \parallel & \parallel \\ Me-C-CH_2-O-NH-C & Me \\ \hline & & \\ F & & \\ Br \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 82 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-04-4 REGISTRY

CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[(2-methyl-2-propenyl)oxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-(2-methylallyloxy)benzamide

FS 3D CONCORD

MF C18 H17 F2 I N2 O2

SR CA

$$\begin{array}{c|c} CH_2 & O \\ \parallel & \parallel \\ Me-C-CH_2-O-NH-C & Me \\ \hline & & \\ F & & \\ \end{array}$$

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 83 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-03-3 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[(2-methyl-2-propenyl)oxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(2-methylallyloxy)benzamide

FS 3D CONCORD

MF C18 H18 F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 84 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212631-02-2 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-(2-thienylmethoxy)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(thiophen-2-ylmethoxy)benzamide

FS 3D CONCORD

MF C19 H15 Br F2 N2 O2 S

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 85 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212631-01-1 REGISTRY
- CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(2thienylmethoxy)- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-(thiophen-2-ylmethoxy)benzamide
- FS 3D CONCORD
- MF C19 H15 F2 I N2 O2 S
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 86 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212631-00-0 REGISTRY
- CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(2-thienylmethoxy)-(9CI) (CA INDEX NAME)

- CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(thiophen-2-ylmethoxy)benzamide
- FS 3D CONCORD
- MF C19 H16 F I N2 O2 S
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE) 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 87 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212630-99-4** REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(2-phenoxyethoxy)benzamide

FS 3D CONCORD

MF C22 H19 Br F2 N2 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 88 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-98-3 REGISTRY
- CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(2phenoxyethoxy)- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-(2-phenoxyethoxy)benzamide
- FS 3D CONCORD
- MF C22 H19 F2 I N2 O3

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 89 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-96-1 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(2-phenoxyethoxy)(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(2-phenoxyethoxy)benzamide

FS 3D CONCORD

MF C22 H20 F I N2 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 90 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-94-9 REGISTRY

CN Benzamide, 5-bromo-N-(cyclopropylmethoxy)-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

CN PD 177168

FS 3D CONCORD

MF C18 H16 Br F2 I N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 91 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-92-7 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide

FS 3D CONCORD

MF C18 H17 Br F2 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 92 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-91-6 REGISTRY

CN Benzamide, N-(cyclopropylmethoxy)-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C18 H17 F2 I N2 O2

SR CA

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 93 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-90-5 REGISTRY

CN Benzamide, N-(cyclopropylmethoxy)-4-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopropylmethoxy-4-fluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C18 H18 F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 94 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-89-2 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-N-(cyclopentyloxy)-3,4-difluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-N-cyclopentyloxy-3,4-difluorobenzamide

FS 3D CONCORD

MF C19 H19 Br F2 N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 95 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-88-1 REGISTRY

CN Benzamide, N-(cyclopentyloxy)-3,4-difluoro-2-[(4-iodo-2-

methylphenyl)amino] - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopentyloxy-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C19 H19 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 96 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-87-0 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-N-(cyclobutyloxy)-3,4-difluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-N-cyclobutyloxy-3,4-difluorobenzamide

FS 3D CONCORD

MF C18 H17 Br F2 N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 97 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-86-9 REGISTRY

CN Benzamide, N-(cyclobutyloxy)-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclobutyloxy-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C18 H17 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 98 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-85-8 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(1-methylethoxy)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-isopropoxybenzamide

FS 3D CONCORD

MF C17 H16 Br F2 I N2 O2

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 99 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN **212630-84-7** REGISTRY
- CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(1-methylethoxy)-(9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-isopropoxybenzamide
- FS 3D CONCORD
- MF C17 H18 F I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 100 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-83-6 REGISTRY
- CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-propoxy-(9CI) (CA INDEX NAME)

- CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-propoxybenzamide
- FS 3D CONCORD
- MF C17 H16 Br F2 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 101 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-82-5 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-propoxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-propoxybenzamide

FS 3D CONCORD

MF C17 H17 Br F2 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 102 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-81-4 REGISTRY

CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-propoxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-propoxybenzamide

FS 3D CONCORD

MF C17 H17 F2 I N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 103 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-80-3 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-propoxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-propoxybenzamide

FS 3D CONCORD

MF C17 H18 F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 104 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-79-0 REGISTRY

CN Benzamide, N-ethoxy-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Ethoxy-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C16 H15 F2 I N2 O2

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 105 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-78-9 REGISTRY
- CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-[(3-methyl-5phenyl-2-penten-4-ynyl)oxy]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
- CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(3-methyl-5-phenylpent-2-en-4-ynyloxy)benzamide
- FS 3D CONCORD
- MF C26 H21 Br F2 N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$Ph-C = C-C = CH-CH_2-O-NH-C \qquad Me$$

$$F \qquad Br$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 106 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-77-8 REGISTRY
- CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[(3-methyl-5-phenyl-2-penten-4-ynyl)oxy]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
- CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-(3-methyl-5-phenylpent-2-en-4-ynyloxy)benzamide
- FS 3D CONCORD
- MF C26 H21 F2 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$Ph-C = C-C - CH-CH_2-O-NH-C - Me$$

$$F$$

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 107 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN212630-76-7 REGISTRY

Benzamide, 5-bromo-3,4-difluoro-N-[[3-(2-fluorophenyl)-2-propynyl]oxy]-2-CN[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME) OTHER NAMES:

CN5-Bromo-3,4-difluoro-N-[3-(2-fluorophenyl)-prop-2-ynyloxy]-2-(4-iodo-2methylphenylamino) benzamide

FS 3D CONCORD

MF C23 H15 Br F3 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & & & \\ & & & \\ & & \\ F & & \\ & &$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- ANSWER 108 OF 327 REGISTRY COPYRIGHT 2002 ACS L2

RN212630-75-6 REGISTRY

CNBenzamide, 3,4-difluoro-N-[[3-(2-fluorophenyl)-2-propynyl]oxy]-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

3,4-Difluoro-N-[3-(2-fluorophenyl)prop-2-ynyloxy]-2-(4-iodo-2-CN methylphenylamino) benzamide

FS 3D CONCORD

MF C23 H16 F3 I N2 O2

SR

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 109 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-74-5 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-[[3-(3-fluorophenyl)-2-propynyl]oxy]- (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-[3-(3-fluorophenyl)prop-2-ynyloxy]benzamide

FS 3D CONCORD

MF C23 H16 Br F3 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 110 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-73-4 REGISTRY
- CN Benzamide, 3,4-difluoro-N-[[3-(3-fluorophenyl)-2-propynyl]oxy]-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

- CN 3,4-Difluoro-N-[3-(3-fluorophenyl)prop-2-ynyloxy]-2-(4-iodo-2-methylphenylamino)benzamide
- FS 3D CONCORD
- MF C23 H16 F3 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c}
 & O \\
 & C \\
 & C \\
 & Me
\end{array}$$

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 111 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-72-3 REGISTRY
- CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-[(3-phenyl-2-propynyl)oxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 3,4-Difluoro-2-(4-bromo-2-methylphenylamino)-N-(3-phenylprop-2-ynyloxy)benzamide
- FS 3D CONCORD
- MF C23 H17 Br F2 N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 112 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-71-2 REGISTRY
- CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[(3-phenyl-2-propynyl)oxy]- (9CI) (CA INDEX NAME)

- CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-(3-phenylprop-2-ynyloxy)benzamide
- FS 3D CONCORD
- MF C23 H17 F2 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$Ph-C = C-CH_2-O-NH-C \qquad Me$$

$$F \qquad \qquad F$$

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 113 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-70-1 REGISTRY

CN Benzamide, 5-bromo-N-(3-butynyloxy)-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-(but-3-ynyloxy)-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C18 H14 Br F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c} \text{HC} = \text{C-CH}_2 - \text{CH}_2 - \text{O-NH-C} \\ \\ \text{Br} \\ \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 114 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-69-8 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-N-(3-butynyloxy)-3,4-difluoro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-N-(but-3-ynyloxy)-3,4-difluorobenzamide

FS 3D CONCORD

MF C18 H15 Br F2 N2 O2

SR CA

$$HC \equiv C - CH_2 - CH_2 - O - NH - C$$
 F
 $HC = CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH_2 - CH_2 - CH_2 - O - NH - C$
 $HC = CH_2 - CH$

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 115 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN **212630-68-7** REGISTRY
- CN Benzamide, N-(3-butynyloxy)-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

- CN N-(But-3-ynyloxy)-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide
- FS 3D CONCORD
- MF C18 H15 F2 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 116 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN, 212630-67-6 REGISTRY
- CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-[(1-methyl-2-propynyl)oxy]- (9CI) (CA INDEX NAME)

- CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(1-methylprop-2-ynyloxy)benzamide
- CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(1-methyl-2-propyn-1-yloxy)benzamide
- FS 3D CONCORD
- MF C18 H15 Br F2 N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 117 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-66-5 REGISTRY
- CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[(1-methyl-2-propynyl)oxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1-methylprop-2-ynyloxy)benzamide
- FS 3D CONCORD
- MF C18 H15 F2 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 118 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-65-4 REGISTRY
- CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(2-propynyloxy)(9CI) (CA INDEX NAME)

- CN 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)benzamide
- FS 3D CONCORD
- MF C17 H13 F2 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$HC \equiv C - CH_2 - O - NH - C$$
 F

Me

 F

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 119 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-64-3 REGISTRY
- CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(2-propynyloxy)(9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(prop-2-ynyloxy)benzamide
- FS 3D CONCORD
- MF C17 H14 F I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 120 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-63-2 REGISTRY
- CN Benzamide, 5-bromo-N-(2-butenyloxy)-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

- CN 5-Bromo-N-(but-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide
- FS 3D CONCORD
- MF C18 H16 Br F2 I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$Me-CH=CH-CH_2-O-NH-C$$

$$Br$$

$$F$$

$$Me$$

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 121 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-62-1 REGISTRY
- CN Benzamide, 5-bromo-3,4-difluoro-N-(3-furanylmethoxy)-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Bromo-3,4-difluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methylphenylamino)benzamide
- FS 3D CONCORD
- MF C19 H14 Br F2 I N2 O3
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 122 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-61-0 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-(3-furanylmethoxy)- (9CI) (CA INDEX NAME)

OTHER NAMES:
CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(furan-3-ylmethoxy)benzamide
FS 3D CONCORD

MF C19 H15 Br F2 N2 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 123 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-60-9 REGISTRY

CN Benzamide, 3,4-difluoro-N-(3-furanylmethoxy)-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C19 H15 F2 I N2 O3

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 124 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212630-59-6** REGISTRY

CN Benzamide, 4-fluoro-N-(3-furanylmethoxy)-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C19 H16 F I N2 O3

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 125 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-58-5 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-(1-methylethoxy)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-isopropoxybenzamide

FS 3D CONCORD

MF C17 H17 Br F2 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 126 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-57-4 REGISTRY

CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(1-

methylethoxy) - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-isopropoxybenzamide

FS 3D CONCORD

MF C17 H17 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 127 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-56-3 REGISTRY

CN Benzamide, 5-bromo-N-ethoxy-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-ethoxy-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C16 H14 Br F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 128 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-55-2 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-N-ethoxy-3,4-difluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-N-ethoxy-3,4-difluorobenzamide

FS 3D CONCORD

MF C16 H15 Br F2 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 129 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-54-1 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-methoxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-methoxybenzamide

FS 3D CONCORD

MF C15 H13 Br F2 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 130 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-53-0 REGISTRY

CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-methoxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-methoxybenzamide

FS 3D CONCORD

MF C15 H13 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 131 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-52-9 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-methoxy- (9CI) (CA

INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-methoxybenzamide

FS 3D CONCORD

MF C15 H14 F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 132 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-51-8 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(phenylmethoxy)(9CI) (CA INDEX NAME)

(9C1) (CA INDEX NAM. OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-phenylmethoxybenzamide

FS 3D CONCORD

MF C21 H18 F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 133 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-50-7 REGISTRY

CN Benzamide, 2-[(4-chloro-2-methylphenyl)amino]-4-fluoro-N-hydroxy- (9CI)

(CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-N-hydroxy-2-(4-chloro-2-methylphenylamino) benzamide

FS 3D CONCORD

MF C14 H12 Cl F N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 134 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-49-4 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-fluoro-2-methylphenyl)amino]-N-[(tetrahydro-2H-

pyran-2-yl)oxy] - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-fluoro-2-methylphenylamino)-N-(terahydro-2H-pyran-2-

yloxy) benzamide

CN 4-Fluoro-2-(4-fluoro-2-methylphenylamino)-N-(tetrahydropyran-2-

yloxy) benzamide

FS 3D CONCORD

MF C19 H20 F2 N2 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 135 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-48-3 REGISTRY
- CN Benzamide, 4-fluoro-N-hydroxy-2-[(2-methylphenyl)amino]- (9CI) (CA INDEX

NAME)

OTHER NAMES:

CN 4-Fluoro-N-hydroxy-2-(2-methylphenylamino)benzamide

FS 3D CONCORD

MF C14 H13 F N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 136 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-47-2 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-fluoro-2-methylphenyl)amino]-N-hydroxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-N-hydroxy-2-(4-fluoro-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C14 H12 F2 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 137 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-46-1 REGISTRY

CN Benzamide, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-N-methoxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-(4-iodo-2-methylphenylamino)-N-methoxybenzamide

FS 3D CONCORD

MF C15 H14 Cl I N2 O2

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 138 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-45-0 REGISTRY
- CN Benzamide, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Chloro-2-(4-iodo-2-methylphenylamino)-N-(terahydropyran-2-yloxy)benzamide
- FS 3D CONCORD
- MF C19 H20 Cl I N2 O3
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 139 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-44-9 REGISTRY
- CN Benzamide, 5-chloro-N-hydroxy-2-[(4-iodo-2-methylphenyl)amino]-N-methyl-(9CI) (CA INDEX NAME)

- CN 5-Chloro-N-hydroxy-2-(4-iodo-2-methylphenylamino)-N-methylbenzamide
- FS 3D CONCORD
- MF C15 H14 Cl I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 140 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212630-43-8** REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-4-fluoro-N-hydroxybenzamide

FS 3D CONCORD

MF C14 H12 Br F N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 141 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-42-7 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-N-hydroxy-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methylphenylamino)benzamide

CN PD 171984

FS 3D CONCORD

MF C14 H10 Br F2 I N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 142 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-41-6 REGISTRY

CN Benzamide, 4-fluoro-N-hydroxy-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Methyl-4-iodophenylamino)-N-hydroxy-4-fluorobenzamide

CN 4-Fluoro-N-hydroxy-2-(4-iodo-2-methylphenylamino)benzamide

CN PD 170611

FS 3D CONCORD

MF C14 H12 F I N2 O2

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 143 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-40-5 REGISTRY

CN Benzenamine, 4-iodo-2-methyl-N-[4-nitro-2-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN [4-Nitro-2-(1H-tetrazol-5-yl)-phenyl]-(4-iodo-2-methylphenyl)amine

FS 3D CONCORD

MF C14 H11 I N6 O2

SR CA

- 4 REFERENCES IN FILE CA (1967 TO DATE)
- 4 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 144 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-39-2 REGISTRY
- CN Benzenamine, 4-iodo-2-methyl-N-[2-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN (4-Iodo-2-methylphenyl) [2-(1H-tetrazol-5-yl)phenyl] amine
- FS 3D CONCORD
- MF C14 H12 I N5
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 145 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-38-1 REGISTRY
- CN Benzenamine, 4-chloro-N-(4-iodo-2-methylphenyl)-2-(1H-tetrazol-5-yl)-(9CI) (CA INDEX NAME)

- CN [4-Chloro-2-(1H-tetrazol-5-yl)phenyl]-(4-iodo-2-methylphenyl)amine
- FS 3D CONCORD
- DR 277315-11-4
- MF C14 H11 Cl I N5
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 146 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-37-0 REGISTRY

CN Benzamide, N-cyclohexyl-2-[(4-iodo-2-methylphenyl)amino]-5-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclohexyl-2-(4-iodo-2-methylphenylamino)-5-nitrobenzamide

FS 3D CONCORD

MF C20 H22 I N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 147 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-36-9 REGISTRY

CN Benzamide, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-(4-iodo-2-methylphenylamino)-N-(3-methylbenzyl)benzamide

FS 3D CONCORD

MF C22 H20 Cl I N2 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 148 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-35-8 REGISTRY

CN Benzamide, 5-bromo-N-cyclohexyl-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-cyclohexyl-2-(4-iodo-2-methylphenylamino) benzamide

FS 3D CONCORD

MF C20 H22 Br I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 149 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-34-7 REGISTRY
- CN Benzamide, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(4-iodo-2-methylphenylamino)-N-(3-methylbenzyl)benzamide

FS 3D CONCORD

MF C22 H20 Br I N2 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 150 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-33-6 REGISTRY

CN Benzamide, 5-chloro-N-cyclohexyl-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-N-cyclohexyl-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C20 H22 Cl I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 151 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-32-5 REGISTRY

CN Benzamide, N-cyclohexyl-5-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclohexyl-5-fluoro-2-(4-iodo-2-methylphenylamino) benzamide

FS 3D CONCORD

MF C20 H22 F I N2 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 152 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-31-4 REGISTRY

CN Benzamide, 5-iodo-2-[(4-iodo-2-methylphenyl)amino]-N-methyl-N-phenyl-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Iodo-2-(4-iodo-2-methylphenylamino)-N-methyl-N-phenylbenzamide

FS 3D CONCORD

MF C21 H18 I2 N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 153 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-30-3 REGISTRY

CN Benzamide, 2-[(4-iodo-2-methylphenyl)amino]-N-[(3-methylphenyl)methyl]-5-nitro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Iodo-2-methylphenylamino)-N-(3-methylbenzyl)-5-nitrobenzamide

FS 3D CONCORD

MF C22 H20 I N3 O3

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 154 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-29-0 REGISTRY

CN Benzamide, 5-iodo-2-[(4-iodo-2-methylphenyl)amino]-N-[(3-

methylphenyl) methyl] - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Iodo-2-(4-iodo-2-methylphenylamino)-N-(3-methylbenzyl)benzamide

FS 3D CONCORD

MF C22 H20 I2 N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 155 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-28-9 REGISTRY

CN Benzamide, 5-iodo-2-[(4-iodo-2-methylphenyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Allyl-5-iodo-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C17 H16 I2 N2 O

SR CA

$$H_2C = CH - CH_2 - NH - C$$

Me

NH

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 156 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-27-8 REGISTRY
- CN Benzamide, N-cyclohexyl-5-iodo-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN N-Cyclohexyl-5-iodo-2-(4-iodo-2-methylphenylamino) benzamide
- FS 3D CONCORD
- MF C20 H22 I2 N2 O
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 157 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-26-7 REGISTRY
- CN Benzamide, 2-[(4-iodo-2-methylphenyl)amino]-5-nitro-N-(phenylmethoxy)-(9CI) (CA INDEX NAME)

- CN N-Benzyloxy-2-(4-iodo-2-methylphenylamino)-5-nitrobenzamide
- FS 3D CONCORD
- MF C21 H18 I N3 O4
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 158 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-25-6 REGISTRY

CN Benzamide, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]-N-methyl-N-phenyl-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(4-iodo-2-methylphenylamino)-N-methyl-N-phenylbenzamide

FS 3D CONCORD

MF C21 H18 Br I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 159 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212630-24-5** REGISTRY

CN Benzamide, N-cyclopropyl-5-iodo-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopropyl-5-iodo-2-(4-iodo-2-methylphenylamino) benzamide

FS 3D CONCORD

MF C17 H16 I2 N2 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 160 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-23-4 REGISTRY

CN Benzamide, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[(3-

methylphenyl) methyl] - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(3-methylbenzyl)benzamide

FS 3D CONCORD

MF C22 H20 F I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 161 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-22-3 REGISTRY

CN Benzamide, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Ally1-5-bromo-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C17 H16 Br I N2 O

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 162 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-21-2 REGISTRY
- CN Benzamide, 2-[(4-iodo-2-methylphenyl)amino]-5-nitro-N-2-propenyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN N-Allyl-2-(4-iodo-2-methylphenylamino)-5-nitrobenzamide
- FS 3D CONCORD
- MF C17 H16 I N3 O3
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$O_2N$$

NH

 $C-NH-CH_2-CH=CH_2$
 O

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 163 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-20-1 REGISTRY
- CN Benzamide, N-[[4-(aminosulfonyl)phenyl]methyl]-5-bromo-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

- CN 5-Bromo-2-(4-iodo-2-methylphenylamino)-N-(4-sulfamoylbenzyl)benzamide
- FS 3D CONCORD
- MF C21 H19 Br I N3 O3 S
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & & & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ &$$

8 REFERENCES IN FILE CA (1967 TO DATE) 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 164 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212630-19-8** REGISTRY

CN Benzamide, N-[[4-(aminosulfonyl)phenyl]methyl]-5-iodo-2-[(4-iodo-2methylphenyl)amino]- (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 5-Iodo-2-(4-iodo-2-methylphenylamino)-N-(4-sulfamoylbenzyl)benzamide

FS 3D CONCORD

MF C21 H19 I2 N3 O3 S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & & & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 165 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-18-7 REGISTRY

CN Benzamide, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-N-methyl-N-phenyl-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-(4-iodo-2-methylphenylamino)-N-methyl-N-phenylbenzamide

FS 3D CONCORD

MF C21 H18 Cl I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 166 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-17-6 REGISTRY

CN Benzamide, 5-bromo-N-cyclopropyl-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-cyclopropyl-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C17 H16 Br I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 167 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-16-5 REGISTRY

CN Benzamide, N-cyclopropyl-2-[(4-iodo-2-methylphenyl)amino]-5-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Cyclopropyl-2-(4-iodo-2-methylphenylamino)-5-nitrobenzamide

FS 3D CONCORD

MF C17 H16 I N3 O3

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 168 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-15-4 REGISTRY

CN Benzamide, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Allyl-5-chloro-2-(4-iodo-2-methylphenylamino) benzamide

FS 3D CONCORD

MF C17 H16 Cl I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$H_2C = CH - CH_2 - NH - C$$
 $C1$
 Me
 NH
 I

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 169 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-14-3 REGISTRY

CN Benzamide, N-[[4-(aminosulfonyl)phenyl]methyl]-5-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(4-sulfamoylbenzyl)benzamide

FS 3D CONCORD

MF C21 H19 F I N3 O3 S

SR CA

$$\begin{array}{c|c} & & & & & & \\ & & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 170 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-13-2 REGISTRY

CN Benzamide, 5-iodo-2-[(4-iodo-2-methylphenyl)amino]-N-(phenylmethoxy)(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Benzyloxy-5-iodo-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C21 H18 I2 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 171 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-12-1 REGISTRY

CN Benzamide, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Allyl-5-fluoro-2-(4-iodo-2-methylphenylamino) benzamide

FS 3D CONCORD

MF C17 H16 F I N2 O

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 172 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN **212630-11-0** REGISTRY
- CN Benzamide, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-methyl-N-phenyl-(9CI) (CA INDEX NAME)

(

OTHER NAMES:

- CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)-N-methyl-N-phenylbenzamide
- FS 3D CONCORD
- MF C21 H18 F I N2 O
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 173 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN **212630-10-9** REGISTRY
- CN Benzamide, 5-chloro-N-cyclopropyl-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

- CN 5-Chloro-N-cyclopropyl-2-(4-iodo-2-methylphenylamino) benzamide
- FS 3D CONCORD
- MF C17 H16 Cl I N2 O
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 174 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-09-6 REGISTRY

CN Benzamide, 2-[(4-iodo-2-methylphenyl)amino]-N-methyl-5-nitro-N-phenyl-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Iodo-2-methylphenylamino)-N-methyl-5-nitro-N-phenylbenzamide

FS 3D CONCORD

MF C21 H18 I N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & & & \\ \text{NH} & & \\ \text{NH} & & \\ \text{C-N-Me} & \\ \parallel & \parallel \\ \text{O Ph} & \\ \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 175 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-08-5 REGISTRY

CN Benzamide, N-(2-hydroxyethyl)-2-[(4-iodo-2-methylphenyl)amino]-5-nitro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-(2-Hydroxyethyl)-2-(4-iodo-2-methylphenylamino)-5-nitrobenzamide

FS 3D CONCORD

MF C16 H16 I N3 O4

SR CA

$$O_2N$$
 $C-NH-CH_2-CH_2-OH$

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 176 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN **212630-07-4** REGISTRY
- CN Benzamide, N-(2-hydroxyethyl)-5-iodo-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

- CN N-(2-Hydroxyethyl)-5-iodo-2-(4-iodo-2-methylphenylamino)benzamide
- FS 3D CONCORD
- MF C16 H16 I2 N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} \mathsf{NH} & \mathsf{NH} \\ \mathsf{NH}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 177 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-06-3 REGISTRY
- CN Benzamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-[(4-iodo-2-methylphenyl)amino]-5-nitro-(9CI) (CA INDEX NAME)

- CN 2-(4-Iodo-2-methylphenylamino)-5-nitro-N-(4-sulfamoylbenzyl)benzamide
- FS 3D CONCORD
- MF C21 H19 I N4 O5 S
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 178 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212630-05-2 REGISTRY

CN Benzamide, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]-N-(phenylmethoxy)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Benzyloxy-5-bromo-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C21 H18 Br I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 179 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212630-04-1** REGISTRY

CN Benzamide, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(phenylmethoxy)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Benzyloxy-5-fluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C21 H18 F I N2 O2

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 180 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212630-03-0 REGISTRY
- CN Benzamide, 5-fluoro-N-(2-hydroxyethyl)-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Fluoro-N-(2-hydroxyethyl)-2-(4-iodo-2-methylphenylamino)benzamide
- FS 3D CONCORD
- MF C16 H16 F I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 181 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN **212630-00-7** REGISTRY
- CN Benzamide, N-cyclopropyl-5-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

- CN N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methylphenylamino) benzamide
- FS 3D CONCORD
- MF C17 H16 F I N2 O
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE) 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 182 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-99-7 REGISTRY

CN 5-Chloro-2-(4-iodo-2-methylphenylamino)thiobenzoic acid S-benzyl ester

FS 3D CONCORD

MF C21 H17 Cl I N O S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} \text{Ph-CH}_2\text{-s-c} & \text{Me} \\ \hline \\ \text{Cl} & \\ \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 183 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-98-6 REGISTRY

CN Benzenecarbothioic acid, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-, S-(phenylmethyl) ester (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)thiobenzoic acid S-benzyl ester

FS 3D CONCORD

MF C21 H17 F I N O S

SR CA

$$\begin{array}{c|c} O & \\ \hline Ph-CH_2-S-C & Me \\ \hline \end{array}$$

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 184 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212629-95-3 REGISTRY
- CN Benzenecarbothioic acid, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-, S-(2-phenylethyl) ester (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Chloro-2-(4-iodo-2-methylphenylamino)thiobenzoic acid S-phenethyl ester
- FS 3D CONCORD
- MF C22 H19 Cl I N O S
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 185 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212629-94-2 REGISTRY
- CN Benzenecarbothioic acid, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-,
 S-(2-phenylethyl) ester (9CI) (CA INDEX NAME)

- CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)thiobenzoic acid S-phenethyl ester
- FS 3D CONCORD
- MF C22 H19 F I N O S
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

ANSWER 186 OF 327 REGISTRY COPYRIGHT 2002 ACS L2

RN212629-93-1 REGISTRY

CN Benzamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-fluoro-2-[(4-iodo-2methylphenyl)amino] - (9CI) (CA INDEX NAME)

OTHER NAMES:

N-(2-Diisopropylaminoethyl)-5-fluoro-2-(4-iodo-2-CNmethylphenylamino) benzamide

FS 3D CONCORD

MF C22 H29 F I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 187 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-92-0 REGISTRY

CNBenzamide, N-[3-(dimethylamino)propyl]-2-[(4-iodo-2-methylphenyl)amino]-5nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

N-(3-Dimethylaminopropyl)-2-(4-iodo-2-methylphenylamino)-5-nitrobenzamide CN

FS 3D CONCORD

C19 H23 I N4 O3 MF

SR CA

$$O_2N$$

NH

 $C-NH-(CH_2)_3-NMe_2$

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 188 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212629-91-9 REGISTRY
- CN Benzamide, 2-[(4-iodo-2-methylphenyl)amino]-5-nitro-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 2-(4-Iodo-2-methylphenylamino)-5-nitro-N-(2-pyrrolidin-1-ylethyl)benzamide
- FS 3D CONCORD
- MF C20 H23 I N4 O3
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 189 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212629-90-8 REGISTRY
- CN Benzamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

- CN N-(3-Diethylamino-2-hydroxypropyl)-5-fluoro-2-(4-iodo-2-methylphenylamino)benzamide
- CN N-[3-(N,N-Diethylamino)-2-hydroxypropyl]-5-fluoro-2-(4-iodo-2-

methylphenylamino) benzamide

FS 3D CONCORD

MF C21 H27 F I N3 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} \text{OH} & \text{O} \\ | & | \\ \text{Et}_2\text{N-CH}_2\text{-CH-CH}_2\text{-NH-C} & \text{Me} \\ \hline \\ \text{F} & \\ \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 190 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-89-5 REGISTRY

CN Benzamide, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(3-piperidin-1-ylpropyl)benzamide

FS 3D CONCORD

MF C22 H27 F I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 191 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-88-4 REGISTRY

CN Benzamide, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(2-morpholin-4-ylethyl)benzamide

FS 3D CONCORD

MF C20 H23 F I N3 O2

SR CA

$$\begin{array}{c|c} F & \begin{array}{c} O \\ C - NH - CH_2 - CH_2 - N \end{array} \end{array}$$

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 192 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-87-3 REGISTRY

CN Benzamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-bromo-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-(2-diisopropylaminoethyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C22 H29 Br I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} \text{(i-Pr)}_{2}\text{N-CH}_{2}\text{-CH}_{2}\text{-NH-C} & \text{Me} \\ \\ \text{Br} & \\ \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 193 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212629-86-2** REGISTRY

CN Benzamide, 2-[(4-iodo-2-methylphenyl)amino]-5-nitro-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Iodo-2-methylphenylamino)-5-nitro-N-(3-piperidin-1-ylpropyl)benzamide

FS 3D CONCORD

MF C22 H27 I N4 O3

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 194 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN **212629-85-1** REGISTRY
- CN Benzamide, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(4-

morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Bromo-2-(4-iodo-2-methylphenylamino)-N-(2-morpholin-4-ylethyl)benzamide
- FS 3D CONCORD
- MF C20 H23 Br I N3 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 195 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212629-84-0 REGISTRY
- CN Benzamide, N-[3-(diethylamino)propyl]-2-[(4-iodo-2-methylphenyl)amino]-5-nitro-(9CI) (CA INDEX NAME)

OTHER NAMES:

- CN N-(3-Diethylaminopropyl)-2-(4-iodo-2-methylphenylamino)-5-nitrobenzamide
- FS 3D CONCORD
- MF C21 H27 I N4 O3
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$O_2N$$

NH

 $C-NH-(CH_2)_3-NEt_2$

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 196 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212629-83-9 REGISTRY
- CN Benzamide, N-[3-(diethylamino)propyl]-5-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN N-(3-Diethylaminopropyl)-5-fluoro-2-(4-iodo-2-methylphenylamino)benzamide
- FS 3D CONCORD
- MF C21 H27 F I N3 O
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c} \text{Et}_2\text{N-} (\text{CH}_2)_3 - \text{NH-C} \\ \\ \text{F} \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 197 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212629-82-8 REGISTRY
- CN Benzamide, 5-fluoro-N-(3-hydroxypropyl)-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Fluoro-N-(3-hydroxypropyl)-2-(4-iodo-2-methylphenylamino)benzamide
- FS 3D CONCORD
- MF C17 H18 F I N2 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 198 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212629-81-7** REGISTRY

CN Benzamide, N-(3-hydroxypropyl)-2-[(4-iodo-2-methylphenyl)amino]-5-nitro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-(3-Hydroxypropyl)-2-(4-iodo-2-methylphenylamino)-5-nitrobenzamide

FS 3D CONCORD

MF C17 H18 I N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 199 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-80-6 REGISTRY

CN Benzamide, 5-bromo-N-[3-(dimethylamino)propyl]-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-(3-dimethylaminopropyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C19 H23 Br I N3 O

SR CA

Br
$$C-NH-(CH_2)_3-NMe_2$$

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 200 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-79-3 REGISTRY

CN Benzamide, N-[2-(diethylamino)ethyl]-5-fluoro-2-[(4-iodo-2-

methylphenyl)amino] - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-(2-Diethylaminoethyl)-5-fluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C20 H25 F I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} \mathsf{Et}_2\mathsf{N}-\mathsf{CH}_2-\mathsf{CH}_2-\mathsf{NH}-\mathsf{C} & \mathsf{Me} \\ \hline \\ \mathsf{F} & \mathsf{NH} & \mathsf{NH} \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 201 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-78-2 REGISTRY

CN Benzamide, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-

piperazinyl)ethyl] - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(4-iodo-2-methylphenylamino)-N-(2-piperazin-1-ylethyl)benzamide

FS 3D CONCORD

MF C20 H24 Br I N4 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 202 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-77-1 REGISTRY

CN Benzamide, 2-[(4-iodo-2-methylphenyl)amino]-5-nitro-N-[2-(1-

piperidinyl)ethyl] - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Iodo-2-methylphenylamino)-5-nitro-N-(2-piperidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C21 H25 I N4 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} O_2N & & O\\ & & \\ C-NH-CH_2-CH_2-N \\ & & \\ NH & & \\$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 203 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-75-9 REGISTRY

CN Benzamide, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-(4-iodo-2-methylphenylamino)-N-(3-piperidin-1-ylpropyl)benzamide

FS 3D CONCORD

MF C22 H27 Cl I N3 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE) 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 204 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-73-7 REGISTRY

CN Benzamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-chloro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-N-(2-diisopropylaminoethyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C22 H29 Cl I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 205 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-71-5 REGISTRY

CN Benzamide, 5-chloro-N-[3-(diethylamino)propyl]-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-N-(3-diethylaminopropyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C21 H27 Cl I N3 O

SR CA

$$Et_{2}N-(CH_{2})_{3}-NH-C \qquad Me$$

$$C1 \qquad NH$$

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 206 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN **212629-69-1** REGISTRY
- CN Benzamide, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Chloro-2-(4-iodo-2-methylphenylamino)-N-(2-morpholin-4-ylethyl)benzamide
- FS 3D CONCORD
- MF C20 H23 Cl I N3 O2
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 207 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212629-68-0 REGISTRY
- CN Benzamide, N-[2-[bis(2-hydroxyethyl)amino]ethyl]-2-[(4-iodo-2-methylphenyl)amino]-5-nitro-(9CI) (CA INDEX NAME)

OTHER NAMES:

- CN N-[2-[Bis(2-hydroxyethyl)amino]ethyl]-2-(4-iodo-2-methylphenylamino)-5-nitrobenzamide
- FS 3D CONCORD
- MF C20 H25 I N4 O5
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 208 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-66-8 REGISTRY

CN Benzamide, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(4-iodo-2-methylphenylamino)-N-(3-piperidin-1-ylpropyl)benzamide

FS 3D CONCORD

MF C22 H27 Br I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 209 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-64-6 REGISTRY

CN Benzamide, 5-bromo-N-(3-hydroxypropyl)-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-(3-hydroxypropyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C17 H18 Br I N2 O2

SR CA

8. REFERENCES IN FILE CA (1967 TO DATE) 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 210 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-62-4 REGISTRY

CN Benzamide, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(2-piperidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C21 H25 F I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 211 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-60-2 REGISTRY

CN Benzamide, 5-chloro-N-[3-(diethylamino)-2-hydroxypropyl]-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-N-(3-diethylamino-2-hydroxypropyl)-2-(4-iodo-2-methylphenylamino)benzamide

CN 5-Chloro-N-[3-(N,N-diethylamino)-2-hydroxypropyl]-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C21 H27 Cl I N3 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2ANSWER 212 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-58-8 REGISTRY

CN Benzamide, 5-chloro-N-(3-hydroxypropy1)-2-[(4-iodo-2-methylpheny1)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-N-(3-hydroxypropyl)-2-(4-iodo-2-methylphenylamino) benzamide

FS 3D CONCORD

C17 H18 Cl I N2 O2 MF

SR CA

LC CA, CAPLUS, TOXCENTER, USPATFULL STN Files:

HO-
$$(CH_2)_3$$
-NH-C Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L₂ ANSWER 213 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-56-6 REGISTRY

Benzamide, N-[2-[bis(2-hydroxyethyl)amino]ethyl]-5-fluoro-2-[(4-iodo-2-CN methylphenyl)amino] - (9CI) (CA INDEX NAME)

OTHER NAMES:

N-[2-[Bis(2-hydroxyethyl)amino]ethyl]-5-fluoro-2-(4-iodo-2-CN methylphenylamino) benzamide

FS 3D CONCORD

C20 H25 F I N3 O3 ΜF

SR CA

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 214 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212629-54-4 REGISTRY
- CN Benzamide, 5-chloro-N-[3-(dimethylamino)propyl]-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Chloro-N-(3-dimethylaminopropyl)-2-(4-iodo-2-methylphenylamino)benzamide
- FS 3D CONCORD
- MF C19 H23 Cl I N3 O
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & \text{Me} \\ & \text{NH} \\ \hline & \text{C-NH-(CH}_2)_3 - \text{NMe}_2 \\ \parallel & \text{O} \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 215 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212629-52-2 REGISTRY
- CN Benzamide, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

- CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(2-pyrrolidin-1-ylethyl)benzamide
- FS 3D CONCORD
- MF C20 H23 F I N3 O
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 216 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-50-0 REGISTRY

CN Benzamide, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(4-iodo-2-methylphenylamino)-N-(2-piperidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C21 H25 Br I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 217 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-48-6 REGISTRY

CN Benzamide, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(4-iodo-2-methylphenylamino)-N-(2-pyrrolidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C20 H23 Br I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 218 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-47-5 REGISTRY

CN Benzamide, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(4-pyridinylmethyl)(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)-N-pyridin-4-ylmethylbenzamide

FS 3D CONCORD

MF C20 H17 F I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 219 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-46-4 REGISTRY

CN Benzamide, N-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl]-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-[3-[4-(2-Hydroxyethyl)piperazin-1-yl]propyl]-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C23 H31 I N4 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$CH_2-CH_2-OH$$
 NH
 NH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE) 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 220 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-45-3 REGISTRY

CN Benzoic acid, 2-[(4-iodo-2-methylphenyl)amino]-5-nitro-, 2-phenylethyl ester (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Iodo-2-methylphenylamino)-5-nitrobenzoic acid phenethyl ester

FS 3D CONCORD

MF C22 H19 I N2 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} Me \\ \hline \\ NH \\ \hline \\ C-O-CH_2-CH_2-Ph \\ \hline \\ O \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 221 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-44-2 REGISTRY

CN Benzamide, N-[2-[bis(2-hydroxyethyl)amino]ethyl]-5-bromo-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-[2-[Bis(2-hydroxyethy1)amino]ethy1]-5-bromo-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C20 H25 Br I N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 222 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-43-1 REGISTRY

CN Benzamide, N-[2-[bis(2-hydroxyethyl)amino]ethyl]-5-chloro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-[2-[Bis(2-hydroxyethyl)amino]ethyl]-5-chloro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C20 H25 Cl I N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 223 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-42-0 REGISTRY

CN Benzamide, 5-bromo-N-[2-(diethylamino)ethyl]-2-[(4-iodo-2methylphenyl)amino]- (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 5-Bromo-N-(2-diethylaminoethyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C20 H25 Br I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} \mathbf{Et_2N-CH_2-CH_2-NH-C} & \mathbf{Me} \\ \hline \\ \mathbf{Br} & \mathbf{NH} \\ \hline \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 224 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212629-41-9** REGISTRY

CN Benzamide, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-(4-iodo-2-methylphenylamino)-N-(2-pyrrolidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C20 H23 Cl I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 225 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-40-8 REGISTRY

CN Benzamide, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-(4-iodo-2-methylphenylamino)-N-(2-piperidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C21 H25 Cl I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 226 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-39-5 REGISTRY

CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-[(4-iodo-2-

methylphenyl)amino] - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-N-(2-diethylaminoethyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C20 H25 Cl I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 227 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-38-4 REGISTRY

CN Benzamide, 5-bromo-N-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl]-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-[3-[4-(2-hydroxyethyl)piperazin-1-yl]-propyl]-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C23 H30 Br I N4 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Br
$$CH_2-CH_2-OH$$
 Me NH I

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 228 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-37-3 REGISTRY

CN Benzamide, 2-[(4-iodo-2-methylphenyl)amino]-5-nitro-N-(4-pyridinylmethyl)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Iodo-2-methylphenylamino)-5-nitro-N-pyridin-4-ylmethylbenzamide

FS 3D CONCORD

MF C20 H17 I N4 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 229 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-36-2 REGISTRY

CN Benzamide, 5-fluoro-N-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl]-2-[(4iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 5-Fluoro-N-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C23 H30 F I N4 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 230 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-35-1 REGISTRY

CN Benzamide, 5-chloro-N-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl]-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-N-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C23 H30 Cl I N4 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

C1
$$CH_2-CH_2-OH$$

Me

NH

I

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 231 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-34-0 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(2-piperidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C21 H24 Br F2 N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 232 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-33-9 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-phenethylbenzamide

FS 3D CONCORD

MF C22 H19 Br F2 N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 233 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-32-8 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-pyridin-4-ylmethylbenzamide

FS 3D CONCORD

MF C20 H16 Br F2 N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 234 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212629-31-7** REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(2-thiophen-2-ylethyl)benzamide

FS 3D CONCORD

MF C20 H17 Br F2 N2 O S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & \text{Br} & \text{NH} \\ & \text{Me} & \text{O} \\ & \text{CH}_2 - \text{CH}_2 - \text{NH} - \text{C} \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 235 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-30-6 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(2-phenylethyl)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-phenethylbenzamide

FS 3D CONCORD

MF C22 H20 F I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 236 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-29-3 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(2-pyrrolidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C20 H22 Br F2 N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2ANSWER 237 OF 327 REGISTRY COPYRIGHT 2002 ACS

212629-28-2 REGISTRY RN

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-(3hydroxypropyl) - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(3-hydroxypropyl)benzamide

FS 3D CONCORD

MF C17 H17 Br F2 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2ANSWER 238 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-27-1 REGISTRY

Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-[2-(4-CN pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(2-pyridin-4ylethyl) benzamide

FS 3D CONCORD

MF C21 H18 Br F2 N3 O

SR

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 239 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-26-0 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(2-pyridin-4-ylethyl)benzamide

FS 3D CONCORD

MF C21 H19 F I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 240 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-25-9 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(4-pyridinylmethyl)(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-pyridin-4-ylmethylbenzamide

FS 3D CONCORD

MF C20 H17 F I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 241 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-24-8 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-N-[3-(dimethylamino)propyl]-3,4-difluoro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-N-(3-dimethylaminopropyl)-3,4-difluorobenzamide

FS 3D CONCORD

MF C19 H22 Br F2 N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$Me_2N-(CH_2)_3-NH-C$$
 Me
 NH
 F
 Br

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 242 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-23-7 REGISTRY

CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(4-

pyridinylmethyl) - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-pyridin-4-ylmethylbenzamide

FS 3D CONCORD

MF C20 H16 F2 I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 243 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-22-6 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-pyridin-4-ylmethylbenzamide

FS 3D CONCORD

MF C20 H15 Br F2 I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 244 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-21-5 REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(2-morpholin-4-ylethyl)benzamide

FS 3D CONCORD

MF C20 H22 Br F2 N3 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 245 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-20-4 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(2-pyrrolidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C20 H23 F I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 246 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-19-1 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(2-thiophen-2-ylethyl)benzamide

FS 3D CONCORD

MF C20 H18 F I N2 O S

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 247 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-18-0 REGISTRY

CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-(3-piperidin-1-ylpropyl)benzamide

FS 3D CONCORD

MF C22 H26 F2 I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 248 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-17-9 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(3-piperidin-1-ylpropyl)benzamide

FS 3D CONCORD

MF C22 H27 F I N3 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE) 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 249 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-16-8 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(4morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(2-morpholin-4-ylethyl)benzamide

FS 3D CONCORD

MF C20 H23 F I N3 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$C-NH-CH_2-CH_2-N$$

NH

Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 250 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212629-15-7** REGISTRY

CN Benzamide, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluoro-N-(2-hydroxyethyl)benzamide

FS 3D CONCORD

MF C16 H15 Br F2 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 251 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-14-6 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Benzyl-4-fluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C21 H18 F I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 252 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-13-5 REGISTRY

CN Benzamide, N-[3-(dimethylamino)propyl]-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-(3-Dimethylaminopropyl)-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C19 H22 F2 I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$Me_2N-(CH_2)_3-NH-C$$
 Me
 NH
 F

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 253 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-12-4 REGISTRY

CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-(2-pyridin-4-ylethyl)benzamide

FS 3D CONCORD

MF C21 H18 F2 I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 254 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-11-3 REGISTRY

CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-(2-pyrrolidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C20 H22 F2 I N3 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 255 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-10-2 REGISTRY

CN Benzamide, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)-N-(2-morpholin-4-ylethyl)benzamide

FS 3D CONCORD

MF C20 H22 F2 I N3 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 256 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212629-09-9 REGISTRY
- CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

 OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-(2-morpholin-4-ylethyl)benzamide

FS 3D CONCORD

MF C20 H21 Br F2 I N3 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 257 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-08-8 REGISTRY

CN Benzamide, 5-bromo-N-[3-(dimethylamino)propyl]-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-(3-dimethylaminopropyl)-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C19 H21 Br F2 I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$Me_2N-(CH_2)_3-NH-C$$
 Br
 F
 Me
 NH
 I

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 258 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-07-7 REGISTRY

CN Benzamide, 4-fluoro-N-(2-hydroxyethyl)-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-N-(2-hydroxyethyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C16 H16 F I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 259 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-06-6 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-(2-pyridin-4-ylethyl)benzamide

FS 3D CONCORD

MF C21 H17 Br F2 I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 260 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-05-5 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-(2-pyrrolidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C20 H21 Br F2 I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 261 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-04-4 REGISTRY

CN Benzamide, 3,4-difluoro-N-(3-hydroxypropyl)-2-[(4-iodo-2-

methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-N-(3-hydroxypropyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C17 H17 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

HO-
$$(CH_2)_3$$
-NH-C Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 262 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-03-3 REGISTRY

CN Benzamide, N-(2,3-dihydroxypropyl)-4-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-(2,3-Dihydroxypropyl)-4-fluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C17 H18 F I N2 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 263 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-02-2 REGISTRY

CN Benzamide, 3,4-difluoro-N-(2-hydroxyethyl)-2-[(4-iodo-2-

methylphenyl)amino] - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-N-(2-hydroxyethyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C16 H15 F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} \mathsf{NH} & \mathsf{NH} \\ & \mathsf{NH} \\ & \mathsf{F} \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 264 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-01-1 REGISTRY

CN Benzamide, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-N-[2-(1-

piperidinyl)ethyl] - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-N-(2-piperidin-1-ylethyl)benzamide

FS 3D CONCORD

MF C21 H23 Br F2 I N3 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 265 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212629-00-0 REGISTRY

CN Benzamide, N-(2,3-dihydroxypropyl)-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-(2,3-Dihydroxypropyl)-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C17 H17 F2 I N2 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} \text{OH} & \text{O} \\ | & \text{I} \\ \text{HO-CH}_2-\text{CH-CH}_2-\text{NH-C} & \text{Me} \\ \hline & & \text{F} \\ \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 266 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212628-99-4 REGISTRY
- CN Benzamide, 5-bromo-3,4-difluoro-N-(2-hydroxyethyl)-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-N-(2-hydroxyethyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C16 H14 Br F2 I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} \mathsf{O} & & \mathsf{O} \\ \mathsf{HO-CH_2-CH_2-NH-C} & & \mathsf{Me} \\ \hline \\ \mathsf{Br} & & \mathsf{F} \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 267 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-98-3 REGISTRY

CN Benzenemethanol, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN [5-Bromo-2-(4-iodo-2-methylphenylamino)phenyl]methanol

FS 3D CONCORD

MF C14 H13 Br I N O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 268 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-97-2 REGISTRY

CN Benzenemethanol, 2-[(4-iodo-2-methylphenyĺ)amino]-5-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN [2-(4-Iodo-2-methylphenylamino)-5-nitrophenyl]methanol

FS 3D CONCORD

MF C14 H13 I N2 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 269 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212628-96-1** REGISTRY

CN Benzenemethanol, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN [5-Chloro-2-(4-iodo-2-methylphenylamino)phenyl]methanol

FS 3D CONCORD

MF C14 H13 Cl I N O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 270 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-95-0 REGISTRY

CN Benzenemethanol, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)benzyl alcohol

FS 3D CONCORD

MF C14 H13 F I N O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 271 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-94-9 REGISTRY

CN Benzamide, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(4-iodo-2-methylphenylamino)-N,N-dimethylbenzamide

FS 3D CONCORD

MF C16 H16 Br I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 272 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-93-8 REGISTRY

CN Benzamide, 5-chloro-N, N-diethyl-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-N, N-diethyl-2-(4-iodo-2-methylphenylamino) benzamide

FS 3D CONCORD

MF C18 H20 Cl I N2 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 273 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-92-7 REGISTRY

CN Benzamide, N-butyl-4-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Butyl-4-fluoro-2-(4-iodo-2-methylphenylamino) benzamide

FS 3D CONCORD

MF C18 H20 F I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 274 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-91-6 REGISTRY

CN Benzamide, N, N-diethyl-2-[(4-iodo-2-methylphenyl)amino]-5-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N, N-Diethyl-2-(4-iodo-2-methylphenylamino)-5-nitrobenzamide

FS 3D CONCORD

MF C18 H20 I N3 O3

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 275 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-90-5 REGISTRY

CN Benzamide, 4-fluoro-N-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl]-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-N-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C23 H30 F I N4 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} & & & \\ &$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 276 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-89-2 REGISTRY

CN Benzamide, N,N-diethyl-4-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N, N-Diethyl-4-fluoro-2-(4-iodo-2-methylphenylamino) benzamide

FS 3D CONCORD

MF C18 H20 F I N2 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 277 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212628-88-1** REGISTRY

CN Benzamide, 5-bromo-N-(2-hydroxyethyl)-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-N-(2-hydroxyethyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C16 H16 Br I N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} \mathsf{O} & & \mathsf{O} \\ \mathsf{HO-CH_2-CH_2-NH-C} & & \mathsf{Me} \\ & & & \mathsf{NH-Me} \\ & & \mathsf{Br} & & \mathsf{I} \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 278 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-87-0 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-propyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-propylbenzamide

FS 3D CONCORD

MF C17 H18 F I N2 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 279 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212628-86-9** REGISTRY

CN Glycine, N-[5-chloro-2-[(4-iodo-2-methylphenyl)amino]benzoyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN [[5-Chloro-2-(4-iodo-2-methylphenylamino)benzoyl]amino]acetic acid

FS 3D CONCORD

MF C16 H14 Cl I N2 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$\begin{array}{c|c} O \\ HO_2C-CH_2-NH-C \\ \hline \\ C1 \\ \end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 280 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-85-8 REGISTRY

CN Benzamide, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-(4-iodo-2-methylphenylamino)-N, N-dimethylbenzamide

FS 3D CONCORD

MF C16 H16 Cl I N2 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 281 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-84-7 REGISTRY

CN Benzamide, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C14 H12 Br I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 282 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-83-6 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-1H-tetrazol-5-yl-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-(1H-tetrazol-5-yl)benzamide

FS 3D CONCORD

MF C15 H12 F I N6 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 283 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-82-5 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N,N-dimethylbenzamide

FS 3D CONCORD

MF C16 H16 F I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 284 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212628-81-4 REGISTRY

CN Benzamide, N-ethyl-4-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Ethyl-4-fluoro-2-(4-iodo-2-methylphenylamino) benzamide

FS 3D CONCORD

MF C16 H16 F I N2 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 285 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212628-80-3** REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]-N-methyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)-N-methylbenzamide

FS 3D CONCORD

MF C15 H14 F I N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 286 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-79-0 REGISTRY

CN Benzamide, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C14 H12 F I N2 O

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 287 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-78-9 REGISTRY

CN Benzamide, 4-methoxy-N-(4-methoxyphenyl)-3-nitro- (9CI) (CA INDEX NAME) OTHER NAMES:

CN 4-Methoxy-N-(4-methoxyphenyl)-3-nitrobenzamide

FS 3D CONCORD

MF C15 H14 N2 O5

SR CA

LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 288 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-77-8 REGISTRY

CN Benzamide, 5-chloro-N-(2-hydroxyethyl)-2-[(4-iodo-2-methylphenyl)amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-N-(2-hydroxyethyl)-2-(4-iodo-2-methylphenylamino)benzamide

FS 3D CONCORD

MF C16 H16 Cl I N2 O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE) 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 289 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-76-7 REGISTRY

CN Benzoic acid, 2-[(4-iodo-2-methylphenyl)amino]-4-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Iodo-2-methylphenylamino)-4-nitrobenzoic acid

FS 3D CONCORD

MF C14 H11 I N2 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 290 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-75-6 REGISTRY

CN Benzoic acid, 2-chloro-6-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-Chloro-6-(4-iodo-2-methylphenylamino) benzoic acid

FS 3D CONCORD

MF C14 H11 Cl I N O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 291 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **212628-74-5** REGISTRY

CN Benzoic acid, 2-[(4-iodo-2-methylphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Methyl-2-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C15 H14 I N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 292 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-73-4 REGISTRY

CN Benzoic acid, 4-fluoro-2-[(4-iodo-2,3-dimethylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(2,3-dimethyl-4-iodophenylamino)benzoic acid

FS 3D CONCORD

MF C15 H13 F I N O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 293 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-72-3 REGISTRY

CN Benzoic acid, 2-fluoro-6-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-Fluoro-6-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H11 F I N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 294 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-71-2 REGISTRY

CN Benzoic acid, 3-chloro-2-[(2-chloro-4-iodophenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3-Chloro-2-(2-chloro-4-iodophenylamino)benzoic acid

FS 3D CONCORD

MF C13 H8 Cl2 I N O2

SR CA

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 295 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-69-8 REGISTRY

CN Benzoic acid, 2-[(4-iodophenyl)amino]-5-methoxy- (9CI) (CA INDEX NAME) OTHER NAMES:

CN 2-(4-Iodophenylamino)-5-methoxybenzoic acid

FS 3D CONCORD

MF C14 H12 I N O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 296 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-67-6 REGISTRY

CN Benzoic acid, 2-[(3-chloro-4-iodo-2-methylphenyl)amino]-4-fluoro- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C14 H10 Cl F I N O2

SR CA

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 297 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-65-4 REGISTRY

CN Benzoic acid, 2,3,5-trifluoro-4-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2,3,5-Trifluoro-4-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H9 F3 I N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)

7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 298 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-63-2 REGISTRY

CN Benzoic acid, 5-iodo-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Iodo-2-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H11 I2 N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 299 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-62-1 REGISTRY

CN Benzoic acid, 5-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Fluoro-2-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H11 F I N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 300 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-61-0 REGISTRY

CN Benzoic acid, 2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H12 I N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 301 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-60-9 REGISTRY

CN Benzoic acid, 4-chloro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Chloro-2-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H11 Cl I N O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 302 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-59-6 REGISTRY

CN Benzoic acid, 3,4-difluoro-2-[(4-iodo-2-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(4-iodo-2-methoxyphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H10 F2 I N O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 303 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-58-5 REGISTRY

CN Benzoic acid, 3-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3-Fluoro-2-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H11 F I N O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 304 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-57-4 REGISTRY

CN Benzoic acid, 2-[(4-bromo-2-methylphenyl)amino]-3,4-difluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-3,4-difluorobenzoic acid

FS 3D CONCORD

MF C14 H10 Br F2 N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 305 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-56-3 REGISTRY

CN Benzoic acid, 2-[(2-bromo-4-iodophenyl)amino]-5-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Bromo-4-iodophenylamino)-5-nitrobenzoic acid

MF C13 H8 Br I N2 O4

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 306 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-55-2 REGISTRY

CN Benzoic acid, 2-[(4-bromo-2-methylphenyl)amino]-4-fluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Bromo-2-methylphenylamino)-4-fluorobenzoic acid

FS 3D CONCORD

MF C14 H11 Br F N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 307 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-54-1 REGISTRY

CN Benzoic acid, 2-[(2-fluoro-4-iodophenyl)amino]-5-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Fluoro-4-iodophenylamino)-5-nitrobenzoic acid

FS 3D CONCORD

MF C13 H8 F I N2 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 308 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-53-0 REGISTRY

CN Benzoic acid, 2-[(4-iodo-2-methylphenyl)amino]-5-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(4-Iodo-2-methylphenylamino)-5-nitrobenzoic acid

FS 3D CONCORD

MF C14 H11 I N2 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 309 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-52-9 REGISTRY

CN Benzoic acid, 4-fluoro-2-[(3-fluoro-4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(3-fluoro-4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H10 F2 I N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 310 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-51-8 REGISTRY

CN Benzoic acid, 2-[(2-chloro-4-iodophenyl)amino]-5-nitro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2-Chloro-4-iodophenylamino)-5-nitrobenzoic acid

FS 3D CONCORD

MF C13 H8 Cl I N2 O4

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 311 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-50-7 REGISTRY

CN Benzoic acid, 5-bromo-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-2-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H11 Br I N O2

SR · CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1967 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)
- L2 ANSWER 312 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 212628-49-4 REGISTRY
- CN Benzoic acid, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]-, monosodium salt (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Sodium 5-Chloro-2-(4-iodo-2-methylphenylamino) benzoate

MF C14 H11 Cl I N O2 . Na

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CRN (212628-48-3)

Na

8 REFERENCES IN FILE CA (1967 TO DATE) 8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 313 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-48-3 REGISTRY

CN Benzoic acid, 5-chloro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H11 Cl I N O2

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 314 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-47-2 REGISTRY

CN Benzoic acid, 5-chloro-2-[(2-chloro-4-iodophenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-(2-chloro-4-iodophenylamino)benzoic acid

FS 3D CONCORD

MF C13 H8 Cl2 I N O2

SR CA

8 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 315 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-46-1 REGISTRY

CN Benzoic acid, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Bromo-3,4-difluoro-2-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H9 Br F2 I N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11 REFERENCES IN FILE CA (1967 TO DATE)

10 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 316 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-45-0 REGISTRY

CN Benzoic acid, 3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4-Difluoro-2-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H10 F2 I N O2

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1967 TO DATE)

12 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 317 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-44-9 REGISTRY

CN Benzoic acid, 3,4,5-trifluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,4,5-Trifluoro-2-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H9 F3 I N O2

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1967 TO DATE)

10 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 318 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 212628-43-8 REGISTRY

CN Benzoic acid, 4-fluoro-2-[(4-iodo-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-Fluoro-2-(4-iodo-2-methylphenylamino)benzoic acid

FS 3D CONCORD

MF C14 H11 F I N O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1967 TO DATE)

10 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 319 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 176317-02-5 REGISTRY

CN Benzene, 1-bromo-2,3,4-trifluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1-Bromo-2,3,4-trifluorobenzene

```
3D CONCORD
FS
     C6 H2 Br F3
MF
     CA
SR
     STN Files:
                  CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, TOXCENTER, USPAT2,
LC
       USPATFULL
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
              25 REFERENCES IN FILE CA (1967 TO DATE)
              25 REFERENCES IN FILE CAPLUS (1967 TO DATE)
     ANSWER 320 OF 327 REGISTRY COPYRIGHT 2002 ACS
L2
     142805-58-1 REGISTRY
RN
     Kinase (phosphorylating), mitogen-activated protein kinase (9CI) (CA
CN
     INDEX NAME)
OTHER NAMES:
     c-Raf-1 protein kinase kinase
CN
CN
     ERKK
CN
     Extracellular signal-regulated kinase protein kinase
CN
     Gene fuz7 protein kinase
     Gene fuz7 serine/threonine tyrosine kinase
CN:
     Gene wis1 MAPK kinase
CN
CN
     MAP kinase kinase
     Map kinase kinase
CN
     MAP kinase kinase 1
CN
     MAP kinase kinase Wisl
CN
CN
     MAP2K
CN
     MAPK kinase
CN
     MAPK-activated protein kinase 2
     MAPK/ERK kinase
CN
CN
     MAPKK
     MARK kinase
CN
CN
     Mek
     MEK kinase
CN
CN
     MEK protein kinase
CN
     MEK tyrosine kinase
CN
     MEK-1 kinase
     MEK-1 protein kinase
CN
CN
     Microtubule-affinity-regulating kinase
CN
     Mitogen-activated protein kinase kinase
CN
     Mitogen-activated protein kinase kinase Mek
CN
     Mitogen-activated protein kinase/extracellular signal-regulated kinase
     kinase 1
CN
     p45 MAP kinase kinase
CN
     Protein kinase MEK
CN
     Protein kinase MEK-1
CN
     Protein kinase p45mapkk
CN
     Wis1 kinase
CN
     Wis1 MEK
     146410-92-6
DR
MF
     Unspecified
     MAN
CI
```

SR CA

LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA, CAPLUS, CIN, EMBASE, PROMT, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

2786 REFERENCES IN FILE CA (1967 TO DATE)

9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

2801 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 321 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN **96515-79-6** REGISTRY

CN Benzaldehyde, 5-chloro-2-fluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5-Chloro-2-fluorobenzaldehyde

FS 3D CONCORD

MF C7 H4 Cl F O

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1967 TO DATE)

13 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 322 OF 327 REGISTRY COPYRIGHT 2002 ACS

RN 79955-99-0 REGISTRY

CN Stromelysin 1 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN E.C. 3.4.24.17

CN Matrix metalloprotease 3

CN Matrix metalloproteinase 3

CN Matrix metalloproteinase MMP-3

CN MMP-3

CN Neutral proteoglycanase

CN Proteoglycanase

CN Stromelysin

CN Transin

DR 107087-03-6, 118368-07-3

MF Unspecified

CI MAN

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CEN, CIN, EMBASE, IPA, PROMT, TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

1814 REFERENCES IN FILE CA (1967 TO DATE)

26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1821 REFERENCES IN FILE CAPLUS (1967 TO DATE)

- L2 ANSWER 323 OF 327 REGISTRY COPYRIGHT 2002 ACS
- RN 57381-34-7 REGISTRY

CN Benzonitrile, 5-chloro-2-fluoro- (9CI) (CA INDEX NAME)

```
OTHER NAMES:
CN
     5-Chloro-2-fluorobenzonitrile
     3D CONCORD
FS
MF
     C7 H3 C1 F N
LC
     STN Files:
                 CA, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, IFICDB, IFIPAT,
       IFIUDB, TOXCENTER, USPATFULL
     Other Sources:
                    EINECS**
         (**Enter CHEMLIST File for up-to-date regulatory information)
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
              10 REFERENCES IN FILE CA (1967 TO DATE)
              10 REFERENCES IN FILE CAPLUS (1967 TO DATE)
    ANSWER 324 OF 327 REGISTRY COPYRIGHT 2002 ACS
L2
     13194-68-8 REGISTRY
RN
CN
     Benzenamine, 4-iodo-2-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
    o-Toluidine, 4-iodo- (6CI, 7CI, 8CI)
OTHER NAMES:
CN
    2-Amino-5-iodotoluene
CN
     4-Iodo-2-methylaniline
CN
     4-Iodo-o-toluidine
FS
     3D CONCORD
MF
     C7 H8 I N
CI
     COM
LC
                  BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,
     STN Files:
       CSCHEM, HODOC*, IFICDB, IFIPAT, IFIUDB, SPECINFO, TOXCENTER, USPAT2,
      USPATFULL
         (*File contains numerically searchable property data)
    Other Sources:
                    EINECS**
         (**Enter CHEMLIST File for up-to-date regulatory information)
       Me
  NH2
```

53 REFERENCES IN FILE CA (1967 TO DATE)

53 REFERENCES IN FILE CAPLUS (1967 TO DATE)

3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
L2
     ANSWER 325 OF 327 REGISTRY COPYRIGHT 2002 ACS
RN
     6723-30-4 REGISTRY
CN
    Hydroxylamine, O-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN
    Pyran-2-yloxyamine, tetrahydro- (7CI)
OTHER NAMES:
     2-(Aminoxy) tetrahydropyran
CN
CN
     2-Tetrahydropyranyloxyamine
     O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine
CN
     O-(Tetrahydropyran-2-yl)hydroxylamine
CN
     3D CONCORD
FS
     59968-87-5
DR
MF
     C5 H11 N O2
CI
     COM
LC
     STN Files:
                  BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS,
       CHEMINFORMRX, CSCHEM, IFICDB, IFIPAT, IFIUDB, SPECINFO, TOXCENTER,
       USPATFULL
         (*File contains numerically searchable property data)
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
             102 REFERENCES IN FILE CA (1967 TO DATE)
             102 REFERENCES IN FILE CAPLUS (1967 TO DATE)
               1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)
     ANSWER 326 OF 327 REGISTRY COPYRIGHT 2002 ACS
L2
     1583-58-0 REGISTRY
RN
     Benzoic acid, 2,4-difluoro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)
CN
OTHER NAMES:
     2,4-Difluorobenzoic acid
CN
     3D CONCORD
FS
     C7 H4 F2 O2
MF
CI
     COM
LC
     STN Files:
                  BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS,
       CHEMINFORMRX, CHEMLIST, CSCHEM, DETHERM*, SYNTHLINE, TOXCENTER,
       USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:
                     EINECS**
         (**Enter CHEMLIST File for up-to-date regulatory information)
          CO<sub>2</sub>H
```

87 REFERENCES IN FILE CA (1967 TO DATE)

87 REFERENCES IN FILE CAPLUS (1967 TO DATE) 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 327 OF 327 REGISTRY COPYRIGHT 2002 ACS RN **352-33-0** REGISTRY CN Benzene, 1-chloro-4-fluoro- (6CI, 8CI, 9CI) (CA INDEX NAME) OTHER NAMES: CN1-Chloro-4-fluorobenzene CN1-Fluoro-4-chlorobenzene CN4-Chlorofluorobenzene CN 4-Fluorochlorobenzene 4-Fluorophenyl chloride CN CN p-Chlorofluorobenzene p-Fluorochlorobenzene CNp-Monofluoromonochlorobenzene CNFS 3D CONCORD MF C6 H4 Cl F CI COM LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DETHERM*, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, SPECINFO, TOXCENTER, ULIDAT, USPATFULL (*File contains numerically searchable property data) Other Sources: EINECS**, NDSL**, TSCA**

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

303 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
303 REFERENCES IN FILE CAPLUS (1967 TO DATE)
69 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

(**Enter CHEMLIST File for up-to-date regulatory information)

=> fil hcapl
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 518.18 521.45

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 18:13:31 ON 07 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jun 2002 VOL 136 ISS 23 FILE LAST UPDATED: 5 Jun 2002 (20020605/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s e1-e327

53 13194-68-8/BI · 2794 142805-58-1/BI 87 1583-58-0/BI 25 176317-02-5/BI 10 212628-43-8/BI 10 212628-44-9/BI 12 212628-45-0/BI 11 212628-46-1/BI 8 212628-47-2/BI 8 212628-48-3/BI 8 212628-49-4/BI 8 212628-50-7/BI 8 212628-51-8/BI 8 212628-52-9/BI 8 212628-53-0/BI 8 212628-54-1/BI 8 212628-55-2/BI 8 212628-56-3/BI 8 212628-57-4/BI 8 212628-58-5/BI 8 212628-59-6/BI 8 212628-60-9/BI 8 212628-61-0/BI 8 212628-62-1/BI 8 212628-63-2/BI 7 212628-65-4/BI 7 212628-67-6/BI 8 212628-69-8/BI 7 212628-71-2/BI 8 212628-72-3/BI 8 212628-73-4/BI 8 212628-74-5/BI 8 212628-75-6/BI 8 212628-76~7/BI 8 212628-77-8/BI 8 212628-78-9/BI 8 212628-79-0/BI 8 212628-80-3/BI 8 212628-81-4/BI 8 212628-82-5/BI 8 212628-83-6/BI 8 212628-84-7/BI 8 212628-85-8/BI 8 212628-86-9/BI 8 212628-87-0/BI 8 212628-88-1/BI 8 212628-89-2/BI 8 212628-90-5/BI

8 212628-91-6/BI

```
8 212628-92-7/BI
8 212628-93-8/BI
8 212628-94-9/BI
8 212628-95-0/BI
8 212628-96-1/BI
8 212628-97-2/BI
8 212628-98-3/BI
8 212628-99-4/BI
8 212629-00-0/BI
8 212629-01-1/BI
8 212629-02-2/BI
8 212629-03-3/BI
8 212629-04-4/BI
8 212629-05-5/BI
8 212629-06-6/BI
8 212629-07-7/BI
8 212629-08-8/BI
8 212629-09-9/BI
8 212629-10-2/BI
8 212629-11-3/BI
8 212629-12-4/BI
8 212629-13-5/BI
8 212629-14-6/BI
8 212629-15-7/BI
8 212629-16-8/BI
8 212629-17-9/BI
8 212629-18-0/BI
8 212629-19-1/BI
8 212629-20-4/BI
8 212629-21-5/BI
8 212629-22-6/BI
8 212629-23-7/BI
8 212629-24-8/BI
8 212629-25-9/BI
8 212629-26-0/BI
8 212629-27-1/BI
8 212629-28-2/BI
8 212629-29-3/BI
8 212629-30-6/BI
8 212629-31-7/BI
8 212629-32-8/BI
8 212629-33-9/BI
8 212629-34-0/BI
8 212629-35-1/BI
8 212629-36-2/BI
8 212629-37-3/BI
8 212629-38-4/BI
8 212629-39-5/BI
8 212629-40-8/BI
8 212629-41-9/BI
8 212629-42-0/BI
8 212629-43-1/BI
8 212629-44-2/BI
8 212629-45-3/BI
8 212629-46-4/BI
8 212629-47-5/BI
8 212629-48-6/BI
8 212629-50-0/BI
8 212629-52-2/BI
8 212629-54-4/BI
```

8 212629-56-6/BI 8 212629-58-8/BI

```
8 212629-60-2/BI
8 212629-62-4/BI
8 212629-64-6/BI
8 212629-66-8/BI
8 212629-68-0/BI
8 212629-69-1/BI
8 212629-71-5/BI
8 212629-73-7/BI
8 212629-75-9/BI
8 212629-77-1/BI
8 212629-78-2/BI
8 212629-79-3/BI
8 212629-80-6/BI
8 212629-81-7/BI
8 212629-82-8/BI
8 212629-83-9/BI
8 212629-84-0/BI
8 212629-85-1/BI
8 212629-86-2/BI
8 212629-87-3/BI
8 212629-88-4/BI
8 212629-89-5/BI
8 212629-90-8/BI
8 212629-91-9/BI
8 212629-92-0/BI
8 212629-93-1/BI
8 212629-94-2/BI
8 212629-95-3/BI
8 212629-98-6/BI
8 212629-99-7/BI
8 212630-00-7/BI
8 212630-03-0/BI
8 212630-04-1/BI
8 212630-05-2/BI
8 212630-06-3/BI
8 212630-07-4/BI
8 212630-08-5/BI
8 212630-09-6/BI
8 212630-10-9/BI
8 212630-11-0/BI
8 212630-12-1/BI
8 212630-13-2/BI
8 212630-14-3/BI
8 212630-15-4/BI
8 212630-16-5/BI
8 212630-17-6/BI
8 212630-18-7/BI
8 212630-19-8/BI
8 212630-20-1/BI
8 212630-21-2/BI
8 212630-22-3/BI
8 212630-23-4/BI
8 212630-24-5/BI
8 212630-25-6/BI
8 212630-26-7/BI
8 212630-27-8/BI
8 212630-28-9/BI
8 212630-29-0/BI
8 212630-30-3/BI
8 212630-31-4/BI
```

8 212630-32-5/BI 8 212630-33-6/BI

```
8 212630-34-7/BI
8 212630-35-8/BI
8 212630-36-9/BI
8 212630-37-0/BI
8 212630-38-1/BI
8 212630-39-2/BI
4 212630-40-5/BI
8 212630-41-6/BI
8 212630-42-7/BI
8 212630-43-8/BI
8 212630-44-9/BI
8 212630-45-0/BI
8 212630-46-1/BI
8 212630-47-2/BI
8 212630-48-3/BI
8 212630-49-4/BI
8 212630-50-7/BI
8 212630-51-8/BI
8 212630-52-9/BI
8 212630-53-0/BI
8 212630-54-1/BI
8 212630-55-2/BI
8 212630-56-3/BI
8 212630-57-4/BI
8 212630-58-5/BI
8 212630-59-6/BI
8 212630-60-9/BI
8 212630-61-0/BI
8 212630-62-1/BI
8 212630-63-2/BI
8 212630-64-3/BI
8 212630-65-4/BI
8 212630-66-5/BI
8 212630-67-6/BI
8 212630-68-7/BI
8 212630-69-8/BI
8 212630-70-1/BI
8 212630-71-2/BI
8 212630-72-3/BI
8 212630-73-4/BI
8 212630-74-5/BI
8 212630-75-6/BI
8 212630-76-7/BI
8 212630-77-8/BI
8 212630-78-9/BI
8 212630-79-0/BI
8 212630-80-3/BI
8 212630-81-4/BI
8 212630-82-5/BI
8 212630-83-6/BI
8 212630-84-7/BI
8 212630-85-8/BI
8 212630-86-9/BI
8 212630-87-0/BI
8 212630-88-1/BI
8 212630-89-2/BI
8 212630-90-5/BI
7 212630-91-6/BI
8 212630-92-7/BI
8 212630-94-9/BI
8 212630-96-1/BI
```

8 212630-98-3/BI

```
8 212630-99-4/BI
 8 212631-00-0/BI
 8 212631-01-1/BI
 8 212631-02-2/BI
 8 212631-03-3/BI
8 212631-04-4/BI
8 212631-05-5/BI
 8 212631-06-6/BI
 8 212631-07-7/BI
 8 212631-08-8/BI
 8 212631-09-9/BI
 8 212631-13-5/BI
 8 212631-15-7/BI
 8 212631-28-2/BI
 8 212631-29-3/BI
 4 212631-30-6/BI
 4 212631-32-8/BI
 8 212631-33-9/BI
 4 212631-34-0/BI
 8 212631-35-1/BI
 8 212631-36-2/BI
 7 212631-37-3/BI
 7 212631-38-4/BI
 8 212631-39-5/BI
 8 212631-40-8/BI
 8 212631-41-9/BI
 8 212631-42-0/BI
 8 212631-43-1/BI
 8 212631-44-2/BI
 8 212631-45-3/BI
 8 212631-46-4/BI
 8 212631-47-5/BI
 8 212631-48-6/BI
 8 212631-49-7/BI
 8 212631-50-0/BI
 8 212631-51-1/BI
 8 212631-52-2/BI
 8 212631-54-4/BI
 8 212631-55-5/BI
 8 212631-56-6/BI
 8 212631-57-7/BI
 8 212631-58-8/BI
 8 212631-59-9/BI
8 212631-60-2/BI
12 212631-61-3/BI
8 212631-62-4/BI
 8 212631-63-5/BI
 8 212631-64-6/BI
 8 212631-65-7/BI
 8 212631-66-8/BI
 8 212631-67-9/BI
 8 212631-68-0/BI
8 212631-69-1/BI
7 212631-70-4/BI
 8 212631-71-5/BI
 8 212631-72-6/BI
 8 212631-73-7/BI
8 212631-75-9/BI
8 212631-76-0/BI
8 212631-77-1/BI
9 212631-78-2/BI
```

24 212631-79-3/BI

```
8 212631-81-7/BI
             8 212631-82-8/BI
             8 212631-83-9/BI
             7 212631-84-0/BI
            10 212631-85-1/BI
             8 212631-86-2/BI
             7 219777-46-5/BI
             7 219777-60-3/BI
             7 219778-04-8/BI
             7 219778-52-6/BI
             7 219794-13-5/BI
             7 219794-21-5/BI
             5 277315-06-7/BI
             5 277315-07-8/BI
             5 277315-08-9/BI
             5 277315-09-0/BI
             5 277315-10-3/BI
             5 277315-12-5/BI
             2 277335-40-7/BI
             6 277335-43-0/BI
             4 278609-85-1/BI
             5 278609-99-7/BI
             6 278610-42-7/BI
             6 278610-51-8/BI
           303 352-33-0/BI
            10 57381-34-7/BI
           102 6723-30-4/BI
          1817 79955-99-0/BI
            13 96515-79-6/BI
L3
          5121 (13194-68-8/BI OR 142805-58-1/BI OR 1583-58-0/BI OR 176317-02-5/
               BI OR 212628-43-8/BI OR 212628-44-9/BI OR 212628-45-0/BI OR
               212628-46-1/BI OR 212628-47-2/BI OR 212628-48-3/BI OR 212628-49-
               4/BI OR 212628-50-7/BI OR 212628-51-8/BI OR 212628-52-9/BI OR
               212628-53-0/BI OR 212628-54-1/BI OR 212628-55-2/BI OR 212628-56-
               3/BI OR 212628-57-4/BI OR 212628-58-5/BI OR 212628-59-6/BI OR
               212628-60-9/BI OR 212628-61-0/BI OR 212628-62-1/BI OR 212628-63-
               2/BI OR 212628-65-4/BI OR 212628-67-6/BI OR 212628-69-8/BI OR
               212628-71-2/BI OR 212628-72-3/BI OR 212628-73-4/BI OR 212628-74-
               5/BI OR 212628-75-6/BI OR 212628-76-7/BI OR 212628-77-8/BI OR
               212628-78-9/BI OR 212628-79-0/BI OR 212628-80-3/BI OR 212628-81-
               4/BI OR 212628-82-5/BI OR 212628-83-6/BI OR 212628-84-7/BI OR
               212628-85-8/BI OR 212628-86-9/BI OR 212628-87-0/BI OR 212628-88-
               1/BI OR 212628-89-2/BI OR 212628-90-5/BI OR 212628-91-6/BI OR
               212628-92-7/BI OR 212628-93-8/BI OR 212628-94-9/BI OR 212628-95-
               0/BI OR 212628-96-1/BI OR 212628-97-2/BI OR 2
=> s MEK
         13998 MEK
            76 MEKS
L4
         14018 MEK
                 (MEK OR MEKS)
=> s 14 and 13
          1397 L4 AND L3
=> s 14 (S) 13
           913 L4 (S) L3
=> s arthir?
L7
             9 ARTHIR?
```

8 212631-80-6/BI

```
=> s arthri?
         26414 ARTHRI?
=> s 18 (S) 16
Ь9
              0 L8 (S) L6
=> s inflam? (S) 16
         143429 INFLAM?
L10
             10 INFLAM? (S) L6
=> d ibib abs kwic
L10 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER:
                            2002:142907 HCAPLUS
DOCUMENT NUMBER:
                             136:194260
TITLE:
                            Methods for modulating multiple lineage kinase
                            proteins and screening compounds which modulate
                            multiple linease kinase proteins
INVENTOR (S):
                             Maroney, Anna; Walton, Kevin M.; Dionne, Craig A.;
                             Neff, Nicola; Knight, Ernest, Jr.; Glicksman, Marcie
PATENT ASSIGNEE(S):
                             Cephalon, Inc., USA
SOURCE:
                             PCT Int. Appl., 114 pp.
                             CODEN: PIXXD2
DOCUMENT TYPE:
                             Patent
LANGUAGE:
                             English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                       KIND DATE
                                                APPLICATION NO. DATE
      -----
                                                 -----
                         A2 20020221
                                                WO 2001-US24822 20010808
     WO 2002014536
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
          RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                                                A 20000811
                                              US 2000-637054
OTHER SOURCE(S):
                            MARPAT 136:194260
     Methods for identifying compds. which modulate activity of a multiple
AB
     linease kinase protein and promotes cell survival or cell death comprising
     the steps of contacting the cell contg. the multiple linease protein with
     the compd., detg. whether the compd. decreases activity of the multiple
     linease protein, and detg. whether the compd. promotes cell survival are
     provided. Methods for identifying compds. which may be useful in the
     treatment of neurodegenerative disorders and/or inflammation are also
     provided. Methods for modulating the activity of a multiple linage kinase
     protein comprising contacting the protein or a cell contg. the protein
     with an indeno- or indolo-compd. of the invention are also provided.
     Methods of treating neurodegenerative disorders and/or inflammation are
     also provided.
ΤТ
     137632-07-6, ERK1 kinase 137632-08-7, ERK2 kinase 142805-58-1,
     MEK-1 kinase 150316-14-6, MEK2 kinase 155215-87-5, Jun kinase
     192230-91-4, MKK4 kinase 194739-73-6, MKK6 kinase 260402-73-1, Protein
     kinase ATF2 260402-76-4, Kinase (phosphorylating), protein, ELK1
     289898-51-7, JNK1 kinase 289899-93-0, JNK2 kinase 291756-39-3, JNK3
     kinase 327046-95-7, MEK5 kinase 335605-46-4, MKK7 kinase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
```

(phosphorylation of; methods for modulating multiple lineage kinase proteins and screening compds. which modulate multiple linease kinase proteins and treatment of neurodegenerative disorders and inflammation)

=> d ibib abs kwic 2-10

L10 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2002:142463 HCAPLUS

DOCUMENT NUMBER: 136:194223

TITLE: Sequences of the human extracellular matrix

metalloproteinase inducer protein EMMPRIN, and uses thereof as cyclophilin receptor antagonists for

treatment of HIV-1 infection and inflammatory diseases

INVENTOR(S): Sherry, Barbara A.; Bukrinsky, Michael I.

PATENT ASSIGNEE(S): The Picower Institute for Medical Research, USA

SOURCE: PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2002013763 A2 20020221 WO 2001-US25178 20010810

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO:

US 2000-637033 A 20000810

OTHER SOURCE(S):
```

OTHER SOURCE(S): MARPAT 136:194223

AB The present invention provides sequence

The present invention provides sequences of the human extracellular matrix metalloproteinase inducer protein (EMMPRIN), also known as CD147, which is a signal-transducing cellular receptor for cyclophilin (CyP).

Accordingly, there is disclosed methods for the treatment of HIV-infection, AIDS, AIDS-related disorders., rheumatoid arthritis (RA), connective tissue disorders, cancer or any condition characterized by local or systemic CyP release, synthesis or binding using the CyP/EMMPRIN interaction as a novel therapeutic intervention target. There is further disclosed pharmaceutical compns. including, anti-EMMPRIN antibodies, and sol. EMMPRIN proteins and peptides that act by inhibiting the CyP/EMMPRIN interaction. The present invention further provides screening assays for the identification of compds. that inhibit the CyP/EMMPRIN interaction.

IT 142008-29-5, Protein kinase A 142243-02-5, Mitogen-activated protein kinase 142805-58-1, Protein kinase mek

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (for drug screening; sequences of human extracellular matrix metalloproteinase inducer protein EMMPRIN, and uses thereof as cyclophilin receptor antagonists for treatment of HIV-1 infection and inflammatory diseases)

L10 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2002:85352 HCAPLUS

DOCUMENT NUMBER: 136:261261

TITLE: Prevention of kidney ischemia/reperfusion-induced

functional injury, MAPK and MAPK kinase activation,

and inflammation by remote transient ureteral

obstruction

Park, Kwon Moo; Kramers, Cornelis; Vayssier-Taussat, AUTHOR (S):

Muriel; Chen, Ang; Bonventre, Joseph \bar{V} .

Medical Services, Massachusetts General Hospital, CORPORATE SOURCE:

Charlestown, MA, 02129, USA

SOURCE: Journal of Biological Chemistry (2002), 277(3),

2040-2049

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular

Biology

DOCUMENT TYPE: Journal LANGUAGE: English

Protection against ischemic kidney injury is afforded by 24 h of ureteral obstruction (UO) applied 6 or 8 days prior to the ischemia. Uremia or humoral factors are not responsible for the protection, since unilateral UO confers protection on that kidney but not the contralateral kidney. Prior UO results in reduced postischemic outer medullary congestion and leukocyte infiltration. Prior UO results in reduced postischemic phosphorylation of c-Jun N-terminal stress-activated protein kinase 1/2 (JNK1/2), p38, mitogen-activated protein kinase (MAPK) kinase 4 (MKK4), and MKK3/6. Very few cells stain pos. for proliferating cell nuclear antigen after obstruction, indicating that subsequent protection against ischemia is not related to proliferation with increased nos. of newly formed daughter cells more resistant to injury. UO increases the expression of heat shock protein (HSP)-25 and HSP-72. The increased HSP-25 expression persists for 6 or 8 days, whereas HSP-72 does not. HSP-25 expression is increased in the proximal tubule cells in the outer stripe of the outer medulla post-obstruction, prior to, and 24 h after ischemia. In LLC-PK1 renal epithelial cells, adenovirus-expressed human HSP-27 confers resistance to chem. anoxia and oxidative stress. Increased HSP-27 expression in LLC-PK1 cells results in reduced H2O2-induced phosphorylation of JNK1/2 and p38. In conclusion, prior transient UO renders the kidney resistant to ischemia. This resistance to functional consequences of ischemia is assocd. with reduced postischemic activation of JNK, p38 MAP kinases, and their upstream MAPK kinases. The persistent increase in HSP-25 that occurs as a result of UO may contribute to the redn. in phosphorylation of MAPKs that have been implicated in adhesion mol. up-regulation and cell death.

REFERENCE COUNT: THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS 51 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 142805-58-1, MEK-1 kinase 150316-14-6, MEK2 kinase 165245-96-5, p38 MAP kinase 172308-13-3, MKK3 protein kinase 192230-91-4, MKK4 protein kinase 194739-73-6, MKK6 protein kinase

289898-51-7, JNK1 kinase 289899-93-0, JNK2 kinase RL: BSU (Biological study, unclassified); BIOL (Biological study) (prevention of kidney ischemia/reperfusion-induced functional injury, MAPK and MAPK kinase activation, and inflammation by remote transient ureteral obstruction)

L10 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:8324 HCAPLUS

DOCUMENT NUMBER: 134:176807

TITLE: Sustained ERK phosphorylation is necessary but not

sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways

AUTHOR (S): Genersch, Elke; Hayess, Katrin; Neuenfeld, Yvette;

Haller, Hermann

CORPORATE SOURCE: Franz Volhard Clinic at the Max Delbruck Center for

> Molecular Medicine, Medical Faculty of the Charite, Humboldt University of Berlin, Berlin, 13125, Germany

SOURCE: Journal of Cell Science (2000), 113(23), 4319-4330

CODEN: JNCSAI; ISSN: 0021-9533

PUBLISHER: Company of Biologists Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

Endothelial expression of matrix metalloproteinase-9 (MMP-9), which degrades native type IV collagen, was implicated as a prerequisite for angiogenesis. Therefore, the aim of this study was to det. signaling requirements that regulate MMP-9 expression in endothelial cells. Both, primary and permanent human umbilical vein endothelial cells (HUVEC and ECV304, resp.) were stimulated with phorbol 12-myristate 13-acetate (PMA) and the cytokine tumor necrosis factor-.alpha. (TNF.alpha.) to induce MMP-9 expression. While both cell types responded to PMA at the protein, mRNA and promoter level by induction of MMP-9, TNF.alpha. caused this response only in ECV304. Inhibitors specific for mitogen-activated protein/ERK kinase 1/2 (MEK1/2), protein kinase C (PKC), and Ras and co-transfections of wild-type and mutant Raf were used to elucidate the signaling cascades involved. Thus, the authors could show that the Raf/MEK/ERK cascade is mainly responsible for MMP-9 induction in endothelial cells and that this cascade is regulated independently of PKC and Ras subsequent to TNF.alpha. stimulation and in a PKC-dependent manner as a result of PMA treatment. In addn., PMA triggers a Ras-dependent signal transduction pathway bypassing the phosphorylation of ERK. Finally, the authors provide evidence that sustained phosphorylation of

ERK1/2 is necessary but not sufficient for expression of MMP-9.

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 137632-07-6 137632-07-6, ERK1 kinase 137632-08-7 137632-08-7, ERK2
kinase 139691-76-2, c-Raf-1 kinase 141436-78-4, Protein kinase C
142805-58-1, MEK-1 kinase 150316-14-6, MEK2 kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(signaling pathway for matrix metalloproteinase-9 regulation in **inflammatory** response of vascular endothelial cells)

L10 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:717103 HCAPLUS

DOCUMENT NUMBER: 134:28372

TITLE: Proteinase-activated receptor-2-mediated matrix

metalloproteinase-9 release from airway epithelial

cells

AUTHOR(S): Vliagoftis, Harissios; Schwingshackl, Andreas; Milne,

Craig D.; Duszyk, Marek; Hollenberg, Morley D.; Wallace, John L.; Befus, A. Dean; Moqbel, Redwan

CORPORATE SOURCE: Pulmonary Research Group, the Department Medicine,

University of Alberta, Edmonton, AB, T6G 2S2, Can.

SOURCE: Journal of Allergy and Clinical Immunology (2000),

106(3), 537-545

CODEN: JACIBY; ISSN: 0091-6749

PUBLISHER: Mosby, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Matrix metalloproteinases (MMPs) digest extracellular matrix components and might be important mediators of tissue remodeling. Proteinase activated receptor-2 (PAR-2) is expressed in a variety of cell types including epithelial cells. PAR-2 receptors are activated by serine proteases such as trypsin and mast cell tryptase and have been implicated in inflammation. The objective was to study the effects of PAR-2-mediated airway epithelial cell activation on the prodn. of MMP-9. A specific PAR-2-activating peptide and trypsin were used to activate the human airway epithelial cell line A549 as well as primary cultures of small airway epithelial cells (SAEC). MMP-2 and MMP-9 mRNA and enzymic activity

were evaluated by RT-PCR and gelatin zymog., resp. PAR-2-activating peptides upregulated MMP-9 mRNA expression and release of MMP-9 enzymic activity from airway epithelial cells but had no effect on MMP-2 prodn. Dexamethasone and budesonide (10-6 to 10-10 mmol) inhibited PAR-2-mediated MMP-9 release. Pretreatment with indomethacin indicated that MMP-9 release was not prostaglandin dependent. Inhibitors of the MAP kinase MEK-1, and NF.kappa.B showed that both pathways are important for PAR-2-mediated MMP-9 release. Trypsin, a physiol. PAR-2 activator, upregulated MMP-9 but also MMP-2 release from airway epithelial cells. PAR-2 receptors appear to play an important role in the regulation of MMP-9 release from airway epithelial cells. As such, these receptors may be crit. elements in tissue remodeling in asthma and other inflammatory conditions in the airways.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 7440-70-2, Calcium, biological studies 142805-58-1, MEK
-1 kinase 146480-35-5, MMP 2 146480-36-6, Matrix metalloproteinase-9
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)

(PAR2 receptor-mediated matrix metalloproteinase release from airway epithelial cells and involved signaling mechanisms in relation to inflammation)

L10 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:566541 HCAPLUS

DOCUMENT NUMBER: 133:251214

TITLE: E-selectin-dependent signaling via the

mitogen-activated protein kinase pathway in vascular

endothelial cells

AUTHOR(S): Hu, Yenya; Kiely, Jeanne-Marie; Szente, Brian E.;

Rosenzweig, Anthony; Gimbrone, Michael A., Jr.

CORPORATE SOURCE: Vascular Research Division, Department of Pathology,

Brigham and Women's Hospital, Boston, MA, 02115, USA

SOURCE: Journal of Immunology (2000), 165(4), 2142-2148

CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists

DOCUMENT TYPE: Journal LANGUAGE: English

E-selectin, a cytokine-inducible adhesion mol., supports rolling and stable arrest of leukocytes on activated vascular endothelium. Previous studies have suggested that this transmembrane protein can also transduce signals into the endothelial cell. The authors now demonstrate activation of the mitogen-activated protein kinase (MAPK) signaling cascade in cultured HUVEC in response to E-selectin-dependent leukocyte adhesion and Ab-mediated crosslinking of cell surface E-selectin. Adhesion of increasing nos. of HL60 cells to IL-1.beta.-activated HUVEC stimulated robust increases in MAPK activity that were abrogated by an E-selectin blocking Ab. Crosslinking of cell surface E-selectin with Abs, as a mimic of multivalent ligand engagement, strongly stimulated MAPK/extracellular signal-related kinase (ERK) kinase (MEK)-dependent MAPK activation and concomitant up-regulation of mRNA for c-fos, an immediate early response gene, whereas Ab crosslinking of HLA class I mols. (present at comparable d.) failed to do so. Coimmunopptn. documented Ras, Raf-1, and phospho-MEK complex formation. Unactivated HUVEC transduced with a full-length adenoviral E-selectin construct also exhibited cross-link-induced MAPK activation, macromol. complex formation, and c-fos up-regulation, whereas HUVEC transduced with a cytoplasmic domain deletion mutant failed to respond. Thus, E-selectin can transduce an activating stimulus via the MAPK cascade into the endothelial cell during leukocyte adhesion.

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(E-selectin-dependent signaling via MAP kinase cascade in vascular endothelial cells in relation to leukocyte recruitment and adhesion in inflammation)

L10 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:115079 HCAPLUS

DOCUMENT NUMBER: 132:260374

TITLE: Inhibition of MAP kinase knase (MEK) results in an

anti-inflammatory response in vivo

AUTHOR (S): Jaffee, Bruce D.; Manos, Elizabeth J.; Collins, Robert

J.; Czerniak, Phillip M.; Favata, Margaret F.;

Magolda, Ronald L.; Scherle, Peggy A.; Trzaskos, James

CORPORATE SOURCE: Inflammatory Diseases Research, DuPont Pharmaceuticals

Company, Wilmington, DE, 19880-0400, USA

SOURCE: Biochemical and Biophysical Research Communications

(2000), 268(2), 647-651 CODEN: BBRCA9; ISSN: 0006-291X

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal LANGUAGE: English

The MAP kinase pathway has been well-characterized as a cascade of AB sequential protein phosphorylation events leading to the upregulation of a variety of genes in response to growth factors and mitogens. We are interested in the role of these kinases in inflammation and have thus examd. their activity in vivo using TPA-induced ear edema in the mouse as a model of inflammation. We show that the activities of both ERK-1 and ERK-2 are upregulated in this model in response to TPA. Increased levels of ERK phosphorylation are measurable as early as 15 min poststimulation and reach a level 8-fold over controls at 4 h. In contrast, minimal activation of JNK or p38 is obsd. Topical treatment of ears with the MEK inhibitor, U0126, prevents ERK phosphorylation and ear swelling in a dose-dependent manner in this model. These results suggest that the MEK/ERK pathway is important during an inflammatory response in vivo. 2000 Academic Press.

REFERENCE COUNT: THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

137632-07-6, ERK-1 kinase 137632-08-7, ERK-2 kinase 142805-58-1 , MEK kinase 155215-87-5, JNK kinase 165245-96-5, p38 Kinase RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(inhibition of MAP kinase knase (MEK) results in an antiinflammatory response in vivo)

L10 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:53395 HCAPLUS

DOCUMENT NUMBER: 132:88207

TITLE: Modulation of the phospholipase A2 pathway as a

therapeutic

INVENTOR (S): Paris, Daniel; Town, Terrence C.; Mullan, Michael J.

PATENT ASSIGNEE(S): University of South Florida, USA

PCT Int. Appl., 77 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
-----
     WO 2000002561
                     A1 20000120
                                         WO 1999-US15947 19990713
            AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
             JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM,
             TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                     A1 20000201
     AU 9949948
                                          AU 1999-49948
                                                            19990713
PRIORITY APPLN. INFO.:
                                        US 1998-92570P P 19980713
                                        WO 1999-US15947 W 19990713
     There is provided a method of modifying vasoactivity by regulating a sol.
AB
     A.beta. pro-inflammatory pathway. Also provided is a method of modifying
     inflammatory reactions in microglia and neurons by regulating a sol.
     A.beta. pro-inflammatory pathway. A method of treating patients with
     vascular disease by modifying an intracellular sol. A.beta.
     pro-inflammatory pathway is also provided. A pharmaceutical compn.
     consisting essentially of an effective amt. of a sol. A.beta.
     pro-inflammatory pathway regulator in a pharmaceutically effective carrier
     is also provided.
REFERENCE COUNT:
                         2
                               THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
     80619-02-9, 5-Lipoxygenase 142243-02-5, MAP kinase 142805-58-1
TT
     , MEK-1 kinase 150316-14-6, MEK2 kinase 165245-96-5, p38 MAP
     kinase
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (inhibitors; modulation of A.beta. amyloid-phospholipase A2 pro-
        inflammatory pathway as a therapeutic by modifying vasoactivity
        and affecting microglia and neurons)
L10 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2002 ACS
                        1999:394118 HCAPLUS
ACCESSION NUMBER:
DOCUMENT NUMBER:
                         131:198461
TITLE:
                         Involvement of p38 MAPK and ERK/MAPK pathways in
                         staurosporine-induced production of macrophage
                         inflammatory protein-2 in rat peritoneal neutrophils
AUTHOR (S):
                         Xiao, Yi-Qun; Someya, Koh-ichiro; Morita, Hiroyuki;
                         Takahashi, Kiyoshi; Ohuchi, Kazuo
                         Graduate School of Pharmaceutical Sciences, Department
CORPORATE SOURCE:
                         of Pathophysiological Biochemistry, Tohoku University,
                         Sendai, Miyagi, 980-8578, Japan
SOURCE:
                        Biochimica et Biophysica Acta (1999), 1450(2), 155-163
                        CODEN: BBACAQ; ISSN: 0006-3002
PUBLISHER:
                        Elsevier Science B.V.
DOCUMENT TYPE:
                        Journal
LANGUAGE:
                        English
     Stimulation of rat peritoneal neutrophils with staurosporine (64 nM)
AB
     induced prodn. of macrophage inflammatory protein-2 (MIP-2) and
     phosphorylation of p38 mitogen-activated protein kinase (MAPK) and
     extracellular signal-regulated kinase/MAP kinase (ERK/MAPK). The
     staurosporine-induced MIP-2 prodn. at 4 h was inhibited by the highly
     specific p38 MAPK inhibitor SB 203580 and the MAPK/ERK kinase (MEK-1)
     inhibitor PD 98059 in a concn.-dependent manner. By treatment with SB
     203580 (1 .mu.M) or PD 98059 (50 .mu.M), the staurosporine-induced
     increase in the levels of mRNA for MIP-2 was only partially lowered,
     although the staurosporine-induced MIP-2 prodn. was completely inhibited.
     Consistent with the inhibition by the protein synthesis inhibitor
     cycloheximide, SB 203580 and PD 98059 inhibited MIP-2 prodn. at 4 h either
```

when added simultaneously with staurosporine or 2 h after stimulation with staurosporine. In contrast, the DNA-dependent RNA polymerase inhibitor actinomycin D did not inhibit MIP-2 prodn. at 4 h when it was added 2 h after staurosporine stimulation. Dot blot anal. demonstrated that treatment with SB 203580 or PD 98059 down-regulates the stability of MIP-2 Apparently, p38 MAPK and ERK/MAPK pathways are involved in

translation of MIP-2 mRNA to protein and stabilization of MIP-2 mRNA. REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

142805-58-1, MEK-1 kinase 165245-96-5, p38 Kinase RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(post-transcriptional p38 MAPK and ERK/MAPK pathways in staurosporine-induced formation of macrophage inflammatory protein-2 in peritoneal neutrophils)

L10 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:463996 HCAPLUS

DOCUMENT NUMBER: 129:188276

TITLE: Binding of human immunodeficiency virus type 1 to CD4

and CXCR4 receptors differentially regulates

expression of inflammatory genes and activates the

MEK/ERK signaling pathway

Popik, Waldemar; Hesselgesser, Joseph E.; Pitha, Paula AUTHOR (S):

CORPORATE SOURCE: Oncology Center, The Johns Hopkins University School

of Medicine, Baltimore, MD, 21231, USA

SOURCE: Journal of Virology (1998), 72(8), 6406-6413

CODEN: JOVIAM; ISSN: 0022-538X American Society for Microbiology

DOCUMENT TYPE: Journal

PUBLISHER:

LANGUAGE: English

The authors have previously shown that binding of human immunodeficiency virus type 1 (HIV-1) virions to CD4 receptors stimulates assocn. of Lck with Raf-1 and results in the activation of Raf-1 kinase in a Ras-independent manner. In the present study, the authors demonstrate that HIV-1 envelope glycoproteins of both T-cell-tropic and macrophage-tropic strains rapidly activate the ERK/mitogen-activated protein (MAP) kinase pathway and the binding of nuclear transcription factors (AP-1, NF-.kappa.B, and C/EBP) and stimulate expression of cytokine and chemokine genes. The activation of this signaling pathway requires functional CD4 receptors and is independent of binding to CXCR4. Binding of the natural ligand stromal cell-derived factor 1 (SDF-1) to CXCR4, which inhibits entry of T-cell-tropic HIV-1, activates also the ERK/MAP kinase pathway. However, SDF-1 did not affect the CD4-mediated expression of cytokine and chemokine genes. These results provide firm mol. evidence that binding of HIV-1 envelope glycoproteins to CD4 receptor initiates a signaling pathway(s) independent of the binding to the chemokine receptor that leads to the aberrant expression of inflammatory genes and may contribute significantly to HIV-1 replication as well as to deregulation of the immune system.

142243~02-5, ERK kinase 142805-58-1, MEK kinase TΤ RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)

(HIV-1 gp120 binding to CD4 inducing expression of inflammatory genes and activating MEK/ERK signaling pathway independent of CXCR4 receptors)

(FILE 'HOME' ENTERED AT 18:10:30 ON 07 JUN 2002)

FILE 'CAPLUS' ENTERED AT 18:10:37 ON 07 JUN 2002 L1 1 S W0200035436/PN SEL RN L1

FILE 'REGISTRY' ENTERED AT 18:11:17 ON 07 JUN 2002 L2 327 S E1-327

FILE 'HCAPLUS' ENTERED AT 18:13:31 ON 07 JUN 2002 L3 5121 S E1-E327 L4 14018 S MEK L5 1397 S L4 AND L3

L6 913 S L4 (S) L3
L7 9 S ARTHIR?
L8 26414 S ARTHRI?
L9 0 S L8 (S) L6
L10 10 S INFLAM? (S) L6

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE

-6.20
-6.20

FILE 'STNGUIDE' ENTERED AT 18:17:18 ON 07 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 31, 2002 (20020531/UP).

=> FIL HCAPLUS

COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION ENTRY FULL ESTIMATED COST 0.06 560.07 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL SESSION ENTRY CA SUBSCRIBER PRICE 0.00 -6.20

FILE 'HCAPLUS' ENTERED AT 18:17:27 ON 07 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jun 2002 VOL 136 ISS 23

FILE LAST UPDATED: 5 Jun 2002 (20020605/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> fil stnq

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.14	562.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.20

FILE 'STNGUIDE' ENTERED AT 18:17:38 ON 07 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 31, 2002 (20020531/UP).

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	562.27
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY 0.00	SESSION -6.20

FILE 'REGISTRY' ENTERED AT 18:18:30 ON 07 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 5 JUN 2002 HIGHEST RN 426206-38-4 DICTIONARY FILE UPDATES: 5 JUN 2002 HIGHEST RN 426206-38-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> SAVE L2 MEKBLOCKERS/A ANSWER SET L2 HAS BEEN SAVED AS 'MEKBLOCKERS/A'

=> FIL HCAPLUS COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 0.38 562.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE TOTAL
ENTRY
SESSION
CA SUBSCRIBER PRICE
0.00 -6.20

FILE 'HCAPLUS' ENTERED AT 18:18:31 ON 07 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jun 2002 VOL 136 ISS 23 FILE LAST UPDATED: 5 Jun 2002 (20020605/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> SAVE L3 MEKRESULT/A
ANSWER SET L3 HAS BEEN SAVED AS 'MEKRESULT/A'

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE TOTAL
ENTRY SESSION
0.00 -6.20

FILE 'STNGUIDE' ENTERED AT 18:18:36 ON 07 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 31, 2002 (20020531/UP).

=> log y COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION ENTRY FULL ESTIMATED COST 0.06 564.85 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY 0.00 SESSION CA SUBSCRIBER PRICE 0.00 -6.20

Welcome to STN International! Enter x:x LOGINID:ssspta1617srh PASSWORD: TERMINAL (ENTER 1, 2, 3, OR ?):2 * * * * * * * * * Welcome to STN International Web Page URLs for STN Seminar Schedule - N. America BLAST(R) searching in REGISTRY available in STN on the Web FSTA has been reloaded and moves to weekly updates NEWS 3 Jan 29 NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update frequency NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02 NEWS 6 Mar 08 Gene Names now available in BIOSIS NEWS 7 Mar 22 TOXLIT no longer available NEWS 8 Mar 22 TRCTHERMO no longer available NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAplus and USPATFULL NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead. NEWS 12 Apr 08 "Ask CAS" for self-help around the clock NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area NEWS 14 Apr 09 ZDB will be removed from STN NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available NEWS 19 Jun 03 New e-mail delivery for search results now available NEWS 20 Jun 10 MEDLINE Reload NEWS 21 Jun 10 PCTFULL has been reloaded February 1 CURRENT WINDOWS VERSION IS V6.0d, NEWS EXPRESS CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002 NEWS HOURS STN Operating Hours Plus Help Desk Availability NEWS INTER General Internet Information NEWS LOGIN Welcome Banner and News Items NEWS PHONE Direct Dial and Telecommunication Network Access to STN NEWS WWW CAS World Wide Web Site (general information) Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:16:03 ON 11 JUN 2002

=> fil capl biosis ipa uspatf

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.42 0.42

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 17:17:00 ON 11 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:17:00 ON 11 JUN 2002 COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'IPA' ENTERED AT 17:17:00 ON 11 JUN 2002 COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'USPATFULL' ENTERED AT 17:17:00 ON 11 JUN 2002 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s mek

L1 24950 MEK

=> s p38 map kinase

2900 P38 MAP KINASE

=> s inflam? or antiinflam?

463915 INFLAM? OR ANTIINFLAM? L3

=> s arthr?

L4396653 ARTHR?

=> s l1 (s) l4

19 L1 (S) L4 L5

=> dup rem 15

PROCESSING COMPLETED FOR L5

19 DUP REM L5 (0 DUPLICATES REMOVED)

=> d ti tot

L6 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2002 ACS

TI Preparation of oxygenated esters of 4-iodophenylamino benzhydroxamic acids as MEK inhibitors

ANSWER 2 OF 19 USPATFULL L6

TΙ Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors

ANSWER 3 OF 19 USPATFULL L6

TI Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors

ANSWER 4 OF 19 USPATFULL L₆

TΤ 3-(anilinomethylene) oxindoles

L6 ANSWER 5 OF 19 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

TΤ Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis.

L6 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2002 ACS

- TI Preparation of (phenylamino)benzenesulfonamides and (phenylamino)benzamides as MEK inhibitors for the treatment of chronic pain
- L6 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2002 ACS
- TI Preparation of 2-phenylaminobenzamides and analogs as MEK inhibitors for the treatment of chronic pain
- L6 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2002 ACS
- TI Preparation of (2-heterocyclylphenyl)(4-iodophenyl)amines as MEK inhibitors for the treatment of chronic pain
- L6 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2002 ACS
- TI Preparation of phenylaminobenzimidazoles and analogs as MEK inhibitors for the treatment of chronic pain
- L6 ANSWER 10 OF 19 USPATFULL
- TI N-adamant-1-y1-N1-[4-chlorobenzothiazol-2-y1] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
- L6 ANSWER 11 OF 19 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
- TI The effect of inhibiting the MEK-ERK MAPK pathway on inflammation and articular cartilage integrity in a rat model of collagen-induced arthritis.
- L6 ANSWER 12 OF 19 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
- TI The effect of inhibiting the MEK-ERK MAPK pathway on inflammation and articular cartilage integrity in a rat model of collagen-induced arthritis.
- L6 ANSWER 13 OF 19 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
- TI Role of the MEK/ERK MAP kinase pathway in type II collagen-induced arthritis in mice.
- L6 ANSWER 14 OF 19 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
- TI Regulation of human neutrophil-mediated cartilage proteoglycan degradation by phosphatidylinositol-3-kinase.
- L6 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2002 ACS
- TI Preparation of benzenesulfonamides as MEK inhibitors
- L6 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2002 ACS
- TI Preparation of sulfohydroxamic acids and sulfohydroxamates as MEK inhibitors
- L6 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2002 ACS
- TI Preparation of 2-(4-bromo or 4-iodo phenylamino)benzoic acid derivatives as MEK inhibitors
- L6 ANSWER 18 OF 19 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
- TI Regulation of rheumatoid synovial cell growth by ceramide.
- L6 ANSWER 19 OF 19 USPATFULL
- TI Antifungal agent produced by arthrinium arundinis ATCC 74359
- => d ibib abs kwic 15-19

L6 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:493507 CAPLUS

DOCUMENT NUMBER: 133:120145

TITLE: Preparation of benzenesulfonamides as MEK inhibitors

INVENTOR(S): Barrett, Stephen Douglas; Tecle, Haile; Booth, Richard

John

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ---------WO 2000042003 A1 20000720 WO 1999-US30435 19991221 W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG JP 1999-53632 JP 2000212157 A2 20000802 19990302 EP 1144371 EP 1999-966496 A1 20011017 19991221 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO BR 9916885 Α 20011120 BR 1999-16885 19991221 PRIORITY APPLN. INFO.: US 1999-115874P Ρ 19990113 US 1999-122422P Ρ 19990302

WO 1999-US30435

W

19991221

OTHER SOURCE(S): MARPAT 133:120145

GΙ

$$R^{7}R^{6}NO_{2}S$$
 R^{4}
 R^{3}
 R^{5}
 R^{5}
 $R^{7}R^{6}NO_{2}S$

AB The title compds. [I; W = OR1, NR2OR1, etc.; R1 = H, alkyl, alkenyl, etc.; R2 = H, Ph, alkyl, etc.; R3 = H, F, Cl, Br, NO2; R4 = H, F; R5 = H, Me, Cl; R6 = H, alkyl, hydroxyethyl, etc.; R7 = H, alkyl, hydroxyethyl, etc.] which are inhibitors of MEK, and are effective in the treatment of proliferative diseases, cancer, stroke, heart failure, xenograft

rejection, arthritis, cystic fibrosis, hepatomegaly, cardiomegaly, Alzheimer's disease, complications of diabetes, septic shock, and viral infection, were prepd. E.g, a multi-step synthesis of II which showed IC50 of 222 nM (APK), was given. REFERENCE COUNT: THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS 2 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT The title compds. [I; W = OR1, NR2OR1, etc.; R1 = H, alkyl, alkenyl, etc.; AB R2 = H, Ph, alkyl, etc.; R3 = H, F, Cl, Br, NO2; R4 = H, F; R5 = H, Me, Cl; R6 = H, alkyl, hydroxyethyl, etc.; R7 = H, alkyl, hydroxyethyl, etc.] which are inhibitors of MEK, and are effective in the treatment of proliferative diseases, cancer, stroke, heart failure, xenograft rejection, arthritis, cystic fibrosis, hepatomegaly, cardiomegaly, Alzheimer's disease, complications of diabetes, septic shock, and viral infection, were prepd. E.g, a multi-step synthesis of II which showed IC50 of 222 nM (APK), was given. ANSWER 16 OF 19 CAPLUS COPYRIGHT 2002 ACS 2000:493506 CAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 133:104872 TITLE: Preparation of sulfohydroxamic acids and sulfohydroxamates as MEK inhibitors INVENTOR(S): Tecle, Haile PATENT ASSIGNEE(S): Warner-Lambert Company, USA SOURCE: PCT Int. Appl., 40 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
PATENT NO.
                                 KIND DATE
                                                                     APPLICATION NO. DATE
        -----
                                                                      -----
       WO 2000042002 A1 20000720
                                                                    WO 1999-US30417 19991221
             WC 1999-US30417 19991221

W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                                                JP 1999-53536
        JP 2000204075
                                  A2 20000725
                                                                                                  19990302
                                                                                               19991221
       EP 1144372
                                     Α1
                                             20011017
                                                                     EP 1999-968151
              R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
       BR 9916894
                                              20011120
                                                                      BR 1999-16894
                                    Α
                                                                                                   19991221
PRIORITY APPLN. INFO.:
                                                                 US 1999-115652P P
                                                                                                  19990113
                                                                 US 1999-122417P P
                                                                                                  19990302
                                                                 WO 1999-US30417 W 19991221
```

OTHER SOURCE(S):

MARPAT 133:104872

GI

The title compds. [I; R1 = H, alkyl, alkenyl, etc.; R2 = H, alkyl, Ph, AB etc.; R3, R4 = H, F, NO2, etc.; R5 = H, F; R6 = H, F, C1, Me], useful as inhibitors of MEK and effective in the treatment of proliferative diseases, cancer, stroke, heart failure, xenograft rejection, arthritis, cystic fibrosis, hepatomegaly, cardiomegaly, Alzheimer's disease, complications of diabetes, septic shock, and viral infection, were prepd. E.g, a 2-step synthesis of I [R1 = cyclopropylmethyl; R2 = H; R3 = H; R4, R5 = F; R6 = C1] was given. Compds. I are effective at 1-300 mg/kg/day.

REFERENCE COUNT: THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS 2 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

The title compds. [I; R1 = H, alkyl, alkenyl, etc.; R2 = H, alkyl, Ph, AΒ etc.; R3, R4 = H, F, NO2, etc.; R5 = H, F; R6 = H, F, C1, Me], useful as inhibitors of MEK and effective in the treatment of proliferative diseases, cancer, stroke, heart failure, xenograft rejection, arthritis, cystic fibrosis, hepatomegaly, cardiomegaly, Alzheimer's disease, complications of diabetes, septic shock, and viral infection, were prepd. E.g, a 2-step synthesis of I [R1 = cyclopropylmethyl; R2 = H; R3 = H; R4, R5 = F; R6 = Cl] was given. Compds. I are effective at 1-300 mg/kg/day.

ANSWER 17 OF 19 CAPLUS COPYRIGHT 2002 ACS

I

ACCESSION NUMBER:

2000:420949 CAPLUS

DOCUMENT NUMBER:

133:73860

TITLE:

Preparation of 2-(4-bromo or 4-iodo

phenylamino) benzoic acid derivatives as MEK inhibitors

INVENTOR(S):

Dudley, David Thomas; Flory, Craig Mason; Saltiel,

Alan Robert

PATENT ASSIGNEE(S):

Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT	NO.		KI	ND	DATE			Α	PPLI	CATI	ON N	ο.	DATE			
		-						-								
WO 2000	0354	36	A.	2	2000	0622		W	0 19	99-U	S297	83	1999	1215		
WO 2000	0354	36	A.	3	2001	1018										
W:	ΑE,	AL,	AU,	BA,	BB,	ВG,	BR,	CA,	CN,	CR,	CU,	CZ,	DM,	EE,	GD,	GE,
	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚP,	KR,	LC,	LK,	LR,	LT,	LV,	MA,	MG,
	MK,	MN,	MX,	NO,	NZ,	PL,	RO,	SG,	SI,	SK,	SL,	TR,	TT,	UA,	US,	UZ,
	VN,	YU,	ZA,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM				
RW:	GH,	GM,	KE,	LS,	MW,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,
	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,
					GN,											

EP 1143957 20011017 EP 1999-966278 A2 19991215

EP 1143957 Α3 20020227

AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRIORITY APPLN. INFO.: US 1998-112544P

> US 1999-164651P P 19991110

Р

19981216

WO 1999-US29783 W 19991215

OTHER SOURCE(S): MARPAT 133:73860 GI

 R^1 Me

Br or I
$$R^{1}$$
 R^{5} R^{4} R^{4} R^{4} R^{5} R^{4} R^{5} R^{6} R^{6

AB The title compds. (I) [wherein R1 = H, OH, alkyl, alkoxy, halo, CF3, or CN; R3-R5 = independently H, OH, halo, CF3, alkyl, alkoxy, NO2, CN, or (O or NH)m-(CH2)n-R9, where R9 = H, OH, CO2H, or NR10R11; m = 0 or 1; n = 00-4; R10 and R11 = H, alkyl, or taken together with the N to which they are attached form a 3-10 membered ring; Z = CO2R7, tetrazoly1, CONR6R7, CONHNR10R11, or CH2OR7; R6 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, acyl, (hetero)aryl, or taken together with the N to which they are attached form a 3-10 membered ring, etc.] were prepd. by std. or combinatorial synthetic methods involving the addn. of halobenzoic acids to haloanilines and optional redn. or amidation of the acid. example, treatment of 2-amino-5-iodotoluene in THF with LDA in THF/heptane/ethenylbenzene soln., followed by addn. of 2,4-difluorobenzoic acid in THF afforded II. In assays against type II collagen induced arthritis in mice and monoarticular arthritis in rats, I showed potent anti-arthritic activity. I inhibited IL-1 induced stromelysin prodn. in rabbit synovial fibroblast cell cultures with IC50 from 9 nM to 192 nM. Interleukin 1-alpha stimulated cartilage degrdn. was reduced by up to 75% in New Zealand white rabbits upon administration of I. Thus, I are potent MEK inhibitors useful in the prevention and treatment of rheumatoid arthritis or osteoarthritis.

The title compds. (I) [wherein R1 = H, OH, alkyl, alkoxy, halo, CF3, or ΔR CN; R3-R5 = independently H, OH, halo, CF3, alkyl, alkoxy, NO2, CN, or (O or NH)m-(CH2)n-R9, where R9 = H, OH, CO2H, or NR10R11; m = 0 or 1; n = 00-4; R10 and R11 = H, alkyl, or taken together with the N to which they are attached form a 3-10 membered ring; Z = CO2R7, tetrazoly1, CONR6R7, CONHNR10R11, or CH2OR7; R6 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, acyl, (hetero)aryl, or taken together with the N to which they are attached form a 3-10 membered ring, etc.] were prepd. by std. or combinatorial synthetic methods involving the addn. of halobenzoic acids to haloanilines and optional redn. or amidation of the acid. example, treatment of 2-amino-5-iodotoluene in THF with LDA in THF/heptane/ethenylbenzene soln., followed by addn. of 2,4-difluorobenzoic acid in THF afforded II. In assays against type II collagen induced arthritis in mice and monoarticular arthritis in rats, I showed potent anti-arthritic activity. I inhibited IL-1 induced stromelysin prodn. in rabbit synovial fibroblast cell cultures with IC50 from 9 nM to 192 nM. Interleukin 1-alpha stimulated cartilage degrdn. was reduced by up to 75% in New Zealand white rabbits upon administration of I. Thus, I are potent

MEK inhibitors useful in the prevention and treatment of rheumatoid **arthritis** or osteoarthritis.

L6 ANSWER 18 OF 19 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2000:166691 BIOSIS DOCUMENT NUMBER: PREV200000166691

TITLE: Regulation of rheumatoid synovial cell growth by ceramide.

AUTHOR(S): Migita, Kiyoshi (1); Honda, Seiyo; Yamasaki, Satoshi;

Hirai, Yasuko; Fukuda, Takaaki; Aoyagi, Takahiko; Kita, Masako; Ida, Hiroaki; Tsukada, Toshiaki; Kawakami, Atsushi;

Kawabe, Yojiro; Eguchi, Katsumi

CORPORATE SOURCE: (1) First Department of Internal Medicine, Nagasaki

University School of Medicine, Sakamoto 1-7-1, Nagasaki,

852-8501 Japan

SOURCE: Biochemical and Biophysical Research Communications.,

(March 5, 2000) Vol. 269, No. 1, pp. 70-75.

ISSN: 0006-291X.

DOCUMENT TYPE: Article
LANGUAGE: English
SUMMARY LANGUAGE: English

Overgrowth of rheumatoid synoviocytes, which results in joint destruction, is due to impaired balance between cell proliferation and cell death (apoptosis). Ceramide is an important lipid messenger involved in mediating a variety of cell functions including apoptosis. We investigated the effects of ceramide on growth-promoting anti-apoptotic signals in rheumatoid synovial cells. Human synovial cells isolated from patients with rheumatoid arthritis (RA) were stimulated with platelet-derived growth factor (PDGF) in the presence or absence of C2-ceramide. The kinase activity of Akt, MEK, and ERK1/2 was analyzed in PDGF-stimulated synovial cells by Western blot analysis. Pretreatment with C2-ceramide completely inhibited PDGF-induced cell cycle progression of rheumatoid synovial cells. PDGF stimulation induced phosphorylation and activation of Akt, MEK, and ERK1/2 in rheumatoid synovial cells. C2-ceramide inhibited the activation of Akt, MEK and ERK1/2 in PDGF-stimulated synovial cells. Our data demonstrated that inhibition of anti-apoptotic kinases, such as Akt and ERK1/2, may play an important role in ceramide-mediated apoptosis of rheumatoid synovial cells.

AB. . . the effects of ceramide on growth-promoting anti-apoptotic signals in rheumatoid synovial cells. Human synovial cells isolated from patients with rheumatoid arthritis (RA) were stimulated with platelet-derived growth factor (PDGF) in the presence or absence of C2-ceramide. The kinase activity of Akt, MEK, and ERK1/2 was analyzed in PDGF-stimulated synovial cells by Western blot analysis. Pretreatment with C2-ceramide completely inhibited PDGF-induced cell cycle progression of rheumatoid synovial cells. PDGF stimulation induced phosphorylation and activation of Akt, MEK, and ERK1/2 in rheumatoid synovial cells. C2-ceramide inhibited the activation of Akt, MEK and ERK1/2 in PDGF-stimulated synovial cells. Our data demonstrated that inhibition of anti-apoptotic kinases, such as Akt and ERK1/2, may. . .

L6 ANSWER 19 OF 19 USPATFULL

ACCESSION NUMBER: 1998:9340 USPATFULL

TITLE: Antifungal agent produced by arthrinium arundinis ATCC

74359

INVENTOR(S): Liesch, Jerrold M., Princeton Junction, NJ, United

States

Meinz, Maria S., Fair Haven, NJ, United States Onishi, Janet C., Westfield, NJ, United States

Schwartz, Robert E., Scotch Plains, NJ, United States

Bills, Gerald F., Clark, NJ, United States

Giacobbe, Robert A., Lavallette, NJ, United States Zink, Deborah L., Manalapan, NJ, United States

Cabello, Angeles, Madrid, Spain Diez, Maria T., Madrid, Spain Martin, Isabella, Madrid, Spain Pelaez, Fernando, Madrid, Spain Vicente, Francisca, Madrid, Spain

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.

corporation)

NUMBER DATE

PRIORITY INFORMATION: US 1996-10932P 19960131 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weber, Jon P.
ASSISTANT EXAMINER: Hanley, Susan

LEGAL REPRESENTATIVE: Korsen, Elliott, Daniel, Mark R.

NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 456

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a compound having the formula ##STR1## which is produced by the fungus, Arthrinium arundinis ATCC 74359, and exhibits antifungal activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD A methanol (MeOH) extract of a liquid fermentation of Arthrinium arundinis MF 6175, corresponding to 600 ml of whole broth was filtered, concentrated to dryness and partitioned between methyl ethyl ketone (MEK) and water. The MEK layer was dried, reconstituted in MeOH/H.sub.2 O and chromatographed on an open Amicon C8 reverse phase colunto using a MeOH/H.sub.2. . .

=> d ibib abs kwic 14

L6 ANSWER 14 OF 19 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:128562 BIOSIS DOCUMENT NUMBER: PREV200100128562

TITLE: Regulation of human neutrophil-mediated cartilage

proteoglycan degradation by phosphatidylinositol-3-kinase.

AUTHOR(S): Hii, C. S. T. (1); Marin, L. A.; Halliday, D.; Roberton, D.

M.; Murray, A. W.

CORPORATE SOURCE: (1) Department of Immunopathology, Women's and Children's

Hospital, 72 King William Road, North Adelaide, SA, 5006

Australia

SOURCE: Immunology, (January, 2001) Vol. 102, No. 1, pp. 59-66.

print.

ISSN: 0019-2805.

DOCUMENT TYPE: Article
LANGUAGE: English
SUMMARY LANGUAGE: English

AB The ability of neutrophils to degrade cartilage proteoglycan suggests that the neutrophils that accumulate in the joints of rheumatoid arthritis patients are mediators of tissue damage. The regulatory

mechanisms which are relevant to the proteoglycan-degrading activity of

neutrophils are poorly understood. Since phosphatidylinositol 3-kinase (PI3-K), protein kinase C (PKC), the extracellular signal-regulated protein kinase (ERK) 1/ERK2 and cyclic adenosine monophosphate (cAMP) have been reported to regulate neutrophil respiratory burst and/or degranulation, a role for these signalling molecules in regulating proteoglycan degradation was investigated. Preincubation of human neutrophils with GF109203X (an inhibitor of PKC), PD98059 (an inhibitor of MEK, the upstream regulator of ERK1/ERK2) or with forskolin or dibutyryl cAMP, failed to suppress proteoglycan degradation of opsonized bovine cartilage. In contrast, preincubation of neutrophils with wortmannin or LY294002, specific inhibitors of PI3-K, inhibited proteoglycan degradation. Incubation of neutrophils with cartilage resulted in the activation of PI3-K in neutrophils, consistent with a role for PI3-K in proteoglycan degradation. Activation of PI3-K and proteoglycan degradation was enhanced by tumour necrosis factor-alpha. Degradation caused by neutrophils from the synovial fluid of rheumatoid arthritis patients was also inhibited by wortmannin. These data demonstrate that the proteoglycan degradative activity of neutrophils required PI3-K but not PKC or the ERK1/ERK2/ERK5 cascades and was insensitive to increases in intracellular cAMP concentrations. The ability of neutrophils to degrade cartilage proteoglycan suggests that AB the neutrophils that accumulate in the joints of rheumatoid arthritis patients are mediators of tissue damage. The regulatory mechanisms which are relevant to the proteoglycan-degrading activity of neutrophils are poorly. . . in regulating proteoglycan degradation was investigated. Preincubation of human neutrophils with GF109203X (an inhibitor of PKC), PD98059 (an inhibitor of MEK, the upstream regulator of ERK1/ERK2) or with forskolin or dibutyryl cAMP, failed to suppress proteoglycan degradation of opsonized bovine cartilage... PI3-K and proteoglycan degradation was enhanced by tumour necrosis factor-alpha. Degradation caused by neutrophils from the synovial fluid of rheumatoid arthritis patients was also inhibited by wortmannin. These data demonstrate that the proteoglycan degradative activity of neutrophils required PI3-K but not.

```
=> s l1 (S) l3
L7 169 L1 (S) L3
```

=> dup rem 17
PROCESSING COMPLETED FOR L7
L8 155 DUP REM L7 (14 DUPLICATES REMOVED)

=> d ibib abs kwic 150-155

L8 ANSWER 150 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1995:544115 BIOSIS DOCUMENT NUMBER: PREV199698558415

TITLE: Activation of the SAPK pathway by the human STE20 homologue

germinal centre kinase.

AUTHOR(S): Pombo, Celia M. (1); Kehrl, John H.; Sanchez, Irma; Katz,

Paul; Avruch, Joseph; Zon, Leonard I.; Woodgett, James R.;

Force, Thomas; Kyriakis, John M.

CORPORATE SOURCE: (1) Diabetes Res. Lab., Mass. Gen. Hosp. E., 149 13th St.,

Charlestown, MA 02129 USA

SOURCE: Nature (London), (1995) Vol. 377, No. 6551, pp. 750-754.

ISSN: 0028-0836.

DOCUMENT TYPE: Article
LANGUAGE: English

AB Eukaryotic cells respond to different extracellular stimuli by recruiting homologous signalling pathways that use members of the MEKK, MEK and ERK families of protein kinases. The MEKK fwdarw MEK fwdarw

ERK core pathways of Saccharomyces cerevisiae may themselves be regulated by members of the STE20 family of protein kinases. Here we report specific activation of the mammalian stress-activated protein kinase (SAPK) pathway by germinal centre kinase (GCK; ref. 3), a human STE20 homologue. SAPKs, members of the ERK family, are activated in situ by inflammatory stimuli, including tumour-necrosis factor (TNF) and interleukin-1, and phosphorylate and probably stimulate the transactivation function of c-Jun. Although GCK is found in many tissues, its expression in lymphoid follicles is restricted to the cells of the germinal centre, where it may participate in B-cell differentiation-3. Activation of the SAPK pathway by GCK illustrates further the striking conservation of eukaryotic signalling mechanisms and defines the first physiological function of a mammalian Ste20.

AB Eukaryotic cells respond to different extracellular stimuli by recruiting homologous signalling pathways that use members of the MEKK, MEK and ERK families of protein kinases. The MEKK fwdarw MEK fwdarw ERK core pathways of Saccharomyces cerevisiae may themselves be regulated by members of the STE20 family of protein kinases.. . . centre kinase (GCK; ref. 3), a human STE20 homologue. SAPKs, members of the ERK family, are activated in situ by inflammatory stimuli, including tumour-necrosis factor (TNF) and interleukin-1, and phosphorylate and probably stimulate the transactivation function of c-Jun. Although GCK is.

ANSWER 151 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC. L8

1995:323177 BIOSIS ACCESSION NUMBER: DOCUMENT NUMBER: PREV199598337477

TITLE: Neuropharmacology of nicotine: Effects on the

autoregulation of acetylcholine release by substance P and

methionine enkephalin in rodent cerebral slices and

toxicological implications.

AUTHOR (S): Sastry, B. V. Rama

CORPORATE SOURCE: Dep. Pharmacol., Vanderbilt Univ. Med. Cent., Nashville, TN

37232-2125 USA

SOURCE: Clinical and Experimental Pharmacology and Physiology,

(1995) Vol. 22, No. 4, pp. 288-290.

ISSN: 0305-1870.

DOCUMENT TYPE: Article LANGUAGE: English

AB 1. The neuronal release of acetylcholine (ACh) and its autoregulation by neuromodulators, substance P (SP) and methionine enkephalin (MEK), have been studied using superfused rodent cerebral slices. Nicotine exerts significant effects on autoregulation of ACh release, which may have toxicological implications. 2. Positive and negative feedback systems have been postulated for autoregulation of ACh release. The components of the positive feedback system include a muscarinic (Ms) receptor, SP, and activation of Ca-2+ influx. Low levels of ACh in the biophase of the cholinergic synaptic gap may trigger the positive feedback system, and high levels of ACh may trigger the negative feedback system. 3. There are also neuronal pathways for direct reciprocal regulations of SP and MEK. 4. Low concentrations of nicotine triggers the release of ACh followed by MEK and SP. Release of SP causes neurogenic inflammation. 5. Nicotine and its metabolite, cotinine, activate platelet activating factor (PAF)-hydrolase and thereby enhance the turnover rate of PAF. This effect may contribute to tobacco-induced arterial thrombosis in peripheral and central nervous systems. AR 1. The neuronal release of acetylcholine (ACh) and its autoregulation by neuromodulators, substance P (SP) and methionine enkephalin (MEK), have been studied using superfused rodent cerebral slices. Nicotine exerts significant effects on autoregulation of ACh release, which may

have. . . ACh may trigger the negative feedback system. 3. There are also neuronal pathways for direct reciprocal regulations of SP and

MEK. 4. Low concentrations of nicotine triggers the release of ACh followed by MEK and SP. Release of SP causes neurogenic inflammation. 5. Nicotine and its metabolite, cotinine, activate platelet activating factor (PAF)-hydrolase and thereby enhance the turnover rate of PAF. This. . .

L8 ANSWER 152 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1994:483579 BIOSIS DOCUMENT NUMBER: PREV199497496579

TITLE: Mapping of the C5a receptor signal transduction network in

human neutrophils.

AUTHOR(S): Buhl, Anne Mette (1); Avdi, Natalie; Worthen, G. Scott;

Johnson, Gary L.

CORPORATE SOURCE: (1) Div. Biostructural Chem., Dep. Chem., University

Aarhus, DK-8000 Aarhus Denmark

SOURCE: Proceedings of the National Academy of Sciences of the

United States of America, (1994) Vol. 91, No. 19, pp.

9190-9194.

ISSN: 0027-8424.

DOCUMENT TYPE: Article LANGUAGE: English

Human neutrophils respond to chemoattractants, resulting in their accumulation at an inflammatory site. Chemoattractants such as the C5a peptide, derived from the C5 complement factor, bind to inhibitory guanine nucleotide binding protein (G-i)-coupled seven membrane-spanning receptors expressed in neutrophils. C5a receptor activation results in the G-i-dependent activation of the mitogen-activated protein (MAP) kinase pathway in human neutrophils. C5a receptor ligation activates both B-Raf and Raf-1, with B-Raf activation overlapping but temporally distinct from that of Raf-1. B-Raf and Raf-1 both efficiently phosphorylate MAP kinase kinase (MEK-1). C5a also stimulates guanine nucleotide exchange and activation of Ras. Ras and Raf activation In response to $\bar{\text{C5}}\text{a}$ involves protein kinase C-dependent and -independent pathways. Activation of both Raf-1 and B-Raf was inhibited by protein kinase A stimulation, consistent with the inhibitory effects of increased cAMP levels on neutrophil function. The findings define a functional signal transduction pathway linking the neutrophil C5a chemoattractant receptor to the regulation of Ras, B-Raf, Raf-1, and MAP kinase.

AB Human neutrophils respond to chemoattractants, resulting in their accumulation at an **inflammatory** site. Chemoattractants such as the C5a peptide, derived from the C5 complement factor, bind to inhibitory guanine nucleotide binding protein. . . with B-Raf activation overlapping but temporally distinct from that of Raf-1. B-Raf and Raf-1 both efficiently phosphorylate MAP kinase kinase (MEK-1). C5a also stimulates guanine nucleotide exchange and activation of Ras. Ras and Raf activation In response to C5a involves protein. . .

L8 ANSWER 153 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1996:422615 BIOSIS DOCUMENT NUMBER: PREV199699153671

TITLE: Lipopolysaccharide signals activation of tumor necrosis

factor biosynthesis through the Ras/Raf-1/MEK/MAPK pathway.

AUTHOR(S): Geppert, Thomas D.; Whitehurst, Charles E.; Thompson,

Patricia; Beutler, Bruce (1)

CORPORATE SOURCE: (1) Howard Hughes Med. Inst., U.T. Southwestern Med.

Center, 5323 Harry Hines Blvd., Y5.210, Dallas, TX

75235-9050 USA

SOURCE: Molecular Medicine (Cambridge), (1994) Vol. 1, No. 1, pp.

93-103.

ISSN: 1076-1551.

DOCUMENT TYPE: Article LANGUAGE: English

Background: Lipopolysaccharide (LPS) is known to activate macrophages, AB causing the release of toxic cytokines that may provoke inflammation and shock. One of the most important and best studied of these cytokines is tumor necrosis factor (TNF). Details of the signaling pathway leading to TNF biosynthesis remain unclear. The pathway is branched in the sense that TNF gene transcription and TNF mRNA translation are both strongly stimulated by LPS. Recent evidence has indicated that MAP kinase homologs become phosphorylated in LPS-stimulated cells, suggesting their possible involvement in signal transduction. We sought to test this hypothesis. Materials and Methods: Measurements of LPS-induced MEK and ERK2 activity were undertaken in LPS-sensitive and LPS-insensitive cells. Transfection studies, in which dominant inhibitors of ras and raf-1 were used to block signaling to the level of MAP kinase, were carried out in order to judge whether the TNF gene transcription and TNF mRNA translation are modulated through this pathway. Results: In RAW 264.7 mouse macrophages, both ERK2 and MEK1 activity are induced by LPS treatment. In the same cell line, dominant negative inhibitors of ras and raf-1 block LPS-induced activation of the TNF promoter, as well as derepression of the translational blockade normally imposed by the TNF 3'-untranslated region. A constitutively active form of raf-1 (raf-BXB) was found to augment, but not replace, the LPS signal. In LPS-insensitive cells (RAW 264.7 times NIH 3T3 fusion hybrid cells and primary macrophages derived from C3H/HeJ mice), ERK2 activity was found to be refractory to induction by LPS. Conclusions: The ras/raf-1/MEK/MAPK pathway is chiefly responsible for transduction of the LPS signal to the level of the TNF gene and mRNA. raf and raf-1 lie upstream from (or actually represent) the physical branchpoints of the transcriptional and translation activation signals generated by LPS. The lesions that prevent LPS signaling in macrophages from C3H/HeJ mice, or in RAW 264.7 times NIH 3T3 fusion hybrid cells, occupy a proximal position in the signaling pathway.

AB Background: Lipopolysaccharide (LPS) is known to activate macrophages, causing the release of toxic cytokines that may provoke inflammation and shock. One of the most important and best studied of these cytokines is tumor necrosis factor (TNF). Details of. . . cells, suggesting their possible involvement in signal transduction. We sought to test this hypothesis. Materials and Methods: Measurements of LPS-induced MEK and ERK2 activity were undertaken in LPS-sensitive and LPS-insensitive cells. Transfection studies, in which dominant inhibitors of ras and raf-1. . . and primary macrophages derived from C3H/HeJ mice), ERK2 activity was found to be refractory to induction by LPS. Conclusions: The ras/raf-1/MEK/MAPK pathway is chiefly responsible for transduction of the LPS signal to the level of the TNF gene and mRNA. raf. . .

L8 ANSWER 154 OF 155 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:179561 CAPLUS

DOCUMENT NUMBER: 110:179561

TITLE: Anti-inflammatory analgesic gels of mefenamic acid for

transdermal administration

INVENTOR(S): Shimizu, Toshito; Nishizawa, Takashi; Sato, Kazunori;

Okada, Taizo; Morioka, Shigeo

PATENT ASSIGNEE(S): Sato Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

JP 63287721 A2 19881124 JP 1987-121184 19870520 JP 06096527 B4 19941130

AB An anti-inflammatory analgesic gel contains mefenamic acid (I) as an active ingredient. I (2 g) was dissolved in a mixt. of propylene carbonate 5, crotamiton 5, HOCHMeCH2CH2OH (II) 40, and MEK 10 g and successively mixed with 1 g Hiviswako 104 (carboxyvinyl polymer) swollen in 10 g H2O, a soln. of 1 g NH(CMe2OH)2 in 10 g EtOH, and EtOH to give 100 g anti-inflammatory analgesic gel. The gel inhibited paw edema caused by fracture in rats 29.5%, vs. 14.8% for a control gel similarly prepd. using indomethacin, poly(ethylene glycol) instead of II, and carbopol 940 (carboxyvinyl polymer).

AB An anti-inflammatory analgesic gel contains mefenamic acid (I) as an active ingredient. I (2 g) was dissolved in a mixt. of propylene carbonate 5, crotamiton 5, HOCHMeCH2CH2OH (II) 40, and MEK 10 g and successively mixed with 1 g Hiviswako 104 (carboxyvinyl polymer) swollen in 10 g H2O, a soln. of 1 g NH(CMe2OH)2 in 10 g EtOH, and EtOH to give 100 g anti-inflammatory analgesic gel. The gel inhibited paw edema caused by fracture in rats 29.5%, vs. 14.8% for a control gel similarly prepd. using indomethacin, poly(ethylene glycol) instead of II, and carbopol 940 (carboxyvinyl polymer).

L8 ANSWER 155 OF 155 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:151779 CAPLUS

DOCUMENT NUMBER: 108:151779

TITLE: Flame-retardant polyester-epoxy adhesive compositions

INVENTOR(S): Hara, Kaoru; Hiramoto, Yoshi
PATENT ASSIGNEE(S): Toray Industries, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE JP 62218465 A2 19870925 -----JP 1986-60772 19860320 AB The title adhesive compns. comprise epoxy resins, curing agents, and flame-retardant polyesters contg. 20-50% mol% phosphate ester moiety OP(O)RR1CO (R = C1-6 alkyl, C6-12 aryl; R1 = C1-6 alkylene, C6-12 arylene) (based on total acid component). Thus, isophthalic acid 83, adipic acid 40, and HOCH2CH2OH 86.8 g were polymd. at 200.degree. for 4 h, then treated with 40.2 g 2-methyl-2,5-dioxo-1-oxa-2-phospholane in the presence of 147 mg Sb2O3 at 290.degree. and 0.1 mmHg for 3 h to give a polyester, 100 parts of which was mixed with MEK 150, BREN-S (brominated epoxy resin) 30, Epikote 152 50, and phthalic anhydride 4.0 parts and stirred to give an adhesive showing UL-94 inflammability V-2 and bonding strength 1.3 kg/cm.

The title adhesive compns. comprise epoxy resins, curing agents, and flame-retardant polyesters contg. 20-50% mol% phosphate ester moiety OP(O)RR1CO (R = C1-6 alkyl, C6-12 aryl; R1 = C1-6 alkylene, C6-12 arylene) (based on total acid component). Thus, isophthalic acid 83, adipic acid 40, and HOCH2CH2OH 86.8 g were polymd. at 200.degree. for 4 h, then treated with 40.2 g 2-methyl-2,5-dioxo-1-oxa-2-phospholane in the presence of 147 mg Sb2O3 at 290.degree. and 0.1 mmHg for 3 h to give a polyester, 100 parts of which was mixed with MEK 150, BREN-S (brominated epoxy resin) 30, Epikote 152 50, and phthalic anhydride 4.0 parts and stirred to give an adhesive showing UL-94 inflammability V-2 and bonding strength 1.3 kg/cm.

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 47.50 47.92 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL SESSION ENTRY CA SUBSCRIBER PRICE -3.10 -3.10

FILE 'STNGUIDE' ENTERED AT 17:23:13 ON 11 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 7, 2002 (20020607/UP).

=> FIL CAPL BIOSIS IPA USPATF

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 0.06 47.98 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE 0.00 -3.10

FILE 'CAPLUS' ENTERED AT 17:23:28 ON 11 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:23:28 ON 11 JUN 2002 COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'IPA' ENTERED AT 17:23:28 ON 11 JUN 2002 COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'USPATFULL' ENTERED AT 17:23:28 ON 11 JUN 2002 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> d ibib abs kwic 145-149

L8 ANSWER 145 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1997:513808 BIOSIS DOCUMENT NUMBER: PREV199799813011

TITLE: Cross-talk between secretory phospholipase A-2 and

cytosolic phospholipase A-2 in rat renal mesangial cells.

AUTHOR(S): Huwiler, Andrea; Staudt, Georgia; Kramer, Ruth M.;

Pfeilschifter, Josef (1)

CORPORATE SOURCE: (1) Dep. Pharmacol., Biozentrum, Univ. Basel,

Klingelbergstrasse 70, CH-4056 Basel Switzerland

SOURCE: Biochimica et Biophysica Acta, (1997) Vol. 1348, No. 3, pp.

257-272.

ISSN: 0006-3002.

DOCUMENT TYPE: Article LANGUAGE: English

AB Incubation of rat glomerular mesangial cells with potent proinflammatory cytokines like interleukin 1-beta (IL-1-beta) triggers the expression of a non-pancreatic secretory phospholipase A-2 (sPLA-2) and increases the formation of prostaglandin E-2. We show here that sPLA-2 acts in an autocrine fashion on mesangial cells and induces a rapid activation of protein kinase C (PKC) isoenzymes delta and epsilon and of p42 mitogen-activated protein kinase (MAPK), two putative activators of

cytosolic phospholipase A-2 (cPLA-2). sPLA-2 also activates Raf-1 kinase in mesangial cells which integrates the signals coming from PKC for further processing along the MAPK cascade. Subsequently a phosphorylation and activation of cPLA-2 is observed. thus arguing for a cross-talk between the two classes of PLA-2. Pretreatment of cells with either the highly specific PKC inhibitor Ro-318220 or the highly specific MAPK kinase (MEK) inhibitor PD 98059 completely blocked the sPLA-2-induced cPLA-2 activation, indicating that both kinases are essential for the cross-talk between the two types of PLA-2. The effect of SPLA-2 is mimicked by lysophosphatidylcholine (LPC), a reaction product of sPLA-2 activity. LPC stimulates PKC-epsilon, Raf-1 kinase and MAPK activation as welt as cPLA-2 activation with a subsequent increase in arachidonic acid release from mesangial cells. These data suggest that sPLA-2 by cleaving membrane phospholipids and generating LPC and other lysophospholipids activates cPLA-2 via the PKC/Raf-1/MAPK signalling pathway. Hence a network of interactions between different PLA-2s is operative in mesangial cells and may contribute to the progression of glomerular inflammatory processes.

. classes of PLA-2. Pretreatment of cells with either the highly AB. specific PKC inhibitor Ro-318220 or the highly specific MAPK kinase (MEK) inhibitor PD 98059 completely blocked the sPLA-2-induced cPLA-2 activation, indicating that both kinases are essential for the cross-talk between the. . . a network of interactions between different PLA-2s is operative in mesangial cells and may contribute to the progression of glomerular inflammatory processes.

ANSWER 146 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: DOCUMENT NUMBER:

1997:17680 BIOSIS PREV199799316883

TITLE:

Mammalian mitogen-activated protein kinase pathways are regulated through formation of specific kinase-activator

complexes.

AUTHOR (S):

Zanke, Brent W. (1); Rubie, Elizabeth A.; Winnett, Elaine; Chan, Joanne; Randall, Susan; Parsons, Michael; Boudreau, Kim; McInnis, Mathew; Yan, Minhong; Templeton, Dennis J.;

Woodgett, James R.

CORPORATE SOURCE:

(1) Dep. Med., Ontario Cancer Inst., Princess Margaret Hosp., 610 University Ave., Toronto, Ontario M5G 2M9 Canada

SOURCE:

Journal of Biological Chemistry, (1996) Vol. 271, No. 47,

pp. 29876-29881. ISSN: 0021-9258.

DOCUMENT TYPE:

Article English

LANGUAGE: Mammalian cells contain at least three signaling systems which are structurally related to the mitogen-activated protein kinase (MAPK) pathway. Growth factors acting through Ras primarily stimulate the Raf/ MEK/MAPK cascade of protein kinases. In contrast, many stress-related signals such as heat shock, inflammatory cytokines, and hyperosmolarity induce the MEKK/SEK(MKK4)/SAPK(JNK) and/or the MKK3 or MKK6/p38-hog pathways. Physiological agonists of these pathway types are either qualitatively or quantitatively distinct, suggesting few common proximal signaling elements, although past studies performed in vitro, or in cells using transient over-expression, reveal interaction between the components of all three pathways. These studies suggest a high degree of cross-talk apparently not seen in vivo. We have examined the possible molecular basis of the differing agonist profiles of these three MAPK pathways. We report preferential association between MAP kinases and their activators in eukaryotic cells. Furthermore, using the yeast 2-hybrid system, we show that association between these components can occur independent of additional eukaryotic proteins. We show that SAPK(JNK) or p38-hog activation is specifically impaired by co-expression of cognate dominant negative MAP kinase kinase mutants, demonstrating

functional specificity at this level. Further divergence and insulation of the stress pathways occurs proximal to the MAPK kinases since activation of the MAPK kinase kinase MEKK results in SAPK(JNK) activation but does not cause p38-hog phosphorylation. Therefore, in intact cells, the three MAPK pathways may be independently regulated and their components show specificity in their interaction with cognate cascade members. The degree of intermolecular specificity suggests that mammalian MAPK signaling pathways may remain distinct without the need for specific scaffolding proteins to sequester components of individual pathways.

AB. systems which are structurally related to the mitogen-activated protein kinase (MAPK) pathway. Growth factors acting through Ras primarily stimulate the Raf/MEK/MAPK cascade of protein kinases. In contrast, many stress-related signals such as heat shock, inflammatory cytokines, and hyperosmolarity induce the MEKK/SEK(MKK4)/SAPK(JNK) and/or the MKK3 or MKK6/p38-hog pathways. Physiological agonists of these pathway types are either.

ANSWER 147 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: DOCUMENT NUMBER:

1996:314952 BIOSIS

PREV199699037308

TITLE:

Endothelial cell inflammatory responses to tumor necrosis

factor alpha.: Ceramide-dependent and -independent

AUTHOR (S):

mitogen-activated protein kinase cascades.

Modur, Vijayanand; Zimmerman, Guy A.; Prescott, Stephen M.;

McIntyre, Thomas M. (1)

CORPORATE SOURCE:

(1) Bldg. 500, CVRTI, Univ. Utah, Salt Lake City, UT 841112

USA

SOURCE:

Journal of Biological Chemistry, (1996) Vol. 271, No. 22,

pp. 13094-13102.

ISSN: 0021-9258.

DOCUMENT TYPE:

Article English

LANGUAGE:

AΒ Ceramide generation by stimulated sphingomyelinase activity has been implicated in tumor necrosis factor alpha (TNF) signaling of apoptosis and differentiation. We examined the role of ceramide in a major action of TNF: the initiation of inflammatory events. Sphingomyelinase C at high levels induced inflammatory protein expression in endothelial cells resulting in leukocyte adhesion, but the pattern of induction of adhesion molecules (E-selectin, ICAM-1, VCAM-1) and cytokines (interleukins 6 and 8) differed from that induced by TNF. TNF induced only a small increase in ceramide: using lower doses of sphingomyelinase to mimic this we found that small amounts of ceramide did not induce protein expression, but still rapidly activated Raf-1, mitogen-activated protein/extracellular regulated kinase (ERK) kinase (MEK) and ERKs. TNF additionally caused rapid p38 and JNK-1 mitogen-activated protein kinase activation and efficient NF-kappa-B translocation, which could not be achieved even by high levels of ceramide. Thus activation of the ERK cascade alone is an incomplete endothelial cell stimulus, and the TNF receptor generates at least two signals: Raf-1 activation, which could be ceramide-dependent; and ceramide-independent efficient NF-kappa-B translocation and activation of p38 and JNK-1 mitogen-activated kinases.

AB. signaling of apoptosis and differentiation. We examined the role of ceramide in a major action of TNF: the initiation of inflammatory events. Sphingomyelinase C at high levels induced inflammatory protein expression in endothelial cells resulting in leukocyte adhesion, but the pattern of induction of adhesion molecules (E-selectin, ICAM-1, . . small amounts of ceramide did not induce protein expression, but still rapidly activated Raf-1, mitogen-activated protein/extracellular regulated kinase (ERK) kinase (MEK) and ERKs. TNF additionally caused rapid p38 and JNK-1 mitogen-activated protein kinase activation and efficient NF-kappa-B translocation, which could not.

L8 ANSWER 148 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1996:313342 BIOSIS DOCUMENT NUMBER: PREV199699035698

TITLE: Aggregation of the Fc-epsilon-RI on mast cells stimulates

c-Jun amino-terminal kinase activity: A response inhibited

by wortmannin.

AUTHOR(S): Ishizuka, Tamotsu; Oshiba, Akihiro; Sakata, Naoki; Terada,

Naohiro; Johnson, Gary L.; Gelfand, Erwin W. (1) (1) Dept. Pediatrics, Natl. Jewish Cent. Immunol.

Respiratory Med., 1400 Jackson St., Denver, CO 80206 USA

SOURCE: Journal of Biological Chemistry, (1996) Vol. 271, No. 22,

pp. 12762-12766. ISSN: 0021-9258.

ISSN: 0021-92

DOCUMENT TYPE: Article LANGUAGE: English

CORPORATE SOURCE:

Aggregation of the high-affinity Fc receptors for immunoglobulin E (IgE) AΒ (Fc-epsilon-RI) on the surface of mast cells initiates intracellular signal transduction pathways including the tyrosine phosphorylation of cellular proteins, phosphoinositide hydrolysis, an increase in intracellular calcium, and protein kinase C activation. These signals are believed to be involved in the exocytic release of inflammatory mediators such as vasoactive amines, cytokines, and lipid metabolites. However, the downstream consequences of these early activation events are not well defined. One exception is the activation of the extracellular signal-regulated kinases/mitogen-activated protein kinases. One member of the mitogen-activated protein kinase superfamily, designated c-Jun amino-terminal kinase (JNK), has been recently identified. JNK is activated following dual phosphorylation at a Thr-Pro-Tyr motif in response to diverse stimuli including tumor necrosis factor-alpha, heat shock, or ultraviolet irradiation. We found that JNK was strongly activated by antigen cross-linking in a mouse mast cell line passively sensitized with ovalbumin-specific IgE. Anti-mouse IgE antibody also activated JNK. MEK kinase 1 (MEKK1) which activates the JNK activator, JNK kinase (JNKK), was similarly activated by antigen stimulation. JNK but not p42-erk2 activation induced by antigen was significantly inhibited in the presence of wortmannin, a known inhibitor of phosphatidylinositol 3-kinase. These results indicate that in response to the aggregation of Fc-epsilon-RI on mast cells, phosphatidylinositol 3-kinase activation is involved in the stimulation of the MEKK1, JNKK, JNK pathway.

AB. . . in intracellular calcium, and protein kinase C activation. These signals are believed to be involved in the exocytic release of inflammatory mediators such as vasoactive amines, cytokines, and lipid metabolites. However, the downstream consequences of these early activation events are not. . . by antigen cross-linking in a mouse mast cell line passively sensitized with ovalbumin-specific IgE. Anti-mouse IgE antibody also activated JNK. MEK kinase 1 (MEKK1) which activates the JNK activator, JNK kinase (JNKK), was similarly activated by antigen stimulation. JNK but not. . .

L8 ANSWER 149 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1996:361111 BIOSIS DOCUMENT NUMBER: PREV199699083467

TITLE: Inhibition of MAP kinase kinase (MEK) blocks endothelial

PGI-2 release but has no effect on von Willebrand factor

secretion or E-selectin expression.

AUTHOR(S): Wheeler-Jones, Caroline P. D. (1); May, Michael J.;

Houliston, Rebecca A.; Pearson, Jeremy D.

CORPORATE SOURCE: (1) Vascular Biol. Res. Centre, King's Coll. London,

Campden Hill Road, Kensington, London W8 7AH UK

SOURCE: FEBS Letters, (1996) Vol. 388, No. 2-3, pp. 180-184.

ISSN: 0014-5793.

DOCUMENT TYPE: Article LANGUAGE: English

We have examined the potential role of MAP kinase in the regulation of endothelial cell PGI-2 synthesis, vWF secretion and E-selectin expression using the specific MEK inhibitor PD98059. PD98059 dose-dependently attenuated the tyrosine phosphorylation and activation of p42-mapk in response to thrombin or inflammatory cytokines. Inhibition of thrombin-induced p42-mapk activation was paralleled by an inhibitory effect of PD98059 on thrombin-driven PGI-2 generation but not on vWF secretion or IL-1-alpha/TNF-alpha-induced E-selectin expression. These results provide evidence for a key role for p42-mapk in the acute regulation of PGI-2 synthesis in human endothelial cells and suggest that activation of the MAP kinase cascade is not obliqatory for cytokine-stimulated E-selectin expression.

AB. . role of MAP kinase in the regulation of endothelial cell PGI-2 synthesis, vWF secretion and E-selectin expression using the specific MEK inhibitor PD98059. PD98059 dose-dependently attenuated the tyrosine phosphorylation and activation of p42-mapk in response to thrombin or inflammatory cytokines. Inhibition of thrombin-induced p42-mapk activation was paralleled by an inhibitory effect of PD98059 on thrombin-driven PGI-2 generation but not.

=> d ibib abs kwic 140-144

ANSWER 140 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

1998:357301 BIOSIS ACCESSION NUMBER: DOCUMENT NUMBER:

PREV199800357301

TITLE: Integrin-dependent homotypic adhesion of neutrophils:

Arachidonic acid activates Raf-1/Mek/Erk via a

5-lipoxygenase-dependent pathway.

AUTHOR (S): Capodici, Constance; Pillinger, Michael H. (1); Han, Gene;

Philips, Mark R.; Weissmann, Gerald

(1) Div. Rheumatol. NB16N1, New York Univ. Med. Cent., 550 CORPORATE SOURCE:

First Avenue, New York, NY 10016 USA

SOURCE: Journal of Clinical Investigation, (July 1, 1998) Vol. 102,

No. 1, pp. 165-174.

ISSN: 0021-9738.

DOCUMENT TYPE:

Article English

LANGUAGE: AΒ AA stimulates integrin-dependent neutrophil adhesion, a critical early step in acute inflammation. However, neither the signaling pathway(s) of AA-stimulated adhesion, nor whether AA acts directly or through the generation of active metabolites, has been elucidated. Previously, we have observed a tight association between neutrophil Erk activation and homotypic adhesion in response to chemoattractants acting through G protein-linked receptors. We now report a similar association between homotypic adhesion and Erk activation in response to AA. Erk activation was cyclooxygenase independent and required AA metabolism to 5(S) hydroperoxyeicosatetraenoic acid (5-HpETE) via 5-lipoxygenase, but not the further lipoxygenase-dependent metabolism of 5-HpETE to leukotrienes. AA stimulation of Erk was accompanied by Raf-1 activation and was sensitive to inhibitors of Raf-1 and Mek. Whereas activation of Erk by AA was pertussis toxin sensitive, (3H)-AA binding to neutrophils was not saturable, suggesting that an AA metabolite activates a G protein. Consistent with this hypothesis, Erk activation by 5(S)hydroxyeicosatetraenoic acid (5HETE; lipoxygenase-independent metabolite of 5-HpETE) was also pertussis toxin sensitive. These data suggest that a 5-lipoxygenase metabolite of AA, e.g., 5-HETE, is released from AA-treated cells to engage a plasma membrane-associated, pertussis toxin-sensitive, G protein-linked receptor, leading to activation of Erk and adhesion via the Raf-1/Mek signal transduction pathway.

AA stimulates integrin-dependent neutrophil adhesion, a critical early step in acute inflammation. However, neither the signaling pathway(s) of AA-stimulated adhesion, nor whether AA acts directly or through the generation of active metabolites,. . . 5-HpETE to leukotrienes. AA stimulation of Erk was accompanied by Raf-1 activation and was sensitive to inhibitors of Raf-1 and Mek. Whereas activation of Erk by AA was pertussis toxin sensitive, (3H)-AA binding to neutrophils was not saturable, suggesting that an. . . cells to engage a plasma membrane-associated, pertussis toxin-sensitive, G protein-linked receptor, leading to activation of Erk and adhesion via the Raf-1/Mek signal transduction pathway.

L8 ANSWER 141 OF 155 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:805885 CAPLUS

DOCUMENT NUMBER: 128:47305

TITLE: Regulation of cytokine production in a hematopoietic

cell

INVENTOR(S): Gelfand, Erwin W.; Johnson, Gary L.

PATENT ASSIGNEE(S): National Jewish Medical and Research Center, USA

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
PATENT NO.
                         KIND DATE
                                                      APPLICATION NO. DATE
      WO 9745736 A1 19971204 WO 1997-US9102 19970530
      WO 9745736
           W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
                 RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU,
                 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
           RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
                 ML, MR, NE, SN, TD, TG
      US 5910417
                                                        US 1996-656563 19960531
                      Α
                                    19990608
      AU 9735672
                             A1
                                                        AU 1997-35672
                                    19980105
                                                                              19970530
                                                    US 1996-656563 A 19960531
WO 1997-US9102 W 19970530
PRIORITY APPLN. INFO.:
```

AB A method useful for regulating cytokine prodn. by a hematopoietic cell by regulating an MEKK/JNKK-contingent signal transduction pathway in such a cell is disclosed. Methods of identifying compds. capable of specifically regulating an MEKK/JNKK-contingent signal transduction pathway in hematopoietic cells, a kit for identifying cytokine regulators, methods to treat diseases involving cytokine prodn., and cells useful in such methods are also described.

IT Allergy inhibitors

Anti-inflammatory agents

Antitumor agents

Sepsis

(control of cytokine prodn. in hematopoietic cells via regulation of **MEK** kinase/JNK kinase signal transduction pathway in relation to)

L8 ANSWER 142 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1997:268395 BIOSIS DOCUMENT NUMBER: PREV199799560113

TITLE: Cdc42Hs, but not Rac1, inhibits serum-stimulated cell cycle

progression at G-1/S through a mechanism requiring p38/RK.

AUTHOR(S): Molnar, Arpad; Theodoras, Anne M.; Zon, Leonard I.;

Kyriakis, John M. (1)

CORPORATE SOURCE: (1) Diabetes Res. Laboratory, Massachusetts General Hosp.

East, 149 13th St., Charlestown, MA 02129 USA

SOURCE: Journal of Biological Chemistry, (1997) Vol. 272, No. 20,

pp. 13229-13235. ISSN: 0021-9258.

DOCUMENT TYPE: Article LANGUAGE: English

Antimitogenic stimuli such as environmental or genotoxic stress, transforming growth factor-beta, and the inflammatory cytokines tumor necrosis factor and interleukin-1 activate two extracellular signal-regulated kinase (ERK)-based signaling pathways: the stress-activated protein kinase (SAPK/JNK) pathway and the p38 pathway. Activated p38 phosphorylates transcription factors important in the regulation of cell growth and apoptosis, including activating transcription factor 2 (ATF2), Max, cAMP response element-binding protein-homologous protein/growth arrest DNA damage 153 (CHDP/GADD153). In turn, p38 lies downstream of the Rho family GTPases Cdc42Hs and Rac1, as well as at least three mitogen-activated protein kinase (MAPK)/ERK-kinases (MEKs): MAPK kinases-3, -6, and SAPK/ERK-kinase-1. Although many of the stimuli that activate p38 can also inhibit cell cycle progression, a clear-cut role for the p38 pathway in cell cycle regulation has not been established. Using a quantitative microinjection approach, we show here that Cdc42Hs, but not Rac1 or RhoA, can inhibit cell cycle progression at G-1/S through a mechanism requiring activation of p38. These results suggest a novel role for Cdc42Hs in cell cycle inhibition. Furthermore, these results suggest that although both Cdc42Hs and Rac1 can activate p38 in situ, the effects of Cdc42Hs and Rac1 on cell cycle progression are, in fact, quite distinct.

Antimitogenic stimuli such as environmental or genotoxic stress, transforming growth factor-beta, and the inflammatory cytokines tumor necrosis factor and interleukin-1 activate two extracellular signal-regulated kinase (ERK)-based signaling pathways: the stress-activated protein kinase (SAPK/JNK) pathway. . . lies downstream of the Rho family GTPases Cdc42Hs and Rac1, as well as at least three mitogen-activated protein kinase (MAPK)/ERK-kinases (MEKs): MAPK kinases-3, -6, and SAPK/ERK-kinase-1. Although many of the stimuli that activate p38 can also inhibit cell cycle progression, a. . .

L8 ANSWER 143 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1997:221081 BIOSIS DOCUMENT NUMBER: PREV199799512797

TITLE: VLA-4 integrin cross-linking on human monocytic THP-1 cells

induces tissue factor expression by a mechanism involving

mitogen-activated protein kinase.

AUTHOR(S): McGilvray, Ian D.; Lu, Ziyue; Bitar, Richard; Dackiw, Alan

P. B.; Davreux, Christopher J.; Rotstein, Ori D. (1)

CORPORATE SOURCE: (1) Toronto Hosp., 200 Elizabeth St. EN9-236, Toronto, ON

M5G 2C4 Canada

SOURCE: Journal of Biological Chemistry, (1997) Vol. 272, No. 15,

pp. 10287-10294. ISSN: 0021-9258.

DOCUMENT TYPE: Article LANGUAGE: English

AB Adhesion molecules such as VLA-4 are important not only for monocyte adhesion to extracellular matrix proteins, but also for subsequent cell activation. Monocyte adherence to fibronectin or engagement of VLA-4 has been demonstrated to stimulate production of potent inflammatory mediators such as tumor necrosis factor-alpha, interleukin-1, and the procoagulant tissue factor protein. However, the intracellular signaling cascades leading to gene expression have not been elucidated. Using the

human monocytic THP-1 cell line, VLA-4 cross-linking by monoclonal antibodies directed against its alpha-4 and beta-1 subunits produced a time-dependent increase in tyrosine phosphorylation of a broad range of cellular proteins. Using Western blot analysis directed against the phosphorylated form of the extracellular signal-related kinase (ERK) mitogen-activated protein (MAP) kinase proteins, as well as immunoprecipitation and in vitro kinase assays, we found that VLA-4 crosslinking increased ERK1/ERK2 tyrosine phosphorylation and activity. In conjunction, integrin cross-linking also increased NF-kappa-B nuclear translocation and 4-h expression of tissue factor. Inhibition of tyrosine kinase activity with genistein (10 mu-q/ml) as well as selective MAP kinase inhibition with the MEK-1 inhibitor PD98059 abolished the VIA-4-dependent ERK tyrosine phosphorylation, inhibited NF kappa-B nuclear binding, and abrogated tissue factor expression induced by both VLA-4 cross-linking and adhesion to fibronectin in THP-1 cells and human peripheral blood monocytes. These studies point to the involvement of the MAP kinase pathway in the activation of monocytic cells during transmigration to inflammatory sites.

AB. . . for subsequent cell activation. Monocyte adherence to fibronectin or engagement of VLA-4 has been demonstrated to stimulate production of potent inflammatory mediators such as tumor necrosis factor-alpha, interleukin-1, and the procoagulant tissue factor protein. However, the intracellular signaling cascades leading to. . . tissue factor. Inhibition of tyrosine kinase activity with genistein (10 mu-q/ml) as well as selective MAP kinase inhibition with the MEK-1 inhibitor PD98059 abolished the VIA-4-dependent ERK tyrosine phosphorylation, inhibited NF kappa-B nuclear binding, and abrogated tissue factor expression induced by. . . These studies point to the involvement of the MAP kinase pathway in the activation of monocytic cells during transmigration to inflammatory sites.

ANSWER 144 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC. SSION NUMBER: 1997:320977 BIOSIS

ACCESSION NUMBER: DOCUMENT NUMBER: PREV199799611465

TITLE: Mast cell tumor necrosis factor alpha production is

regulated by MEK kinases.

AUTHOR (S): Ishizuka, Tamotsu; Terada, Naohiro; Gerwins, Par;

Hamelmann, Eckard; Oshiba, Akihiro; Fanger, Gary R.;

Johnson, Gary L.; Gelfand, Erwin W. (1)

CORPORATE SOURCE: (1) Dep. Pediatrics, Natl. Jewish Med. Res. Cent., 1400

Jackson St., Denver, CO 80206 USA

SOURCE: Proceedings of the National Academy of Sciences of the

United States of America, (1997) Vol. 94, No. 12, pp.

6358-6363.

ISSN: 0027-8424.

DOCUMENT TYPE: Article LANGUAGE: English

Mast cells synthesize and secrete specific cytokines and chemokines which play an important role in allergic inflammation. Aggregation of the high-affinity Fc receptor (Fc-epsilon-RI) for immunoglobulin E (IgE) in MC/9 mouse mast cells stimulates the synthesis and secretion of tumor necrosis factor alpha (TNF-alpha). Fc-epsilon-RI aggregation activates several sequential protein kinase pathways, leading to increased activity of extracellular signal-regulated kinases (ERKs), c-Jun amino-terminal kinases (JNKs), and the p38 mitogen-activated protein (MAP) kinase. Inhibition of ERKs with the compound PD 098059 had little effect on Fc-epsilon-RI-stimulated TNF-alpha production. Aggregation of Fc-epsilon-RI stimulated MEK kinase 1 (MEKK1) activity, which activates JNK kinase (JNKK), the kinase that phosphorylates and activates JNKs. Expression of activated MEKK1 (DELTA-MEKK1) in MC/9 cells strongly stimulated JNK activity but only weakly stimulated p38 activity, and it induced a large activation of TNF-alpha promoter-regulated luciferase gene expression. Inhibitory mutant JNK2 expressed in MC/9 cells significantly blunted Fc-epsilon-RI stimulation of TNF-alpha promoter-driven luciferase expression. Wortmannin, an inhibitor of phosphatidylinositol 3-kinase, diminished Fc-epsilon-RI-mediated TNF-alpha synthesis, significantly blunted JNK activation and TNF-alpha promoter-driven luciferase expression, and only weakly inhibited p38 kinase activation. Inhibition of NF-kappa-B activation resulting from DELTA-MEKK1 expression or Fc-epsilon-RI stimulation did not affect TNF-alpha promoter-driven luciferase expression. Our findings define a MEKK-regulated JNK pathway activated by Fc-epsilon-RI that regulates TNF-alpha production in mast cells.

AB Mast cells synthesize and secrete specific cytokines and chemokines which play an important role in allergic inflammation. Aggregation of the high-affinity Fc receptor (Fc-epsilon-RI) for immunoglobulin E (IgE) in MC/9 mouse mast cells stimulates the synthesis and. . . kinase. Inhibition of ERKs with the compound PD 098059 had little effect on Fc-epsilon-RI-stimulated TNF-alpha production. Aggregation of Fc-epsilon-RI stimulated MEK kinase 1 (MEKK1) activity, which activates JNK kinase (JNKK), the kinase that phosphorylates and activates JNKs. Expression of activated MEKK1. . .

=> FIL STNGUIDE COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 26.10 74.08 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -0.62 -3.72

FILE 'STNGUIDE' ENTERED AT 17:26:48 ON 11 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 7, 2002 (20020607/UP).

=> d ibib abs kwic 140-144
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, BIOSIS, IPA, USPATFULL' - CONTINUE?
(Y) /N:n

=> FIL CAPL BIOSIS IPA USPATF COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 1.74 75.82 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE 0.00 -3.72

FILE 'CAPLUS' ENTERED AT 17:44:17 ON 11 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:44:17 ON 11 JUN 2002 COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'IPA' ENTERED AT 17:44:17 ON 11 JUN 2002 COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'USPATFULL' ENTERED AT 17:44:17 ON 11 JUN 2002 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> d ibib abs kwic 135-139

L8 ANSWER 135 OF 155 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:606418 CAPLUS

DOCUMENT NUMBER: 129:329553

TITLE: IL-13 suppresses TNF-induced activation of nuclear

factor-.kappa.B, activation protein-1, and apoptosis

AUTHOR(S): Manna, Sunil K.; Aggarwal, Bharat B.

CORPORATE SOURCE: Cytokine Research Laboratory, Department of Molecular

Oncology, University of Texas M. D. Anderson Cancer

Center, Houston, TX, 77030, USA

SOURCE: Journal of Immunology (1998), 161(6), 2863-2872

CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists

DOCUMENT TYPE: Journal LANGUAGE: English

IL-13 is known to suppress the prodn. of inflammatory cytokines such as AB TNF. Whether IL-13 also modulates the biol. effects of TNF is not known. Here, the authors examd. the effect of IL-13 on TNF-induced activation of nuclear transcription factors NF-.kappa.B, activation protein-1 (AP-1), and apoptosis. Pretreatment of cells with IL-13 blocked TNF-induced NF-.kappa.B activation, nuclear translocation of p65 subunit, and degrdn. of I.kappa.B.alpha.. IL-13 also inhibited NF-.kappa.B activation by LPS, okadaic acid, H2O2, and ceramide. TNF-induced NF-.kappa.B-dependent gene transcription was also blocked by IL-13. TNF-induced activation of another nuclear transcription factor, AP-1, was suppressed by IL-13. activation of N-terminal c-Jun kinase and mitogen-activated protein kinase kinase, implicated in the regulation of AP-1 and NF-.kappa.B, was also down-regulated by IL-13. TNF-mediated cytotoxicity and activation of caspase-3 were abolished by IL-13. The inhibitory effects of IL-13 on TNF were sensitive to H-7, neomycin, and wortmannin, suggesting that the pathway consisting of protein kinase C, phosphatidylinositol 3-kinase, and phospholipase C must be involved in IL-13 signaling. Thus, overall, these results demonstrate that IL-13 is a potent inhibitor of TNF-mediated activation of NF-.kappa.B, AP-1, and apoptosis, which may contribute to its previously described immunosuppressive and anti-inflammatory effects.

IT 9001-86-9, Phospholipase C 115926-52-8, Phosphatidylinositol 3-kinase
141436-78-4, Protein kinase C 146702-84-3, MEK kinase
155215-87-5, JNK kinase 169592-56-7, Caspase-3
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(interleukin-13 suppression of tumor necrosis factor-induced activation of nuclear factor-.kappa.B, activation protein-1, and apoptosis in relation to its immunosuppressive and anti-inflammatory

activities)

L8 ANSWER 136 OF 155 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 14 ACCESSION NUMBER: 1998:713152 CAPLUS

DOCUMENT NUMBER: 130:75737

TITLE: MEK inhibitors: the chemistry and biological activity

of U0126, its analogs, and cyclization products

AUTHOR(S): Duncia, John V.; Santella, Joseph B.; Higley, C. Anne; Pitts, William J.; Wityak, John; Frietze, William E.;

Rankin, F. Wayne; Sun, Jung-Hui; Earl, Richard A.; Tabaka, A. Christine; Teleha, Christopher A.; Blom, Karl F.; Favata, Margaret F.; Manos, Elizabeth J.; Daulerio, Andrea J.; Stradley, Deborah A.; Horiuchi, Kurumi; Copeland, Robert A.; Scherle, Peggy A.; Trzaskos, James M.; Magolda, Ronald L.; Trainor, George L.; Wexler, Ruth R.; Hobbs, Frank W.; Olson,

Richard E.

CORPORATE SOURCE: Chemical and Physical Sciences Department, DuPont

Pharmaceuticals Company, Wilmington, DE, 19880, USA Bioorganic & Medicinal Chemistry Letters (1998),

8(20), 2839-2844

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

SOURCE:

AB In search of antiinflammatory drugs with a new mechanism of action, U0126 was found to functionally antagonize AP-1 transcriptional activity via noncompetitive inhibition of the dual specificity kinase MEK with an IC50 of 0.07 .mu.M for MEK 1 and 0.06 .mu.M for MEK 2. U0126 can undergo isomerization and cyclization reactions to form a variety of products, both chem. and in vivo, all of which exhibit less affinity for MEK and lower inhibition of AP-1 activity than parent, U0126.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB In search of antiinflammatory drugs with a new mechanism of action, U0126 was found to functionally antagonize AP-1 transcriptional activity via noncompetitive inhibition of the dual specificity kinase MEK with an IC50 of 0.07 .mu.M for MEK 1 and 0.06 .mu.M for MEK 2. U0126 can undergo isomerization and cyclization reactions to form a variety of products, both chem. and in vivo, all of which exhibit less affinity for MEK and lower inhibition of AP-1 activity than parent, U0126.

ST U0126 analog structure MEK kinase inhibitor; antiinflammatory AP1 protein MEK kinase inhibitor

IT Anti-inflammatory agents

(chem. and biol. activity of U0126, its analogs, and cyclization products as **MEK** kinase inhibitors)

L8 ANSWER 137 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1998:341686 BIOSIS DOCUMENT NUMBER: PREV199800341686

TITLE: Growth factor-like action of lysophosphatidic acid on human

B lymphoblasts.

AUTHOR(S): Rosskopf, Dieter (1); Daelman, Wim; Musch, Stefan;

Schuerks, Markus; Hartung, Kathrin; Kribben, Andreas;

Michel, Martin C.; Siffert, Winfried

CORPORATE SOURCE: (1) Inst. Pharmakologie, Universitaetsklinikum Essen,

Hufelandstr. 55, D-45147 Essen Germany

SOURCE: American Journal of Physiology, (June, 1998) Vol. 274, No.

6 PART 1, pp. C1573-C1582.

ISSN: 0002-9513.

DOCUMENT TYPE: Article LANGUAGE: English

AB Proliferation and immunoglobulin secretion of B lymphocytes are regulated by specific antigens and numerous accessory immunomodulatory factors. Lysophosphatidic acid (LPA) is a glycerophospholipid mediator that is released from activated blood platelets, attains high levels in serum, and exerts potent stimulatory effects on, e.g., neutrophils, monocytes, and T lymphocytes. LPA is also generated by a secretory, cytokine-inducible phospholipase A2 present in high concentrations in inflammatory exudates and septic states. We investigated effects of LPA on human Epstein-Barr virus-immortalized B lymphoblasts, a model for immunoglobulin-secreting B cells. Intracellular Ca2+ was determined with

fura 2 and the formation of inositol 1,4,5-trisphosphate by anion-exchange chromatography. LPA stimulated an increase in inositol 1,4,5-trisphosphate levels and induced a transient rise in intracellular free Ca2+ concentration from 105 +- 17 to 226 +- 21 nM. This Ca2+ signal resulted from Ca2+ mobilization and Ca2+ influx and was subject to homologous desensitization. Pertussis toxin inhibited these responses by apprx70%. Furthermore, LPA stimulated a 27.5% increase in guanosine 5'-O-(3-thiotriphosphate) binding to permeabilized B lymphoblasts, which suggests the direct activation of pertussis toxin-sensitive G proteins by LPA. LPA stimulated a strong increase in the specific phosphorylation of the mitogen-activated protein kinase (immunoblot analysis) that was prevented by the MEK inhibitor PD-98059. Finally, LPA triggered a 2-fold increase in DNA synthesis ((3H)thymidine incorporation) and a 2-fold increase in B lymphoblast number and evoked a 20- to 50-fold increase in immunoglobulin formation. By RT-PCR we detected specific mRNA transcripts for the recently cloned human LPA receptor. Thus our data suggest that LPA behaves as a B cell growth factor.

AB. . . neutrophils, monocytes, and T lymphocytes. LPA is also generated by a secretory, cytokine-inducible phospholipase A2 present in high concentrations in **inflammatory** exudates and septic states. We investigated effects of LPA on human Epstein-Barr virus-immortalized B lymphoblasts, a model for immunoglobulin-secreting B. . . stimulated a strong increase in the specific phosphorylation of the mitogen-activated protein kinase (immunoblot analysis) that was prevented by the MEK inhibitor PD-98059. Finally, LPA triggered a 2-fold increase in DNA synthesis ((3H)thymidine incorporation) and a 2-fold increase in B lymphoblast. .

L8 ANSWER 138 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1998:492192 BIOSIS DOCUMENT NUMBER: PREV199800492192

TITLE: Cross-linking of intercellular adhesion molecule-1 induces

interleukin-8 and RANTES production through the activation

of MAP kinases in human vascular endothelial cells.

AUTHOR(S): Sano, Hideki; Nakagawa, Noriaki; Chiba, Ryuichi; Kurasawa,

Kazuhiro; Saito, Yasushi; Iwamoto, Itsuo (1)

CORPORATE SOURCE: (1) Dep. Internal Med. II, Chiba Univ. Sch. Med., 1-8-1

Inohana, Chiba City, Chiba 260-0865 Japan

SOURCE: Biochemical and Biophysical Research Communications, (Sept.

29, 1998) Vol. 250, No. 3, pp. 694-698.

ISSN: 0006-291X.

DOCUMENT TYPE: Article LANGUAGE: English

We investigated whether intercellular adhesion molecule-1 (ICAM-1) transduces outside-in signals for the production of chemokines IL-8 and RANTES in endothelial cells. Cross-linking of ICAM-1 induced IL-8 and RANTES mRNA expressions and increased their protein synthesis and secretions in endothelial cells. Furthermore, ICAM-1 cross-linking activated 44- and 42-kDa mitogen-activated protein (MAP) kinases (ERK1 and ERK2) in endothelial cells, as indicated by the electrophoretic mobility shift of MAP kinases on SDS-polyacrylamide gels. Finally, the specific MEK inhibitor PD98059 inhibited ICAM-1-induced HA and RANTES production in endothelial cells. Taken together, these results indicate that stimulation of ICAM-1 induces IL-8 and RANTES production through the activation of 44- and 42-kDa MAP kinases in endothelial cells, suggesting that ICAM-1-induced chemokine production in endothelial cells would further attract and activate leukocytes to induce intense inflammation.

AB. . . ERK2) in endothelial cells, as indicated by the electrophoretic mobility shift of MAP kinases on SDS-polyacrylamide gels. Finally, the specific MEK inhibitor PD98059 inhibited ICAM-1-induced HA and RANTES production in endothelial cells. Taken together, these results

indicate that stimulation of ICAM-1. . . in endothelial cells, suggesting that ICAM-1-induced chemokine production in endothelial cells would further attract and activate leukocytes to induce intense inflammation.

L8 ANSWER 139 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1999:28009 BIOSIS DOCUMENT NUMBER: PREV199900028009

TITLE: Pharmacological analysis of protein kinases responsible for

chemotaxis of rat peritoneal neutrophils.

AUTHOR(S): Xiao, Yi-Qun; Minami, Ken-Ichi; Mue, Suetsuqu; Ohuchi,

Kazuo (1)

CORPORATE SOURCE: (1) Dep. Pathophysiol. Biochem. Fac. Pharmaceutical Sci.,

Tohoku Univ., Sendai, Miyagi 980-8578 Japan

SOURCE: European Journal of Pharmacology, (Nov. 6, 1998) Vol. 360,

No. 2-3, pp. 195-204.

ISSN: 0014-2999.

DOCUMENT TYPE: Article LANGUAGE: English

Several types of kinase inhibitors were used to investigate the possible signaling pathways leading to the chemotaxis of rat peritoneal neutrophils toward macrophage inflammatory protein-2, cytokine-induced neutrophil chemoattractant-1, and platelet-activating factor. The chemotaxis and shape changes induced by each of these chemoattractants were strongly inhibited by a tyrosine kinase inhibitor (herbimycin A) and protein kinase C inhibitors (H-7 (1-(5-isoquinolinesulphonyl)-2methylpiperazine dihydrochloride) and calphostin C). The formation of phosphatidyl 3,4,5-triphosphate in chemoattractant-stimulated neutrophils was completely inhibited by 100 nM of wortmannin, an inhibitor of phosphatidylinositol 3-kinase, whereas the chemotaxis toward each of these chemoattractants was partially inhibited (50% inhibition). The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK-1) inhibitor PD 98059 did not inhibit the neutrophil chemotaxis. These findings suggest that the activation of tyrosine kinase and protein kinase C strongly participates in neutrophil chemotaxis and that the activation of phosphatidylinositol 3-kinase is partially involved, but that the activation of mitogen-activated protein kinase is not involved in neutrophil chemotaxis. The cross-linking of the signaling pathways for chemotaxis toward each chemoattractant was also examined.

AB. . . kinase inhibitors were used to investigate the possible signaling pathways leading to the chemotaxis of rat peritoneal neutrophils toward macrophage inflammatory protein-2, cytokine-induced neutrophil chemoattractant-1, and platelet-activating factor. The chemotaxis and shape changes induced by each of these chemoattractants were strongly.

. whereas the chemotaxis toward each of these chemoattractants was partially inhibited (50% inhibition). The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK-1) inhibitor PD 98059 did not inhibit the neutrophil chemotaxis. These findings suggest that the activation of tyrosine kinase and protein.

=> FIL STNGUIDE

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE TOTAL

CA SUBSCRIBER PRICE

ENTRY
SESSION

-1.24

-4.96

FILE 'STNGUIDE' ENTERED AT 17:46:18 ON 11 JUN 2002

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jun 7, 2002 (20020607/UP).

=> d ibib abs kwic 130-134

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, BIOSIS, IPA, USPATFULL' - CONTINUE? (Y)/N:y

L8 ANSWER 130 OF 155 IPA COPYRIGHT 2002 ASHP

ACCESSION NUMBER:

2000:1621 IPA

DOCUMENT NUMBER:

37-01621

TITLE:

Monitor: molecules

AUTHOR:

Terrett, N.

CORPORATE SOURCE:

Discovery Chem., Pfizer Central Res., Sandwich, Kent, England Internet: nick terrett@sandwich.pfizer.com

SOURCE:

Drug Discovery Today (England), (Feb 1999) Vol. 4, pp.

93-94.

CODEN: DDTOF; ISSN: 1359-6446.

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB An overview of the chemistry, pharmacological significance, and biological relevance of new molecules reported in the literature is presented; molecules discussed include substituted pyrazoles as novel D4 receptor ligands, novel fluoroquinolones, MEK inhibitors as anti-inflammatory agents, a gonadorelin (luteinizing hormone-releasing hormone; LHRH) receptor antagonist, and a p38 kinase inhibitor.

Ellen Katz Neumann

AB . . . new molecules reported in the literature is presented; molecules discussed include substituted pyrazoles as novel D4 receptor ligands, novel fluoroquinolones, MEK inhibitors as anti-inflammatory agents, a gonadorelin (luteinizing hormone-releasing hormone; LHRH) receptor antagonist, and a p38 kinase inhibitor. Ellen Katz Neumann

L8 ANSWER 131 OF 155 USPATFULL

ACCESSION NUMBER:

1998:162314 USPATFULL

TITLE:

MEKK-related signal transduction kinases Johnson, Gary L., Boulder, CO, United States

INVENTOR(S):
PATENT ASSIGNEE(S):

National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, United States (U.S. corporation)

		NUMBER	KIND	DATE
PATENT	INFORMATION:	US 5854043		19981229

APPLICATION INFO.:

US 1994-323460 19941014 (8)

RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 1993-49254, filed

on 15 Apr 1993, now patented, Pat. No. US 5405941

DOCUMENT TYPE: FILE SEGMENT:

Utility Granted

11

PRIMARY EXAMINER:

Teng, Sally P.

LEGAL REPRESENTATIVE:

Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Kara,

Catherine J.

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS:

66 Drawing Figure(s); 32 Drawing Page(s)

LINE COUNT: 3248

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention relates to isolated MEKK proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to use such proteins to regulate signal transduction in a cell. The present invention also includes therapeutic compositions comprising such proteins or nucleic acid molecules that encode such proteins and their use to treat animals having medical disorders including cancer, inflammation, neurological disorders, autoimmune diseases, allergic reactions, and hormone-related diseases. When MEKK is expressed, it phosphorylates and activates MEKs including MEK-1, MEK-2 and JEK.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . proteins or nucleic acid molecules that encode such proteins and their use to treat animals having medical disorders including cancer, inflammation, neurological disorders, autoimmune diseases, allergic reactions, and hormone-related diseases. When MEKK is expressed, it phosphorylates and activates MEKs including MEK-1, MEK-2 and JEK.

ANSWER 132 OF 155 USPATFULL

ACCESSION NUMBER:

1998:134851 USPATFULL

TITLE:

SOK-1 and methods of use

INVENTOR(S):

Force, Thomas, Natick, MA, United States Kyriakis, John M., Dedham, MA, United States

Pombo, Celia M., Santa Cruz, Spain

Bonventre, Joseph, Wayland, MA, United States

PATENT ASSIGNEE(S):

The General Hospital Corporation, Boston, MA, United

States (U.S. corporation)

NUMBER KIND DATE -----

US 5830699 US 1997-852743

PATENT INFORMATION: APPLICATION INFO.:

NUMBER DATE

19961102 19970507 (8)

PRIORITY INFORMATION:

US 1996-16774P 19960507 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

Granted

PRIMARY EXAMINER:

Carlson, Karen Cochrane LEGAL REPRESENTATIVE: Fish & Richardson P.C.

NUMBER OF CLAIMS:

16

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 6 Drawing Page(s)

LINE COUNT:

1412

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A SOK polypeptide, an isolated DNA having a nucleotide sequence encoding a SOK polypeptide, and a method of determining whether a candidate compound modulates SOK-1 activity or expression, comprising the steps of providing a first and a second recombinant cell expressing a SOK gene; introducing a candidate compound into the first cell, but not into the second cell; measuring a SOK function in the first and second cells; and comparing the results obtained with the first and second SOK transformed cells, wherein an increase or decrease in the SOK function in the first cell compared to the second cell is an indication that the candidate compound modulates SOK expression or activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . cascades is a three-tiered module of serine/threonine kinases

that consists of a MAPK-extracellular signal regulated kinase kinase (a MEKK), a MEK, and a MAPK or extracellular signal regulated kinase (ERK). In simple eukaryotes, such as the budding yeast Saccharomyces cerevisiae (S. . . Cell Biol. 7:197 (1995)). In mammals, these cascades have evolved to allow responses to complex stimuli (e.g., growth factors and inflammatory cytokines), but in many cases, such as the response to osmolar challenge (Galcheva-Gargova et al., Science 265:806 (1994); Han et. . .

L8 ANSWER 133 OF 155 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1999:13926 BIOSIS DOCUMENT NUMBER: PREV199900013926

TITLE: Modes of action of aspirin-like drugs: Salicylates inhibit

Erk activation and integrin-dependent neutrophil adhesion. Pillinger, Michael H. (1); Capodici, Constance; Rosenthal,

Pamela; Kheterpal, Neil; Hanft, Simon; Philips, Mark R.;

Weissman, Gerald

CORPORATE SOURCE: (1) Dep. Med., Room NB16N1, N.Y. Univ. Med. Cent., 550

First Ave., New York, NY 10016 USA

SOURCE: Proceedings of the National Academy of Sciences of the

United States of America, (Nov. 24, 1998) Vol. 95, No. 24,

pp. 14540-14545. ISSN: 0027-8424.

DOCUMENT TYPE: Article LANGUAGE: English

AUTHOR (S):

The anti-inflammatory effects of high-dose salicylates are well recognized, incompletely understood and unlikely due entirely to cyclooxygenase (COX) inhibition. We have previously reported a role for activation of the kinase Erk in CD11b/CD18 integrin-dependent adhesiveness of human neutrophils, a critical step in inflammation. We now report the effects of salicylates on neutrophil Erk and adhesion. Exposure of neutrophils to aspirin or sodium salicylate (poor COX inhibitor) inhibited Erk activity and adhesiveness of formylmethionyl-leucylphenylalanine- and arachidonic acidstimulated neutrophils, consistent with anti-inflammation but not COX inhibition (IC50s = 1-8 mM). In contrast, indomethacin blocked neither Erk nor adhesion. Inhibition of Mek (proximal activator of Erk) also blocked stimulation of Erk and adhesion by formylmethionyl-leucyl-phenylalanine- and arachidonic acid. Salicylate inhibition of Erk was independent of protein kinase A activation and generation of extracellular adenosine. These data are consistent with a role for Erk in stimulated neutrophil adhesion, and suggest that anti-inflammatory effects of salicylates may be mediated via inhibition of Erk signaling required for integrin-mediated responses.

ΔR The anti-inflammatory effects of high-dose salicylates are well recognized, incompletely understood and unlikely due entirely to cyclooxygenase (COX) inhibition. We have previously. . . reported a role for activation of the kinase Erk in CD11b/CD18 integrin-dependent adhesiveness of human neutrophils, a critical step in inflammation . We now report the effects of salicylates on neutrophil Erk and adhesion. Exposure of neutrophils to aspirin or sodium salicylate (poor COX inhibitor) inhibited Erk activity and adhesiveness of formylmethionylleucyl-phenylalanine- and arachidonic acidstimulated neutrophils, consistent with anti-inflammation but not COX inhibition (IC50s = 1-8 mM). In contrast, indomethacin blocked neither Erk nor adhesion. Inhibition of Mek (proximal activator of Erk) also blocked stimulation of Erk and adhesion by formylmethionyl-leucyl-phenylalanineand arachidonic acid. Salicylate inhibition of Erk. . . generation of extracellular adenosine. These data are consistent with a role for Erk in stimulated neutrophil adhesion, and suggest that anti-inflammatory effects of salicylates may be mediated via inhibition of Erk signaling required for integrin-mediated responses.

L8 ANSWER 134 OF 155 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 13

ACCESSION NUMBER: 1998:463996 CAPLUS

DOCUMENT NUMBER: 129:188276

TITLE: Binding of human immunodeficiency virus type 1 to CD4

and CXCR4 receptors differentially regulates

expression of inflammatory genes and activates the MEK/ERK signaling pathway

AUTHOR(S): Popik, Waldemar; Hesselgesser, Joseph E.; Pitha, Paula

М.

CORPORATE SOURCE: Oncology Center, The Johns Hopkins University School

of Medicine, Baltimore, MD, 21231, USA

SOURCE: Journal of Virology (1998), 72(8), 6406-6413

CODEN: JOVIAM; ISSN: 0022-538X American Society for Microbiology

DOCUMENT TYPE: Journal LANGUAGE: English

PUBLISHER:

The authors have previously shown that binding of human immunodeficiency virus type 1 (HIV-1) virions to CD4 receptors stimulates assocn. of Lck with Raf-1 and results in the activation of Raf-1 kinase in a Ras-independent manner. In the present study, the authors demonstrate that HIV-1 envelope glycoproteins of both T-cell-tropic and macrophage-tropic strains rapidly activate the ERK/mitogen-activated protein (MAP) kinase pathway and the binding of nuclear transcription factors (AP-1, NF-.kappa.B, and C/EBP) and stimulate expression of cytokine and chemokine genes. The activation of this signaling pathway requires functional CD4 receptors and is independent of binding to CXCR4. Binding of the natural ligand stromal cell-derived factor 1 (SDF-1) to CXCR4, which inhibits entry of T-cell-tropic HIV-1, activates also the ERK/MAP kinase pathway. However, SDF-1 did not affect the CD4-mediated expression of cytokine and chemokine genes. These results provide firm mol. evidence that binding of HIV-1 envelope glycoproteins to CD4 receptor initiates a signaling pathway(s) independent of the binding to the chemokine receptor that leads to the aberrant expression of inflammatory genes and may contribute significantly to HIV-1 replication as well as to deregulation of the immune system.

TI Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of **inflammatory** genes and activates the MEK/ERK signaling pathway

IT Transcription factors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(AP-1 (activator protein 1); HIV-1 gp120 binding to CD4 inducing expression of **inflammatory** genes and activating **MEK** /ERK signaling pathway independent of CXCR4 receptors)

IT Transcription factors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(C/EBP (CCAAT box/enhancer element-binding protein); HIV-1 gp120 binding to CD4 inducing expression of **inflammatory** genes and activating MEK/ERK signaling pathway independent of CXCR4 receptors)

IT Chemokine receptors

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(CXCR4; HIV-1 gp120 binding to CD4 inducing expression of **inflammatory** genes and activating **MEK**/ERK signaling pathway independent of CXCR4 receptors)

IT Human immunodeficiency virus 1
 Signal transduction, biological
 T cell (lymphocyte)

(HIV-1 gp120 binding to CD4 inducing expression of inflammatory

```
genes and activating MEK/ERK signaling pathway independent of
        CXCR4 receptors)
IT
    CD4 (antigen)
     RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
     (Properties); BIOL (Biological study); PROC (Process)
        (HIV-1 gp120 binding to CD4 inducing expression of inflammatory
        genes and activating MEK/ERK signaling pathway independent of
        CXCR4 receptors)
IT
     Interleukin 2
     Macrophage inflammatory protein 1.alpha.
     Macrophage inflammatory protein 1.beta.
     RANTES (chemokine)
     Tumor necrosis factors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (HIV-1 gp120 binding to CD4 inducing expression of inflammatory
        genes and activating MEK/ERK signaling pathway independent of
        CXCR4 receptors)
TΨ
     Transcription factors
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
       (NF-.kappa.B (nuclear factor .kappa.B); HIV-1 gp120 binding to CD4
        inducing expression of inflammatory genes and activating
        MEK/ERK signaling pathway independent of CXCR4 receptors)
IT
     Gene
        (expression; HIV-1 qp120 binding to CD4 inducing expression of
        inflammatory genes and activating MEK/ERK signaling
        pathway independent of CXCR4 receptors)
TΤ
     Envelope proteins
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); BIOL (Biological study)
        (gp120env; HIV-1 gp120 binding to CD4 inducing expression of
        inflammatory genes and activating MEK/ERK signaling
        pathway independent of CXCR4 receptors)
TΤ
     Cytokines
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (inflammatory; HIV-1 gp120 binding to CD4 inducing expression
        of inflammatory genes and activating MEK/ERK
        signaling pathway independent of CXCR4 receptors)
TТ
     Interferons
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (.gamma.; HIV-1 gp120 binding to CD4 inducing expression of
        inflammatory genes and activating MEK/ERK signaling
        pathway independent of CXCR4 receptors)
TΤ
     142243-02-5, ERK kinase 142805-58-1, MEK kinase
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (HIV-1 gp120 binding to CD4 inducing expression of inflammatory
        genes and activating MEK/ERK signaling pathway independent of
        CXCR4 receptors)
=> log y
COST IN U.S. DOLLARS
                                                  SINCE FILE
                                                                  TOTAL
                                                      ENTRY
                                                                SESSION
FULL ESTIMATED COST
                                                        0.90
                                                                 104.72
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
                                                 SINCE FILE
                                                                  TOTAL
                                                      ENTRY
                                                                SESSION
CA SUBSCRIBER PRICE
                                                       0.00
                                                                  -5.58
```

STN INTERNATIONAL LOGOFF AT 17:58:29 ON 11 JUN 2002

Was to the	the transfer of the second		· **
T)	y	4	
.*			A. 18 4
ž .	,		
1. 			
*			
×			
ke .			
Fogo			
¥ " = 1			
			¥
			**
ide Landa de la companya			
			ř.
			4
· ·			
*			
* *			
<u>.</u>			
	`		
*			

)
			- X
÷			
		A Committee of the Comm	